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Research project summary 
Investigation of vitamin D metabolism, its biological role and the relevant quantitative methods of 
assessment has exponentially increased over the past two decades. Vitamin D plays a significant 
role in multiple physiological functions in humans. Also, there is some evidence linking vitamin D 
inadequacy with numerous pathologies in both children and adults. However, research into the role 
of vitamin D is hampered by lack of large-scale, prospective studies.  
Emerging evidence of the association between early life vitamin D deficiency and increased risk of 
childhood pathologies such as food allergy, eczema and infections, suggests that vitamin D likely 
plays a role in early development of infants’ immune system and health. In Victoria, the prevalence 
of both vitamin D insufficiency and challenge-proven food allergy in infants is high and the two 
could be linked. However, it remains unclear whether low vitamin D levels play a causal role in the 
development of food allergy, and if so, whether there is a “window of opportunity” during which 
adequate vitamin D levels are most important for immune development and immune responses to 
food. Potentially, vitamin D status at birth has implications on the prevalence of food allergy and 
other pathologies. We have therefore aimed to determine the frequency of vitamin D inadequacy in 
newborns from Melbourne, Victoria and investigate the relationship between vitamin D level at 
birth and food allergy in infants.   
Vitamin D conventionally is measured as 25-hydroxy vitamin D3 in serum / plasma and the 
interpretation cut-offs for adults are well-defined. However, for large-scale population studies 
sample handling procedures including; collection, transport and storage are cumbersome for 
serum/plasma specimens.  Accordingly, the interest in the use of dried blood spots (DBS) as an 
alternative matrix for vitamin D assessment has increased. Furthermore, there is a particular interest 
in newborn blood spot screening (NBS) samples as they collect information on various biomarkers 
including vitamin D at birth. This timing is important as it is prior to the onset of disease, and also 
because some of the immune deviations that lead to diseases including food allergy are already 
 xviii 
 
thought to be present at birth or shortly afterwards. However, this is limited by the lack of an 
accurate method for measuring vitamin D levels from DBS/NBS samples.  
Analysis of DBS vitamin D has been previously demonstrated. However, there are some analytical 
and post analytical challenges to be considered such as; traceability, sensitivity and assay 
robustness. Therefore, to advance the literature regarding measurement of vitamin D we aimed to 
develop a sensitive and robust local DBS vitamin D method, that is traceable to serum for use in 
population-based studies.  
Following the aims of the project, we collected 2700 archived NBS Guthrie cards from the Victorian 
Clinical Genetics Services at the Murdoch Children's Research Institute for measurement of 25-
hyroxy vitamin D3 (25-OHD3). We examined the association between season of birth, parents’ 
ethnicity and supplementation intake and vitamin D levels at birth, as well as the association 
between vitamin D levels and parent-reported eczema and challenge proven food allergy at one year 
of age, using data from the HealthNuts study. HealthNuts is a long-term population-based study 
designed to assess different aspects of paediatric food allergy in Victoria, Managed by Murdoch 
Childrens Research Institute.  
To alleviate the potential errors associated with the dried matrix of DBS sample which could span 
the total testing process, we developed a simple method to estimate haematocrit in archived DBS 
samples. A formic acid solution was used to elute the haemoglobin content of 3.2 mm spotted blood 
disk from its dry matrix. A direct spectrometry method was utilised to obtain the spectrum of the 
extracted haemoglobin in the visible range and the linear relationship between individuals’ 
haematocrit percentage and haemoglobin concentration applied to estimate the haematocrit level of 
the blood spot. This method potentially can be incorporated into various DBS analytical sample 
preparation process for correction of measured analytes of interest. 
To evaluate the vitamin D status in NBS samples we then developed a method to quantitate vitamin 
D from DBS.  25-hydroxy vitamin D3 was eluted and extracted from one 3.2 mm DBS disk using 
a water-methanol mixture (3:5) followed by a supported liquid extraction and derivatisation 
 xix 
 
procedures prior to LC-MS/MS analysis. The extracted and derivatised DBS samples were injected 
onto a LC-MS/MS system (reversed phase Kinetex F5 analytical column, methanol/water gradient) 
which was operated in positive ESI multiple reactions monitoring mode. The assay has a linear 
range of 0.2 to 353 nmol/L, with a between run imprecision, assessed from the in-house DBS 
control samples of 12.9% at 45 nmol/L. NIST-972a traceable commercial standard material was 
used to calibrate vitamin D measures. 
The developed method has been utilised to analyse archived NBS samples to determine the vitamin 
D status in a Melbourne neonatal population. This was the largest longitudinal population study 
determining the distribution of vitamin D at birth in Melbournian infants, and has examined whether 
vitamin D status at birth predicts the risk of food allergy and eczema in early childhood. We found 
that the prevalence of vitamin D inadequacy is very high among the studied cohort (born between 
September 2007 and August 2011), comparing the DBS measures with the Institute of Medicine 
adult values and our defined quintiles for 25-OHD3 measures. However, there was no evidence of 
an association between the NBS vitamin D levels and challenge proven food allergy (to sesame, 
peanuts and egg) or eczema in this large cohort of 2615 participants. As would be predicted, season 
of birth and maternal vitamin D supplementation were associated with DBS vitamin D levels. While 
no other significant predictor (such as; gender, parents’ region of birth and gestational age) of 
vitamin D level in DBS samples was observed.   
This study confirmed a significant rate of vitamin D inadequacy among infants born in Victoria. 
Further prospective studies are required to determine if age-adjusted decision limits for infants 
(different from suggested cut-offs for adults) are required. Current evidence supports the feasibility 
of safe sun exposure and season-focused supplementation during pregnancy and early infancy, but 
further studies are required to define recommendations for optimal dosage and timing of 
supplementation. In conclusion, the outcomes of this PhD project including development of method 
and analysis of newborn vitamin D levels, did not provide any evidence of association between 
vitamin D levels at birth and prevalence of food allergy in early childhood.  
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Literature review 
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1. Literature review 
1.1. Introduction 
Investigation of vitamin D metabolism, its biological role and the relevant quantitative methods of assessment 
has exponentially increased over the past two decades. Vitamin D plays a significant role in multiple 
physiological functions in human including; general well-being, immune system development, bone health as 
well as normal cell growth and maturation (1). However, vitamin D deficiency for children and pregnant 
women is still a critical global health challenge. Reported rates of vitamin D insufficiency (VDI) (25-hydroxy 
vitamin D level below 50 nmol/L) in some populations of Victorian children is up to 54.9%  (2). This 
population group might be at substantial risk of bone related diseases and other chronic illnesses or disabilities 
(3). Also, relatively high prevalence (80%) of vitamin D deficiency (25-hydroxy vitamin D below 22.5 nmol/L) 
is reported in the metropolitan Melbourne population study among the dark skinned or veil-wearing pregnant 
women (4).  
Emerging evidence of the association between early life vitamin D deficiency and increased risk of childhood 
pathologies such as food allergy, eczema and infections, suggests that vitamin D likely plays a role in early 
development of infants’ immune system and health (5). Furthermore, evidence-based studies show that, the 
rate of food allergy in developing countries is increasing (6-8). Hypothetically, the significant increased 
incidence of vitamin D inadequacy in pregnant women and infants could be considered as an underlying cause 
of allergic disorders in children including paediatric food allergy and eczema (9). 
Measurement of vitamin D metabolites remains challenging due to their low circulatory concentration, binding 
proteins and the structural similarity of their analogues. This chapter aims to provide an insight into the 
complexity of vitamin D measurement and investigates alternative analytical methods which could be 
applicable to paediatric studies. In addition, this review summarises the general biochemical specification, 
metabolism and pathophysiology of vitamin D, with the special attention to its role in paediatric food allergy. 
This chapter also incorporates the findings of two published review papers, which discuss the details of clinical 
and technical aspects of the project background (9, 10).  
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1.1.1 Chemical structure  
Vitamin D is chemically a group of seco-steroids which possess an open cyclo-pentano-perhydrophenanthrene 
ring (ring B on carbon 9, 10). These seco-steroids are structurally comparable to the steroid hormone group, 
and the biologically active vitamin D metabolite; 1,25-dihydroxy vitamin D (1α,25-(OH)2D) (which appears 
to be the only active form of vitamin D) that exhibits hormone-like behaviour (11). Besides its seco-steroid 
form, the presence of a side chain provides a more flexible molecular structure compared to the classic steroids 
(12) (Figure 1.1). 25-hydroxy vitamin D (25-OHD) is the main  circulatory analogue of vitamin D with the 
longest half-life in adults; while its epimer (3-epi-25-OHD) (which appears to be metabolised into a 
physiologically inactive metabolite) is present in significant levels in paediatric group (13).  
 
 
Figure 1.1. Molecular structure of vitamin D3 metabolites; vitamin D metabolites are the group of seco-steroids with the similar molecular structure. 
1,25-(OH)2D3 is the most active of the analogues which presents with hormone like biological activity.  
 
1.1.2 Biochemical pathways and metabolism 
There are two distinct metabolic pathways for production and metabolism of vitamin D; 1) vitamin D2 
(Ergocalciferol), which is sourced from plants and 2) vitamin D3 (Cholecalciferol), that forms naturally in the 
skin in response to sun exposure (ultra-violet radiation) from its primary precursor cholesterol (11). Ultra-
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violet rays initiate a series of photochemical reactions to convert this seco-steroid to pre-vitamin D3 in the 
malpighian layer of skin. Pre-vitamin D3 can isomerise to vitamin D3 within 2-3 days. To become biologically 
active, vitamin D must be double-hydroxylated at position 1 and 25 (Figure 1.2).  
Vitamin D metabolites possess a high affinity to the plasma vitamin D binding protein (VDBP).  VDBP carries 
cholecalciferol to the liver; where the 25-hydroxylase enzyme accelerates formation of 25-OHD3. VDBP 
circulatory level is in a high molar excess compared to the vitamin D metabolites concentration. As such, only 
very limited portion of metabolites circulate freely (14). The complex of VDBP-25-OHD3 then travels to the 
kidney for a further hydroxylation step. 1α-hydroxylase enzyme catalyses 25-OHD secondary hydroxylation 
to produce; 1) the active hormone-like 1α,25-(OH)2D3 (Calcitriol) and 2) the presumably inactive 24,25-
(OH)2D3 metabolites (15) (Figure 1.2). 
The enzymes responsible for biological activation of vitamin D3 are cytochrome P-450 family members. 
Hepatic vitamin D 25-hydroxylases (CYP2R1, CYP2D11 and CYP2D25) induce the formation of 25-OHD. 
In the kidney cytochrome P-450 mono-oxygenase 25(OH)-D 1-alpha hydroxylase (CYP27B1; 1α-(OH) ase) 
enzymes facilitate the production of the active form of vitamin D; 1α,25-(OH)2D. This CYP27B1 is also 
expressed in other organs and cells including; placenta during pregnancy, monocytes-macrophages, 
endothelial, colon, breast, prostate and pancreatic cells. These are consequently known as extra-renal 
production sites for 1α,25(OH)2D (16). 
24,25(OH)2D could be synthesised in  kidney by the 24-hydroxylase enzyme (CYP24A1), which compared to 
1α,25-(OH)2D is considered a relatively inactive metabolite (17). Hence, vitamin D metabolic degradation and 
deactivation is recognised as the central function of CYP24A1.  Also, CYP24A1 largely is found in all vitamin 
D target tissues such as; stomach isthmus cells, entero-endocrine cells, pyloric muscle cells, teeth pulp cells, 
thymus reticular cells, epithelium, neuron cells, adrenal medullary cells, kidney macula densa cells, podocytes, 
liver Ito cells, female and male reproductive organs, and atrial cardio-myocytes (15, 18). Finally, CYP24A1 
mediates a set of reactions resulting in production of excretory forms; calcitroic acid and 1-desoxycalcitroic 
acid; from the different metabolites of vitamin D (Figure 1.2). These final products of vitamin D metabolic 
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pathway are predominantly excreted through the bile into the faeces, whereas are only rarely expelled through 
the urine (19, 20) (Figure1. 2). 
Plants and invertebrates synthesize vitamin D2 from ergosterol  (21). Chemically, vitamin D2 and D3 are quite 
similar, and the side chain is the only notable difference between them (Figure 1). This difference is alleged to 
alter the vitamins’ corresponding manner of binding to VDBP and the metabolic pathway (22). Furthermore, 
it is understood that the efficacy of vitamin D3 in raising plasma concentration of 25-OHD is significantly 
higher than vitamin D2. As such, specifically vitamin D3 supplementation is recommended for treatment of 
vitamin D inadequacy (23). 
1.1.3 Regulation 
Regulation of 1α,25-(OH)2D is controlled by the complex positive and negative feedback systems, which 
affect the expression of the hydroxylase enzymes (24). Low circulatory calcium concentration increases 1-α-
hydroxylase gene activation and transcription. In turn, elevated parathyroid hormone (PTH) suppresses the 
gene transcription (25, 26). Besides, the regulation of 24-hydroxylase is controlled through 1α,25-(OH)2D 
status, plasma calcium concentration and PTH level (25). 
Due to highly lipophilic molecular structure of vitamin D metabolites, their circulatory forms are mainly bound 
to VDBP (27). This binding protein is known to facilitate the dispersal of deactivated and excretory forms of 
vitamin D to cells which can further deactivate and excrete them (28). Additionally, VDBP-bound sterols are 
important reservoirs for normal physiological activities and also during limited production / intake 
circumstances. However, it has been argued that, whereas binding protein accessibility in plasma is an 
important factor to maintain total circulating levels of 1,25(OH)2D3, VDBP concentration does not affect 
calcitriol’s biologically active pool (29). 
Other factors which can affect metabolism of vitamin D include fibroblast growth factor-23 (FGF-23) which 
is a phosphatiruric factor for renal phosphate excretion, and a known physiological regulator for vitamin D 
biosynthesis and metabolism. Primarily, production of FGF-23 in bone is stimulated by 1α,25-(OH)2D. In 
turn, expression of 1α-hydroxylase is suppressed by elevated levels of FGF-23. Furthermore, increased FGF-
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23 induces the 24-hydroxylase activity in renal cells (30). Also, it is reported that, production of 1α,25-(OH)2D 
is stimulated by oestrogen in combination with progesterone or androgen.Also, it is suggested that, oestrogen 
alone may suppress the synthesis of 24,25-(OH)2D (31). 
Within 15-30 minutes of full body skin sun exposure, 10,000 to 20,000 IU of vitamin D3 will be produced. 
After two hours sun exposure the body will have reached the maximum capacity of vitamin D3 IU intake. The 
excess amount of pre-vitamin D converts to other inert metabolites such as; Lumisterol and Tachysterol, which 
are degraded into other inactive metabolites (e.g. Suprasterol). Thus, it is believed that prolonged skin sun-
exposure cannot induce vitamin D toxicity (32). 
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Figure 1.2. Vitamin D metabolism; 7-Dihydroxycholestrol is the precursor for the endogenous synthesis of vitamin D in the skin tissue. The activation and metabolism of vitamin D is mediated by a 
group of cytochromes P-450 enzymes in the liver, kidney and other target tissues. It appears likely that this group of enzymes play a significant regulatory role for vitamin D function in various organs. 
Calcitriol (1,25(OH)2-vitamin D3) is known as the most active form of vitamin D with the hormone-like behaviour. 
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1.2. Are vitamins A and D important in the development of food allergy? 
This section has been peer reviewed and published with contribution of other co-authors as review paper (9). 
My contribution to this study and subsequent publication was included; developing the concept for the study 
in conjunction with my senior supervisor (RG), performing the literature search / study, collecting data, 
analysis and interpretation of data, writing the first draft of the publication and reviewing and incorporating all 
suggestions from the co-authors. 
1.2.1 Introduction 
Food allergy has a dramatic impact on a child and family’s quality of life (33) and places a major financial 
burden on the community (34).  Of further concern, hospitalizations for food allergy-related anaphylaxis, the 
most severe expression of a food allergic reaction and a life-threatening condition, have dramatically increased 
since the early 1990s.  Recent studies demonstrate that 8-10% of one-year old infants living in Melbourne 
Australia have challenge-proven IgE-mediated food allergy (6).  This is the highest reported prevalence of 
challenge-proven food allergy in the world (Figure 1.3) (35).  The cause of this epidemic is unknown and 
identifying contemporary environmental factors that may underlie the increase in food allergy is actively being 
investigated. 
The increase in food allergy may relate to the concordant rise in prevalence of vitamin D insufficiency (VDI) 
(8).  Previous studies have shown that greater than one third (39%) of Australian women of child bearing age 
has VDI (36). The high rate of VDI may relate to a number of factors including reduced sun exposure, low 
dietary intake of foods that are naturally rich in vitamin D, as well that lack of routine vitamin D 
supplementation in this country – unlike in the US and Europe.  A number of recent findings suggest an 
association between early life VDI and food allergy.  This is an important hypothesis with clear public health 
implications.  The initial findings of a latitude gradient in the prescription of adrenaline auto-pens for the 
treatment of food allergy anaphylaxis (higher rates further from the equator) have recently been extended by a 
large cross-sectional study which found a clear link between low vitamin D status (which was directly 
measured) and proven food allergy in young infants of Australian born parents (37). 
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Vitamin A has an important role in immune function (38). The health impact of vitamin A deficiency in 
developing countries has been recognised for some time; this includes vitamin A’s association with increased 
risk of morbidity in malnourished infants whom die due to impaired immune system associated by vitamin A 
deficiency (39).  Hence, vitamin A supplementation in association with vaccination programs have been 
established to combat deficiency in preschool children in these countries (40). Recent evidence suggests that 
neonatal supplementation of vitamin A is associated with an increase in atopic sensitization and atopic disease 
(41).  In addition, it has also been proposed that retinoic acid (one of the three forms of vitamin A) may 
influence the acquisition of immune intolerance (42-44).  Indeed vitamin A appears to play a key role in 
enabling humans to consume a wide range foods without stimulating an adverse immune reaction (38). 
 
Figure 1.3.  Variation in the documented global prevalence of food allergy in children ≤5 years of age.   
This map represents information from 14* countries globally and is derived from a mixture of sources which includes parent reports, symptoms and 
sensitization and oral food challenges (OFC).  This data is adapted from information provided through the World Allergy Organization and information 
provided in reference no. 4.  The map was developed using online software from http://www.aneki.com/map.php. 
The prevalence, based on percentage reports in the population: 
OFC High prevalence (>8%) – i.e. Australia 
OFC Medium prevalence (4 – 8%) – i.e. China, Norway, United Kingdom 
OFC Low prevalence (< 4%) – i.e. Denmark, Iceland, Thailand 
Non OFC proven food allergy. Korea, Sweden, Taiwan* have data based on sensitisation studies. The documented incidence is from 3.2 to 
11%. 
Non OFC proven food allergy. Canada, Finland, France, Hong Kong*, Japan and the USA have data based on parent reports.  The 
documented incidence range is from 4.1 to 9.2%. 
Information not available or not provided 
*Note: the software used to generate this map does not distinguish Taiwan and Hong Kong from mainland China. 
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Together, these hypotheses have prompted further investigation into the circulating levels of vitamins A and 
D in relation to food allergy prevalence.  Whilst there is no clear evidence examining an interaction between 
vitamin A and D in association with food allergies, it is expedient to be able to measure these vitamins together.  
Ideally, the analytical methods utilised for the measurement of these vitamins are both precise and accurate.  
We also desire methods that are sensitive and specific.  The higher order methods which are reported to achieve 
these desired method characteristics are based on chromatographic techniques for both vitamins. 
The chromatographic method group, whilst of a higher order, is technically more challenging and has been 
shown in recent years to not always be as robust as hoped (45, 46). An alternative method group, immunoassay, 
is also widely utilised for vitamin D analysis and is considered by many to be an acceptable alternative (47). 
However, often a limitation of both groups (chromatography and immunoassay) remains their inability to 
distinguish the various forms or precursors of vitamin D and A respectively (48). 
This review aims to examine the relationship between vitamin A and vitamin D and food allergy, and includes 
a discussion of the measurement techniques, to provide the precise and accurate data required to assess vitamin 
status in paediatric populations. 
1.2.2 What is the link between vitamin A & D and food allergy? 
Generally, food allergy is defined as a maladaptive immune response to an inoffensive food related antigen 
(49).  Available epidemiological data propose a dramatic increase in food allergy and related anaphylaxis 
during the last two decades (50).  There are several studies available which provide indirect and direct evidence 
for vitamin D and suggestive evidence for vitamin A levels in relation to food allergy prevalence. 
Vitamin D: The Indirect Evidence 
There is some evidence that variation in food allergy prevalence within countries might be linked with ambient 
ultra violet radiation (UVR) exposure and thus potentially with vitamin D levels.  Although few studies 
internationally have measured food allergy prevalence in population-based samples using the gold standard of 
oral food challenges, several have assessed the correlation between proxy markers of food allergy status and 
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latitude.  Four studies have been published which report that areas further from the equator with lower ambient 
UVR levels may have more food allergy (49, 51-53).  In Australia, parent-reported egg and peanut allergy are 
more common in southern States i.e. further from the equator, which have less year round sunlight (54).  Also 
in Australia, prescriptions of hypoallergenic formulas which are used for the treatment of food allergy are more 
common in southern States, as are prescriptions for epinephrine auto-injectors for the treatment of anaphylaxis 
(52).  Similar trends in prescription of auto-injectors have been described in the US, with these being more 
common in areas further from the equator (55). 
Comparisons between countries with varying ambient UVR levels are theoretically possible.  In practice, such 
studies are hampered by the lack of standardized protocols for measuring food allergy.  This limits the ability 
to make accurate comparisons between studies.  The EuroPrevall studies which does use standardized protocols 
to measure food allergy across multiple countries may provide further insight into potential links between UVR 
and food allergy prevalence (56).  However, even these comparisons are complicated by differences between 
countries in sun exposure behaviour, such as the use of sunscreen and time spent outside.  Such comparisons 
are further complicated by the varying recommendations for maternal and infant vitamin D supplementation 
and food chain fortification with vitamin D.  In addition to a potential link between UVR exposure on a 
population level and food allergy, there is some indirect evidence to support a link between individual UVR 
exposure and food allergy. 
Food allergy is widely believed to have increased over recent decades and the available evidence, although 
scarce and mixed, seems to overall support an increase.  Examination of changing vitamin D exposure and 
food allergy prevalence at the population level over time may support a causal link between vitamin D and 
food allergy, although the evidence is not clear.  The indirect evidence for and against is: 
1) Supporting evidence.  Two studies have shown that patients with food allergy were more likely to 
have been born in autumn/winter when ambient UVR levels are lower and vitamin D stores may 
therefore be lower (51, 52).  In addition, there has been a contemporaneous decrease in vitamin D 
levels in many parts of the world due to changes in behaviour leading to less sun exposure over time 
(57). 
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2) Contrary evidence.  On the other hand, time trends over a longer period may not support a link between 
vitamin D and food allergy (58).  To this effect, Wjst argue that in the 1900s when low vitamin D 
levels were common in England, seen in high rates of rickets, allergic disease in general and 
presumably food allergy also appears to have been uncommon (59).  This observation, whilst 
important, is of course complicated by a wide range of other environmental factors that have changed 
over the last century.  It has been argued, for instance, that low vitamin D status may only be a risk 
factor for food allergy in the presence of a ‘Westernised’ gut microbiota (60). 
Vitamin D: The Direct Evidence 
Only a few studies to date have examined the relationship between measured serum vitamin D levels and either 
food sensitization or allergy.  These studies are: 
1) In the US-based National Health and Nutrition Examination Survey (NHANES 2003-2006), 
children with 25-hydroxy vitamin D (25-OHD) <37.5 nmol/L of blood were more likely (odds ratio 
2.39; 95% CI, 1.29–4.45) to have allergic sensitization to peanuts than children with 25OHD levels 
>75 nmol/L (61). 
2) A separate study found that in children with four specific genotypes, low vitamin D at birth (cord 
blood 25-OHD level <27.5 nmol/L i.e. <11 ng/mL) was associated with food sensitization, while this 
association was not present in children with other genotypes (62). This finding of a gene-vitamin D 
interaction provides some evidence to support a causal relationship between vitamin D levels and food 
sensitization.   
3) In a recent Australian population-based cohort study of one year old infants, those with vitamin D 
insufficiency were three times more likely to be egg allergic and eleven times more likely to be peanut 
allergic compared to those with sufficient serum vitamin D levels (37).  Among sensitized infants, 
those with VDI were six times more likely to be food allergic.  This association was only present 
among infants of Australian-born parents, suggesting a possible gene-environment interaction.  
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4) Some studies have also suggested that high vitamin D levels or oral supplementation with vitamin 
D may be associated with an increased risk of allergic disease in general, although these have generally 
not examined food allergy specifically (57). 
5) One recent small study found that higher maternal and cord blood vitamin D levels were associated 
with a higher risk for food sensitization and allergy in the first two years of life (63). This study, 
however, was limited by significant loss to follow-up. 
These apparently conflicting findings might be explained by a differential immune effect of oral vitamin D 
supplementation compared with vitamin D derived from UVR exposure.  Alternatively, there is some evidence 
to support a ‘u-shaped association’ whereby both high and low serum vitamin D levels may increase the risk 
of allergic disease.  The timing of adequate vitamin D exposure may also be important, and longitudinal studies 
investigating the effect of serum vitamin D levels at different time periods from birth through the first years of 
life are still required to investigate this. 
Vitamin A:  Is it worth studying as a potential risk factor? 
To date no study has looked at the role of vitamin A in the development of food allergy, although there is 
reasonable evidence that it plays a role in immune development. Therefore, the investigation of the role of 
vitamin A alongside vitamin D in the risk of food allergy development is a worthwhile line of investigation – 
especially since many foods such as dairy, fish and eggs contain reasonable quantities of both of these fat-
soluble vitamins. The role of vitamin A in immune health is reviewed below. 
1) Role in the gut.  Vitamin A plays a vital role in epithelial cell differentiation and immune system 
development (64, 65)  and has a well - established role in gut mucosal immune system development 
(38).  There is emerging evidence that vitamin A may also play a role in immune tolerance and 
tolerance to food proteins through imprinting of gut-homing specificity on T cells (66).  Since the 
body mucosal surface is the front-line barrier exposed to food allergens, the development of mucosal 
immune tolerance is essential to normal development.  
   
Rosita Zakariaee Abkoo  
14 
 
2) Role on immune response.  Vitamin A appears to play a key role in maintaining an adequate number 
of peripheral naïve T cells.  To achieve oral tolerance, vitamin A is likely to be essential in enhancing 
conversion of T cells to regulatory T cells by a TGF mediated mechanism (67-69).  There is also some 
evidence regarding an association of elevated circulatory vitamin A  levels and increased risk of  IgE 
mediated sensitization (70).  This is through action on T helper-2 cells response resulting in skewing 
of the immune system (71). 
3) Vitamin A supplementation.  There is a direct association between vitamin supplementation in early 
childhood and the prevalence of food allergy related asthma (70).  Vitamin A deficiency is common 
in developing countries and to prevent clinical consequences, vitamin A is supplemented in early 
infancy (72). Although water-based preparations of vitamin A are available, fat soluble based 
preparations such as peanut oil is usually advocated because of improved preparation and storage. 
Moreover, peanut oil contains omega-3 and omega-6 fatty acids (72) which are recommended to 
reduce autoimmune disease and prevent allergy (73, 74).  Moreover, it is reported in young children 
that, the water-soluble form of supplementation increases the odds of developing allergic diseases 
compared  with fat-soluble forms possibly because it is so poorly absorbed (72).  
4) Potential interplay with vitamin D. Vitamins A and D compete for the same receptor sites. The main 
relevance of this is that preparation containing both vitamins (such as cod liver oil) may behave 
differently to pure forms of either. Indeed, this is a factor that should be considered when evaluating 
the observation that increasing cod liver oil supplementation over the 20th century was associated with 
an increase in allergic disease (28). 
Further research needs to be conducted to establish evidence for or against the role of vitamin A in food 
allergies. 
1.2.3 What is the biological plausibility of vitamin D in relation to food allergy? 
The role of vitamin D in immune system development and innate epithelial defence and maintaining of 
intestinal mucosal barrier integrity has been recently demonstrated (60, 75, 76).  Vitamin D potentially can 
promote the pro-sensitization immune imbalance which can compromise immunologic tolerance (77).  Hence, 
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it is suggested that the rapid rise in food allergy may be associated with the increase of vitamin D insufficiency.  
It is proposed that there is a robust link between vitamin D and food allergy, due to the significant role of 
vitamin D in maintaining mucosal immunity, healthy gastro-intestinal  microbiota and allergen tolerance (49).  
Additionally, the expression of IL-10-secreting regulatory T cells can be induced by vitamin D (78).  On the 
other hand, there is a correlation between allergen specific T-regulatory cells and food intolerance reactions 
(63).  Thus, vitamin D’s potential role in food tolerance promotion among food sensitized individuals is now 
thought to be substantial. 
1.2.4 How are these vitamins measured? 
Vitamins A and D are classified as fat soluble vitamins and both are recognised to have hormonal like actions 
on nuclear receptors in target tissues.  As both compounds are hydrophobic they are transported in the 
circulation by their respective carrier proteins.  To exert their effect both vitamins require conversion to their 
active forms.  To assess the levels of vitamins A and D in blood, the main circulating forms (i.e. retinol and 
25-OHD3 respectively) are routinely measured on serum or plasma samples.  There has been extensive 
discussion in the literature relating to the lack of agreement between methods for these vitamins.  The following 
section briefly outlines the method characteristics for the measurement of the main circulating form of these 
vitamins.  
Vitamin A methods 
In paediatric laboratories in developed countries1, serum vitamin A levels are most commonly measured to 
monitor cystic fibrosis patients and to screen newly arrived immigrants from developing countries.  Whereas, 
in developing countries, vitamin A is almost exclusively measured to assess clinical deficiency; which is 
supported by World Health Organization (WHO) programs to combat the vitamin A deficiency epidemic 
                                                     
1 According to the International Monetary Fund, advanced economies comprise 65.8% of global nominal GDP and 52.1% 
of global GDP (PPP) in 2010/ IMF GDP data September 2011. 
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observed in low gross domestic product (GDP) countries.  The lower reference limit for serum vitamin A is 
clearly defined by the WHO as 0.7 umol/L (with clinical signs of deficiency at 0.35 umol/L) in children (79). 
The upper reference limit is less clearly defined with variations see between laboratories (80).  Analysis of this 
vitamin is almost exclusively by chromatographic separation techniques in laboratories worldwide (80, 81). 
Measurement of vitamin A, due to its low circulatory concentration and structural similarity of related 
analogues remains a challenge.  Most laboratories use high performance liquid chromatography with 
spectrophotometric detection to measure retinol (80, 82).  More recently mass spectrometry based detection 
methods have been reported (83-85).  Prior to sample analysis, the serum is prepared by liquid- liquid 
extraction techniques and includes a protein precipitation step to remove vitamin A from its binding protein.  
In all assays an internal standard is added to correct for losses in the preparation technique.  Commercial 
calibrators available for vitamin A are usually based on the National Institute for Standards and Technology 
(NIST) reference material; currently NIST SRM 968e. 
Whilst the NIST reference material is available and utilised by commercial calibrator manufacturers, 
agreement between laboratories for vitamin A results remains a problem (45).  This hinders harmonisation 
efforts in laboratory medicine and presents problems with the transportability of results.  In addition, currently 
there is no reference method available for retinol measurement (86).  However, liquid chromatography coupled 
with tandem mass spectrometry can be considered as a prospective nominee for a retinol measurement 
reference method which is able to meet precision and accuracy requirements (87).   
Further confounding the interpretation of vitamin A results is the problem that serum retinol levels do not 
always accurately reflect liver retinyl ester levels (i.e. the storage form of vitamin A) (88).  However, once 
vitamin A liver supply is diminished, circulatory levels will diminish too.  Hence, serum retinol concentration 
is still of value to dichotomise deficient from replete patients.  Retinol levels are also relevant for acute toxicity 
but have been reported to be of less value in isolation for chronic toxicity(89).  In addition, blood collection is 
the least invasive collection method to assess vitamin A status. 
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Vitamin D methods 
In general vitamin D refers to two major groups of metabolites; ergocalciferol (vitamin D2) and cholecalciferol 
(vitamin D3).  Ergocalciferol is basically driven from plant sources which are typically ingested in 
supplementation form. Predominantly cholecalciferol is the endogenous form of vitamin D, that is formed 
from conversion of 7-dehydrocholesterol to pre-vitamin D3 due to skin tissue UV exposure. Liver 
hydroxylation results in the 25-hydroxyvitamin form of both D2 and D3.  The bio-active form is generated by 
the kidney as; 1-alpha,25-dihydroxy for either D2 or D3 (24,25-(OH)2D) in combination with the insignificant 
24,25-(OH)2D3 analogue (90-92). 
Isomerisation of the vitamins D at position 3 of the structure results in a shift in the hydrogen atom at position 
three from the beta to alpha.  Whilst this isomerisation occurs with a number of the compounds in the vitamin 
D pathway, this process is significant for 25-OHD3, when the epi-25-OHD3 is produced.  Significant amounts 
of 3-epi have been observed in paediatric serum samples (93). Whilst 3epi-25-OHD3 is an inactive isomer of 
25-OHD3 it actively cross-reacts and causes overestimation in vitamin D determination (94).  3epi-
1,25(OH)2D3 may be formed from 3epi-25-OHD3 hydroxylation.  It is suggested that some of the biological 
activity of cholecalciferol may relate to 3epi-1,25(OH)2D3 (95).   
25-OH-Vitamin D3 has a higher circulatory concentration and longer half-life compare with1,25-(OH)2D3.  
25-OHD3 is considered the appropriate analyte to measure in commercial immunoassays (96).  The early 
measurement techniques of competitive binding protein and radio immunoassay techniques were developed to 
evaluate the circulating levels of vitamin D (97-101).  The advantage of these assays was the ability of 
providing equal recognition of 25-OHD2 and 25-OHD3.  Due to molecular structure similarity of the vitamin 
D analogues (Figure 1.4), as well as, non-specific interference of lipids and other circulatory metabolites; even 
under further sample solvent extraction pre-treatment, the specificity and sensitivity of immunoassay methods 
always has been critically questioned (68). 
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Figure 1.4.  LC-MS/MS-MRM chromatogram of 25-OHD analogues and retinol separation in serum sample; 25-OHD3-d3 is the deuterated analogue 
added to the sample for use as the internal standard.The x-axis represents the acquisition time (minute) and the y-axis is the ion counts.  Each of the 
vitamin D analogues are secosteroids i.e. steroid like chemical structure with the second ring opened.  Vitamin A, measured as retinol, is a cyclohexene 
ring attached to a tetra-isoprene chain.  (This figure is modified from reference (102)). 
 
Current immunoassay based technology for the measurement of 25-OHD is the most broadly used (47).  Many 
of these assays are now fully automated and do not require any sample pre-treatment e.g. extraction.  The 
antibodies employed between manufacturers target 25-OHD3 with varying cross reactivity with 25-OHD2 and 
other forms of vitamin D.  Overestimation of vitamin D status is the result of other vitamin D metabolites (such 
as; 24,25-(OH)2D, 25,26-(OH)2D, and  25,26-(OH)2D-26, 23-lactone) interference (103, 104).  Thus, 
measured vitamin D may be overestimated by 10-20% using either competitive binding or immunoassay 
techniques (105).  This problem of standardisation with established trueness for vitamin D is considered a 
major disadvantage of immunoassays. 
Liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS) system, potentially provides 
exceptional specificity in terms of different analytes separation and measurement.  LC-MS/MS based methods 
are superior to immunoassays for result interpretation (106, 107).  Utilising multiple reactions monitoring 
mode (MRM) delivers the greatest specificity, along with liquid chromatography separation of structurally 
related isomers separation.  However, in regard to vitamin D measurement, separation of the 25-OHD3 from 
   
Rosita Zakariaee Abkoo  
19 
 
epi-25-OHD3 is still challenging (108). With clear separation of the vitamin D epimers, LC-MSMS is generally 
considered the working “gold standard” method, for separation and quantitation of 25-OHD2 and 25-OHD3 
and epi- 25-OHD3 (109). 
3epi-25-OHD3 and 3epi-1,25-(OH)2D3 are product of 25-OHD3 and 1,25-(OH)2D3 epimerization (110).  3-
epi-25-OHD3 is biologically considered as an inactive cholecalciferol isomer, which is expressed more 
significantly in younger children rather than adults (13).  Since 3epi-25-OHD3 can cross-react and impede the 
routine measurement methods, still cannot be neglected with regard to vitamin D determination in both adults 
and children (93). 
Recently a more sensitive method utilising LC-MS/MS, has been described for 3epi-25-OHD3 measurement.  
Using this method enables us to separate and quantify 25-OHD2 and 25-OHD3, together with 25-OHD3 
epimer (3epi-25-OHD3) and its isobars (1-α-OHD3) as well as 7-a-OH-4-cholesten-3-1.  The assay sensitivity 
is equal to 0.62 nmol/L (0.25 ng/mL).  Thus, this developed assay can be considered as the very first, specific, 
reliable, reproducible and robust LC-MS/MS method for the accurate evaluation of Vitamin D (108).  
However, most of the chromatographic-mass spectrometry methods required a large sample volume.  Recently 
a two-dimensional ultra-performance liquid chromatography separation technique, coupled with tandem mass 
spectrometry (UPLC-MS/MS) is developed to quantitate 25-OHD3, epi-25-OHD3, and 25-OHD2, requiring a 
small sample volume (50µl) with 2 nmol/L (0.8 ng/ml) analytical sensitivity.  
Assessment of analytical methods due to low circulatory concentration and molecular similarities of the 
analyte, as well as the samples matrix effect caused by lipophilic nature of retinol and cholecalceferol are 
critical factors to consider  in fat soluble vitamins measurement (54).  Routine measurement methods, which 
are able to maintain clinically desirable and fit for purpose results in terms of sensitivity and specificity, are 
typically based on chromatography and mass spectrometry techniques.  Generally, the requirement of large 
amounts of blood sample and deep freeze storage condition are critical disadvantages of the methods currently 
available for population-based assessment of fat soluble vitamins (111).  However, few groups around the 
world have successfully derived vitamin D from Guthrie cards (111, 112) and none to our knowledge have 
optimized measurement of vitamin A from these sources. 
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Combined Vitamin A and D analysis 
Given the potential for vitamin A, in addition to vitamin D, to have a role in relation to the prevalence of food 
allergies, it would be ideal to measure these analytes simultaneously.  This would be advantageous in terms of 
laboratory efficiency plus also for the determination the pattern of vitamin A alongside vitamin D.  Any such 
method would still require clear separation of the carbon-3-epimer.  Recently, such a method has been 
presented (102) indicating that simultaneous measurement is possible.   
1.2.5 Alternative sample collection – Guthrie cards 
Classically, analytical methods for vitamin A and vitamin D utilise either serum or plasma separated from 
whole blood.  Mostly, in large population - based studies, especially involving children and infant participants, 
we face some uncertainties in terms of sample collection and storage.  Blood spot card (Guthrie) are suggested 
as the alternative sampling method (dried capillary blood spot) to store and undertake further blood analyses 
for large population-based studies.  These studies already utilise chromatography / mass spectrometry 
measurement methods (113-115).  It has been demonstrated that retinol, 25-OHD2 and 25-OHD3 are stable in 
dried blood spot card and measurable, utilising such LC-MS/MS method (112, 116). 
Several studies report a high level of agreement for the cholecalciferol and retinol concentrations between 
venous blood samples and Guthrie.  Venous blood samples have a higher haematocrit than capillary samples 
(117).  The implication of this is that dried blood sample may have a slightly lower serum fraction than samples 
derived from venepuncture.  Accordingly, it is expected that lower values for either retinol or cholecalciferol 
will be obtained from Guthrie compare to serum/plasma, unless adjusted for sample used for analysis.  
Therefore, in the estimation of vitamin D in dried blood samples such as Guthrie cards, assessment of blood 
spot size and haemoglobin concentration, needs to be taken into account (118). 
1.2.6 Where to from here? 
In summary, the increase of food allergy may be related to a concordant rise in prevalence of vitamin D 
insufficiency.  In addition, vitamin A is linked to immunity and it is plausible that it may also have a role in 
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the risk of developing food allergies.  However, further studies need to be conducted to investigate, the impact 
of vitamin A and D insufficiency or excess at birth on food allergy in early childhood.  Furthermore, 
understanding the adverse effects of a high prevalence of VDI in the general population is an important public 
health initiative, since VDI may be corrected with the simple and inexpensive intervention of dietary Vitamin 
D supplementation. 
Chromatographic separation coupled with mass spectrometric detection is considered the higher order methods 
for both vitamins.  These analytical methods should be fully validated for use in paediatric populations to 
ensure they are fit for their clinical purpose, including chromatographic separation of the 25-OHD3 from its 
epimer.  To utilise blood spots for the investigation of these vitamins at birth, the LC-MS/MS methods will 
require further optimisation in order to evaluate the small volume samples driven from dried blood spot cards. 
Finally, it is essential to provide the integral population data regarding vitamin D and other fat-soluble vitamins 
such as vitamin A levels to determine if the hypothesized relationships do exist in early life.” 
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1.3  Advantages and challenges of dried blood spot analysis by mass 
spectrometry across the total testing process  
This section has been peer reviewed and published with contribution of other co-authors as a review paper 
(10). My contribution to this study and subsequent publication was included; developing the concept for the 
study in conjunction with my senior supervisor (RG), performing the literature search / study, collecting data, 
analysis and interpretation of data, writing the first draft of the publication and reviewing and incorporating all 
suggestions from the co-authors. 
1.3.1 Introduction  
“A century ago, for the very first time, Ivar Bang described a dried blood matrix as an unconventional sampling 
method (119).  Later, Robert Guthrie in 1963 introduced the dried blood spot (DBS) technique for screening.  
Guthrie application of the dried blood spot, and his personal crusade to utilise this approach to screen 
intellectually disabled children, heralded the introduction of newborn blood spot screening (NBS).  Although 
the particular assay is now defunct, the term “Guthrie card” remains to colloquially describe the DBS collection 
technique which still underpins today’s newborn screening programs worldwide (120).  
The original semi-quantitative bacterial inhibition test developed by Guthrie to screen for phenylketonuria 
(PKU) was highly sensitive but had a low analytical throughput (121).  Through the introduction of advanced 
analytical techniques, that expanded testing options and improved throughput, the scope of newborn screening 
blood spot sample applications were extended, this included screening applications for congenital 
hypothyroidism and cystic fibrosis in many centres (122).  Further to this expansion was the introduction of 
tandem mass spectrometry for newborn screening DBS analysis in 1990s (123). 
Mass spectrometry is now the most common technique reported in the literature for dried blood spot analysis 
(124-127).  DBS analysis offers the advantage of collecting a small sample volume, which is easily transported.  
However, this also means that the concentration of the target analyte is potentially quite low (e.g. less than 1 
ng/L) which requires a sensitive and specific assay for detection and quantification.  These considerations, 
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coupled with the expansion of mass spectrometry into clinical laboratories, have led to a surge in the utilisation 
of this sampling method outside of the scope of newborn screening in the published literature.  
Clinicians and researchers have become optimistic about the potential applications of dried blood spot-based 
mass spectrometry applications (DBS-MS) and it has been used for a range of clinical utilities including drug 
toxicology and sports doping screening.  Scientists and technical analysts on the other hand face challenges 
regarding how to ensure optimal sensitivity, reproducibility and overall accuracy of DBS quantification.  In 
this review, we aim to bring together clinical and analytical facets to discuss the advantages and current 
challenges of non-newborn screening applications of DBS quantification by MS. 
To address these aims, we performed a key word search of PubMed and MEDLINE online databases in 
conjunction with individual manual searches to gather information.  Keywords for the initial search included; 
“blood spot” and “mass spectrometry”; while excluding “newborn”; and “neonate”.  In addition, databases 
were restricted to English language and human specific.  No time period limit was applied.  As a result of this 
selection criteria, 191 references were identified for review.  For presentation, this information is divided into 
clinical applications and analytical considerations across the total testing process. It is not our intention in this 
review to highlight all analytical aspects related to quality MS application (as this has been covered extensively 
elsewhere) but rather to address the analytical aspects pertinent to the DBS matrix. 
1.3.2 Clinical Applications  
The first application of MS to DBS analysis was reported 40 years ago (in 1976) for fatty acid determination 
by direct chemical ionisation (128).  By the mid-1980s, when gas chromatography (GC) was the technique of 
choice for separation and analysis of volatile small molecules, derivatised fatty acids were measured from DBS 
samples using GC-MS (129).  In 1990s, when electrospray ionisation became commercially available, liquid 
chromatography - tandem mass spectrometry (LC-MS/MS) began to be incorporated into the analytical tools 
for newborn screening laboratories, leading to the significant expansion of screening applications with 
phenylalanine and tyrosine being two of the early markers (123, 130).  Today DBS-MS applications are the 
workhorse for many NBS laboratories worldwide; and additional tests are continually being added to the 
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repertoire.  Outside of NBS, an epidemiological study analysing benzoylecgonine was the first reported DBS-
MS application (131). 
Now, many potentially reliable and compatible MS detection methods are available across a wide range of 
disciplines (132).  Our literature search identified 97 references encompassing 121 distinct biomarkers 
determined from DBS samples utilising MS technology beyond its application in NBS.  Notably, the role of 
DBS analysis by MS now encompasses translational research and clinical diagnostic analytes in the areas of 
therapeutic drug monitoring (TDM); pharmakinetics (PK); toxicokinetics (TK); forensic; endocrinology and 
metabolism; and other areas of bio-analysis.  Table 1 provides a list of these biomarkers. 
Therapeutic and toxicological drug analysis are the most extensively reported DBS-MS applications in the 
literature (Table 1).  These DBS-MS applications, (encompassing both LC-MS/MS and GC-MS techniques) 
are particularly fit for population-based studies of multiple biomarkers (133, 134).  Similarly, DBS-MS 
applications are now applied in sport related doping tests for the detection of anabolic, ergogenic and masking 
agents (135-137). 
  Table 1.1 The list of biomarkers determined from DBS samples utilising MS technology, beyond its application in newborn screening studies. 
Table 1.1.a) The list of abbreviations    
2D: two dimensional  
AnalTech: analytical technique    
APTDCI-MS: atmospheric pressure thermal desorption chemical ionisation Mass spectrometry 
D: day      
DAA: drug abuse athletics    
Dab: drug abuse     
Dad: drug adherence      
ESI: electrospray ionisation    
FIA-ESI-MS/MS: flow Injection Analysis-electrospray ionisation tandem mass spectrometry 
FT-ICR-MS: fourier transform ion cyclotron resonance mass spectrometry 
GC: gas chromatography    
GC-HRMS: gas chromatography–high resolution mass spectrometry 
HILIC-MS/MS: hydrophilic Interaction chromatography tandem mass spectrometry 
ID:  illicit drug     
IDES-MS/MS: isotope-dilution electrospray tandem mass spectrometry 
LC: liquid chromatography    
LC-HRMS: Liquid chromatography–high resolution mass spectrometry 
LLOQ: lower limit of quantitation     
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Table 1.1.a) The list of abbreviations cont. 
M: month      
MetV: method validation    
MI: metabolic intermediate  
MS: mass spectrometry 
NR: not reported  
PD: pharmaceutical drugs    
PS-MS: paper spray mass spectrometry     
PK: pharmakinetics     
Ref: reference     
RepU: reporting unit     
Stab: stability   
TDM: therapeutic drug monitoring    
TK: toxicokinetic     
TLC-MS: thin-layer chromatography mass spectrometry  
W: week 
Y: yes     
 
Table 1.1.b) List of biomarkers 
 
No Analyte AnalTech LLOQ RepU Stab MetV Ref 
Metabolic Intermediate 
1 Acylcarnitines  
APTDCI-MS/MS NR 
µmol/L 
NR NR (138) 
ESI-MS/MS NR NR NR (139) 
2 Adrenal steroids LC-ESI-MS/MS 0.75-6.3 nmol/L NR Y (140) 
3 Amino acids profile LC-MS/MS 0.25 μmol/L NR Y (141) 
4 Bile Acids ESI-MS/MS 1 μmol/L 10d Y (142) 
5 Carnitine 
IDES-MS/MS 1 μmol/L NR Y (143) 
ESI-MS/MS NR μmol/L NR NR (139, 144) 
6 Creatine FIA-ESI-MS/MS 0.25-3.57 μmol/L NR Y (145) 
7 Creatinine LC-MS/MS 116 μmol/L 7d Y (146-148) 
8 CYP450enzymes LC-MS/MS 0.1 ng/ml 4w Y (149) 
9 Cystathionine LC-MS/MS 0.1-2.5 μmol/L 14d Y (150) 
10 F2-isoprostanes LC-MS/MS 6  pg/mL NR Y (151) 
11 Gamma-butyrobetaine ESI-MS/MS NR μmol/L NR NR (144) 
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Table 1.1.b) List of biomarkers cont. 
No Analyte AnalTech LLOQ RepU Stab MetV Ref 
12 Glucosylceramide LC-MS/MS NR μg/mL NR Y (152) 
13 Guanidinoacetate  FIA-ESI-MS/MS 0.25-3.57 μmol/L NR Y (145) 
14 Haemoglobin peptides LC-MS/MS NR Ratio NR NR (153) 
15 Haemoglobin variants MS NR NR NR NR (154) 
16 Haemoglobins α- and β-chains FT-ICR-MS NR % NR NR (155) 
17 Homocysteine 
LC-MS/MS 1 μmol/L 3m Y (156) 
LC-MS/MS 0.1-2.5 μmol/L 14d Y (150) 
18 Insulin-like growth factor-1 LC-MS/MS 50 ng/ml 8d Y (137) 
19 Methotrexate polyglutamates LC-MS/MS 5 nmol/L NR Y (157) 
20 Methylmalonic acid LC-MS/MS 10 nmol/L 8w Y (158) 
21 Methylmalonyl-carnitine LC-MS/MS 0.025 μmol/L NR Y (159) 
22 Nucleoside profile  LC-MS/MS NR μmol/L NR Y (160) 
23 Orotic acid HILIC-MS/MS 0.18  μmol/L NR Y (161) 
24 Protein profile LC-MS/MS NR NR NR NR (162) 
25 Proteomics LC-MS/MS NR μmol/L NR NR (163) 
26 Peptide profile LC-MS/MS NR μg/ml 10d NR (164) 
27 Stroles APTDCI-MS NR Ratio NR NR (138, 165) 
28 Succinylacetone 
LC-MS/MS 0.67 μmol/L NR Y (166) 
LC-MS/MS 0.25 μmol/L NR Y (141) 
29 Succinyl-carnitine LC-MS/MS 0.025 μmol/L NR Y (159) 
30 Sulfatides LC-MS/MS NR μg/mL NR NR (124) 
31 Vitamin D  LC-MS/MS 4.8 nmol/L >20y Y (167-171) 
Pharmaceutical Drugs 
32 Acetaminophen (Paracetamol) 
LC-MS/MS 50 ng/ml NR NR (172) 
PS-MS 0.25-0.75 ng/ml NR NR (125) 
TLC-MS 5.0-50 ng/ml NA NR (173) 
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Table 1.1.b) List of biomarkers cont. 
No Analyte AnalTech LLOQ RepU Stab MetV Ref 
33 Amitriptyline 
PS-MS 0.25-0.75 ng/ml NR NR (125) 
LC-MS/MS 20 μg/L 1m Y (174) 
34 Amprenavir LC–MS 11.7 ng/ml 3m Y (175) 
35 Paroxetine 
GC-MS/MS 1.0-20 ng/ml 30d Y (176) 
LC–MS 11.7 ng/ml 3m Y (175) 
36 Atazanavir LC-MS/MS 0.1 mg/L 7d Y (177) 
37 Atenolol LC-HRMS 25 ng/ml 2m Y (178) 
38 Benzodiazepines LC-MS/MS NR ng/mL NR NR (179) 
39 Benzethonium chloride 
TLC-MS 5.0-50 ng/ml NR NR (173) 
PS-MS 0.25-0.75 ng/ml NR NR (125) 
40 Bisoprolol LC-HRMS 0.5-5.0 ng/ml 12w Y (180) 
41 Bosentan LC-MS/MS 2 ng/ml 5w Y (181) 
42 Busulfan LC-MS/MS 50 ng/ml NR Y (182) 
43 Citalopram PS-MS 0.25-0.75 ng/ml NR NR (125) 
44 Clarithromycin LC-MS/MS 0.05-0.15 mg/L 2m Y (183) 
45 Clomipramine LC-MS/MS 20 μg/L 1m Y (174) 
46 Cyclosporin A LC-MS/MS 116 μmol/L 7d Y 
(146, 148, 
184-186) 
47 Darunavir 
LC-MS/MS 0.1 mg/L 7d Y (187) 
LC–MS 11.7 ng/ml 3m Y (175) 
48 Dasatinib LC-MS/MS 2.5-50 μg/L 28d Y (188) 
49 Dexamethasone LC-MS 15 ng/ml 28d Y (189) 
50 Efavirenz 
LC-MS/MS 41-102 ng/ml NR N (175) 
LC-MS/MS 0.1 mg/L 7d Y (187) 
51 Emtricitabine LC-MS/MS 2.5 ng/ml 6 d Y (190) 
52 Endoxifen LC-MS/MS 0.5 ng/ml 20d Y (127) 
53 Ertapenem LC-MS/MS 0.2 mg/L 30d Y (191) 
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Table 1.1.b) List of biomarkers cont. 
No Analyte AnalTech LLOQ RepU Stab MetV Ref 
54 Etravirine 
LC-MS/MS 50 ng/ml 7d Y (192) 
LC–MS 11.7 ng/ml 3m Y (175) 
55 Everolimus LC-MS/MS 116 μmol/L 
7d 
Y 
(146, 148, 
184, 186, 
193) 
56 Fluoxetine GC-MS/MS 1.0-20 ng/ml 30d Y (176) 
57 Flurbiprofen LC-MS/MS 0.35-250 ng/ml 5d Y (194) 
58 Gamma-hydroxybutyric acid GC-MS 1 μg/ml 15d Y (195, 196) 
59 HIV protease inhibitors LC-MS/MS 0.025-10 μg/ml 7d Y (197) 
60 Ibuprofen TLC-MS 5.0-50 ng/ml NR NR (173) 
61 Imatinib LC-MS/MS 20.5-50 μg/L 28d Y (188) 
62 Imipramine LC-MS/MS 20 μg/L 1m Y (174) 
63 Linezolid LC-MS/MS 0.4 mg/L 1m Y (198) 
64 Loratadine LC-MS/MS 0.2 ng/ml 271d Y (199) 
65 lopinavir 
LC–MS/MS 0.1 mg/L 7d Y (187) 
LC-MS 11.7 ng/ml 3m Y (175) 
66 Losartan LC-MS/MS 1 ng/ml 30d Y (200) 
67 Mefloquine LC-MS/MS 2.5 nmol/L 3w Y (201) 
68 Midazolam LC-MS/MS 0.35-250 ng/ml 5d Y (194) 
69 MK-1775 (Wee1 inhibitor) HILIC-MS/MS 2 ng/ml 14m Y (202) 
70 N-desmethyltamoxifen LC-MS/MS 0.5 ng/ml 20d Y (127) 
71 Nevirapine 
LC-MS/MS 41.102 ng/ml NR N (187) 
LC-MS/MS 0.1 mg/L 7d Y (203) 
72 Nilotinib LC-MS/MS 2.5-50 μg/L 28d Y (188) 
73 NIM811 (cyclophilin inhibitor) LC-MS/MS 10 ng/ml 24h Y (204) 
74 Nitisinone 
LC-MS/MS 0.1 μmol/L NR Y (205) 
LC-MS/MS 0.25 μmol/L NR Y (141) 
75 Norfluoxetine GC-MS/MS 1.0-20 ng/ml 30d Y (176) 
76 Nortriptyline LC-MS/MS 20 μg/L 1m Y (174) 
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Table 1.1.b) List of biomarkers cont. 
No Analyte AnalTech LLOQ RepU Stab MetV Ref 
77 O-desmethylvenlafaxine LC-MS/MS 20 μg/L NR Y (206) 
78 Omeprazole  LC-MS/MS 0.35-250 ng/ml 5d Y (194) 
79 Oseltamivir LC-MS/MS 5 ng/mL 7d Y (207) 
80 Paclitaxel 
LC-MS/MS 0.2 ng/ml 45d Y (208) 
PS-MS 0.25-0.75 ng/ml NR NR (125) 
81 Paroxetine 
GC-MS/MS 1.0-20 ng/ml 30d Y (176) 
LC–MS 11.7 ng/ml 3m Y (175) 
82 Phenobarbital LC-MS/MS 1 mg/L 10d Y (209) 
83 Phenytoin LC-MS/MS 0.3 mg/L 30d Y (210) 
84 Posaconazole LC-MS/MS 5 ng/ml 13d Y (211) 
85 Proguanil 
TLC-MS 5.0-50 ng/ml NR NR (173) 
PS-MS 0.25-0.75 ng/ml NR NR (125) 
86 Propranolol LC-MS/MS 2.5 μg/L 30d Y (212) 
87 Raltegravir LC-MS/MS 0.125 μg/L 7d Y (213) 
88 Ramipril  LC-HRMS 0.5-5.0 ng/ml 12w Y (180) 
89 Reboxetine GC-MS/MS 1.0-20 ng/ml 30d Y (176) 
90 Ribavirin LC-MS/MS 0.05 ng/ml 140d Y (214) 
91 Rifampicin LC-MS/MS 0.05-0.15 mg/L 2m Y (183) 
92 Rifapentine LC-MS/MS 51 ng/ml 11w Y (215) 
93 Rifaximin LC-MS 0.1 ng/ml 30d Y (216) 
94 Ritonavir LC-MS 11.7 ng/ml 3m Y (175) 
95 Rosiglitazone LC-MS/MS 0.35-250 ng/ml 5d Y (194) 
96 Saquinavir LC–MS 11.7 ng/ml 3m Y (175) 
97 Simvastatin 
LC-HRMS 0.5-5.0 ng/ml 12w Y (180) 
TLC-MS 5.0-50 ng/ml NR NR (173) 
PS-MS 0.25-0.75 ng/ml NR NR (125) 
98 Sirolimus LC-MS/MS 116 μmol/L 
7d 
Y 
(146, 148, 
184, 186) 
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Table 1.1.b) List of biomarkers cont. 
No Analyte AnalTech LLOQ RepU Stab MetV Ref 
99 Sitamaquine 
TLC-MS 5.0-50 ng/ml NR NR (173) 
PS-MS 0.25-0.75 ng/ml NR NR (125) 
100 Sunitinib PS-MS 0.25-0.75 ng/ml NR NR (125) 
101 Tacrolimus LC-MS/MS 1 μg/L 
20d 
Y 
(126, 146-
148, 184, 
186, 217, 
218) 
102 Tamoxifen LC-MS/MS 0.5 ng/ml 20d Y (127) 
103 Tenofovir  LC-MS/MS 2.5 ng/ml 6d Y (190) 
104 Topiramate LC-MS/MS 10 μg/ml 194d Y (219) 
105 Valproic acid 
LC-MS 10 μmol/L 42d Y (220) 
GC-MS 5 μmol/L 21d Y (221) 
106 Vemurafenib LC-MS/MS 1 μg/ml NR Y (222) 
107 Venlafaxine  LC-MS/MS 20 μg/L NR Y (206) 
108 4-nitrophthalic acid TLC-MS 5.0-50 ng/ml NR NR (173) 
109 4-hydroxytamoxifen LC-MS/MS 0.5 ng/ml 20d Y (127) 
Illicit Drug 
110 Amphetamines 
ESI-MS/MS & GC-
MS 
2.3-11 ng/ml 
NR 
Y (223) 
2D-LC-MS/MS 5 ng/ml 6 m Y (224) 
111 Caffeine LC-MS/MS 0.35-250 ng/ml 5d Y (194) 
112 Cocainics  
ESI-MS/MS & GC-
MS 
2.3-11 ng/ml 
NR 
Y (223) 
2D-LC-MS/MS 5 ng/ml 6 m Y (224) 
113 Novel psychoactive substances  LC-ESI-MS/MS 1.0-10 ng/ml 1w Y (225) 
114 Opiates 
2D-LC-MS/MS 5 ng/ml 6m Y (224) 
ESI-MS/MS & GC-
MS 
2.3-11 ng/ml 
NR 
Y (223) 
115 Δ9-tetrahydrocannabinol LC-MS/MS 100 ng/ml 3m Y (226) 
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Irrespective of the clinical application, there are specific analytical considerations.  Several parameters can 
impact on the accuracy of DBS measurement (128).  The following sections of this review will focus on 
important considerations for DBS-MS quantification in the pre-analytical, analytical and post-analytical 
phases. 
1.3.3 Pre-analytical 
The pre-analytical phase of testing incorporates the processes of 1) blood collection from the patient, 2) its 
application onto the filter paper, 3) drying and 4) transport and storage of the DBS sample.  In addition to the 
pre-analytical variables identified for routine blood collection, DBS faces additional challenges, including the 
quality of DBS sample (which is subject to sample collection and spotting variations), choice of collection 
card, collection (bleeding and blotting), transport and storage.  Moreover, biological factors such as sample 
viscosity, haematocrit level and the nature of the target analyte, may lead to variation in sample quality.  To 
sustain the quality management of the pre-analytical phase, there are defined recommendations for positive 
patient identification (231), sample collection of capillary blood (232), choice of filter paper (233), application 
of the sample onto the filter paper (234) and shipment of the DBS sample (235).  An example of a standardised 
protocol for DBS pre-analytical processes is provided in Table 1.2.  
Table 1.1.b) List of biomarkers cont. 
No Analyte AnalTech LLOQ RepU Stab MetV Ref 
Drug Abuse Athletics 
116 Anabolic steroid esters LC-MS/MS 0.1 ng/ml 28d Y (136) 
117 Centchroman metabolites LC-MS/MS 1.5-4.5 ng/ml 3m Y (227) 
118 Testosterone glucuronides GC-MS NR pg/mL NR NR (135) 
119 Therapeutic proteins LC-MS NR ng/mL 2w NR (228) 
Chemical Exposure 
120 Benzene oxide-Hb GC-MS NR pmol/g NR NR (229) 
121 Polybrominated diphenylethers GC-HRMS 0.05 ng/ml 30d Y (230) 
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Sample Collection 
The sample collection technique is important for accurate analysis of the DBS.  Capillary blood collection is a 
common approach, as it usually requires less sample volume and is more patient friendly, compared to 
venepuncture.  Both the World Health Organization (WHO) and the United Nations International Children's 
Emergency Fund (UNICEF) certify the quality of DBS samples and maintain healthcare workers safety 
through the provision of guidance manuals and standard operating procedures for DBS sample collection (236, 
237).  Due to the likelihood of significant sources of artefact formation, specific DBS collection training points 
are highlighted, including the choice of prick point, lancet type/size, prick depth, pressure rate during blood 
drop collection, dropping size/speed consistency, uniformity of sample diffusion on the collection card and 
DBS contamination due to extended air or light exposure during the drying process.  Importantly, WHO 
highlight that “working with DBS, whole blood or plasma requires the same biohazard safety precautions as 
whole blood” (237). 
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Table1. 2. Example dried blood spot sample collection and transport protocol. 
 
 
  Record the following information in the logbook; a) Participants first name and surname, b) Participants date of birth, c) 
Study number, d) Card bar code number, e) Date of collection, f) Any other relevant information   
6. 
7. 
 Allow samples to air dry for a minimum of 2 hours (longer may needed in humid or cold environment) 
  Store in Biohazard / Specimen Transport Bag in dry place at room temperature until shipment to the destination lab 
8. 
  From a capillary collection, allow one drop of blood to penetrate each position of the filter paper. This should be one large 
drop of blood approx. 20µl 
2. 
3. 
  Repeat for all positions  
4. 
  Record at least two (prefer 3) identifier on the card (e.g. Name, date of birth, study number, Health record number) 
5. 
  Record sample collection date and time 
1. 
 Positive patient identification  
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10. 
  Attach a copy of the import (shipping) permit to the outside of the package 
11. 
  Attach a copy of a “manufacturer declaration” signed on your letterhead to the outside of the package. Use the following 
wording for the manufacturer's declaration;  
  “Manufacturer's declaration 
   To Whom It May Concern: 
    The shipment xxx (shipping number) xxx from the Department xxx (your location) xxx contains Human blood. 
    This item is covered in Permit xxx (permit number) xxx under condition number xxx (condition number) xxx. 
    This material is non-toxic, non-infectious, and is intended for clinical laboratory studies. 
    Yours Sincerely,   Add your signature line here”  
12.  Ensure that the samples are packaged according to the required standards of shipping bloods (secondary container / 
absorbent material etc). 
  Label the package with specific destination address. The following details should be used in association with the Permit xxx 
(permit number) xxx; 
  “Attention: Contact person’s name 
     Address: Destination lab postal address 
     Phone: Destination lab / contact person’s contact number including area code 
     Email: Contact person’s email address” 
13. 
  Send an email to Destination lab contact person to advice of shipment  14. 
 Send dried blood spot sample cards following the protocol to the destination lab with a copy of the logbook entries 
9. 
   
Rosita Zakariaee Abkoo  35 
 
Selection of filter paper 
Collection of DBS samples is onto one of two types of untreated solid support: pure cotton filter paper 
and glass microfiber paper.  The choice of paper, including its thickness and density, influences the rate 
of adsorption and dispersion.  As an example, the rate of membrane non-specific analyte adsorption is 
reduced in glass micro-fibre paper (63).  Accordingly, dissimilarities in these solid supports may induce 
variations in the DBS sample attributes leading to potential differences in analyte stability, 
commutability, volume per area, and analytical effects (covered later in this review) (238).  These DBS 
specific pre-analytical variables require standardisation and the Clinical and Laboratory Standards 
Institute (CLSI) offer a guideline NBS01-6 to support DBS collection (233).   
The CLSI guideline recommends the use of two specific collection cards: the Whatman 903 and 
Ahlstrom 226.  Both filter papers are approved by the Food and Drug Administration (FDA), Newborn 
Screening Quality Assurance Program (NSQAP) and also the Centers for Disease Control and 
Prevention (CDC) (234).   
Sample application to filter paper 
Both the Whatman 903 and Ahlstrom 226 cards have a target collection area printed on the paper to 
indicate and ensure the 50-75 µl sample volume limits (234).  The whole blood drop should be spotted 
onto the mid-point of the collection area to allow for radial dispersion to the designated edge of the 
spot.  This lateral distribution is uneven; as clearly evaluated by autoradiography (239).  Usually, the 
concentration of biomarkers is decreased along the edge of the DBS, while the middle is affected by 
the volcano effect (paper chromatography effect) and  occasionally a speckled pattern (240).  The 
physical characteristics of the DBS sample is also potentially affected by the patient’s haemoglobin and 
haematocrit level; which also influences the spreading area of the blotted blood.   
Variations in haematocrit (Hct)/haemoglobin (Hb) will affect the relative plasma percentage of the spot.  
This is important for analytes predominately found in serum / plasma, as the relative amount of plasma 
in a disk punched from different spots can vary; and particularly exaggerated when the Hct is extremely 
   
Rosita Zakariaee Abkoo  36 
 
high or low (241).  Whole blood samples with a higher Hct tend to distribute to a lesser extent across 
the filter paper (i.e. smaller blood spot diameter), and consequently the target analyte diffusion distance 
is shorter.  The inverse applies for lower Hcts.  As a result, the determined concentration compared with 
the “normal” Hct sample would be over or under estimated due to the change in the analyte’s 
distribution and infusion pattern across the blood spot (242, 243).  Hence, for accurate quantitation, 
ideally the patient’s Hct needs to be determined, by either a separate capillary drop / sample collected 
at the time of the DBS collection or directly from the DBS card. Figure 1.5 provides a visual 
demonstration of the effect of Hct on diffusion. 
 
 
 
 
Figure 1.5. Whole blood samples with different levels of Hb/Hct do not diffuse similarly on the collection card; for a fixed punch size; a high 
level of Hb/Hct results a higher amount of blood on the punch thus the measured target analyte is falsely elevated. This figure is a visual 
demonstration of the effect of haematocrit on diffusion. 
Analytes stability (storage and transport condition) 
DBS samples should be allowed to completely dry before transport and/or storage.  It has been 
demonstrated that rapid drying and storage in low humidity conditions improves the stability of DBS 
samples (134).  The length of time required for air-drying will depend on the local environmental 
conditions such as air conditioning, room temperature and humidity.  DBS drying usually takes from 
90 minutes to approximately 4 hours and ideally, the DBS samples should not be left exposed to direct 
strong sunlight during this period. 
The appropriately dried DBS sample can then be placed in an envelope or similar container for the 
logistically simple and cost effective transport process (134).  As the low volume of the dried specimen 
significantly reduces the risk of infection transmission compared to the other biological samples (244, 
245), it can be transported in small lightweight packages that do not require temperature regulation.  
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This negates the often cumbersome and expensive processes associated with transport of liquid 
biological samples (134).  Once the DBS samples are received at the destination, the size and properties 
of the DBS samples make storage relatively easy as minimal space is required; and they can often be 
stored at room temperature. 
The stability of the DBS sample does require consideration, as the relevant stability for different 
analytes on DBS is quite variable.  The stability of numerous blood biomarkers on blotting paper at 
room temperature has been confirmed for a minimum of 7 days (63), several months (pharmaceutical 
drugs, opiates and nucleic acids) (246, 247), and even greater than 20 years (vitamin D) (167).  Freezing 
at -20 oC or -80 oC has been shown to further increase the stability of DBS samples; often extending the 
stability from days / months to years (248-250).  In addition, some reports show that some metabolites 
have better stability in the form of card-blotted whole blood compared to plasma (251). 
Despite these exciting reports of long-term stability, there are many recognized potential influences, in 
addition to storage time, which could affect stability; including the type of filter paper, light exposure, 
temperature, humidity as well as the nature of the target analyte.  Examples of changes to the collection 
process to improve stability include: 1) rapidly lowering the pH of the spotted blood sample to extend 
the stability time of some structurally unstable drugs which degrade during the drying process; and 2) 
use of  EDTA as an anticoagulant to preserve and stabilise DBS samples for enzyme activity 
determination (252, 253).  As a result of variations in stability, analyte specific protocols need to be 
administered for the collection and storage of DBS samples.  Table1.1 provides a guide to the stability 
of DBS samples for different analytes found in the literature. 
1.3.4 Analytical considerations 
The solid form of the DBS sample is not compatible with the most analytical techniques and requires 
elution of the sample from the filter paper.  Accordingly, the testing process commonly includes three 
main stages: primary sample preparation, sample pre-treatment and sample analysis.  Analysis can be 
further divided into chromatographic and MS separation and detection.  In addition, the overall quality 
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of the analytical process needs consideration.  In this section of the review, we will discuss each of these 
aspects in turn.  Figure 1.8 provides a general summary of the DBS-MS process. 
 
Primary sample preparation 
The punch  
Sample preparation usually starts with deportation of a segment of the DBS from the blotter using a 
manual or automated puncher.  Commonly, to minimise the assay bias due to punch location, it is 
Collection 
Figure 1.6. Summary of the DBS-MS process 
   
Rosita Zakariaee Abkoo  39 
 
recommended to take the DBS punch either from the centre or close to the outer edge, consistently 
(254). The punch size may vary from 3mm punch size to 6mm or whole spot, depending on the method.   
Techniques have been developed to overcome the haematocrit impact issue and minimize the labour 
associated with the sample preparation process. These are a number of strategies to overcome the 
haematocrit effect: 1) Pre-cut DBS and perforated DBS techniques are introduced in DBS handling 
procedures to recover the haematocrit effect and eliminate the chance of carry-over between the 
punches. 2) To disregard the haematocrit effect and improve the assay bias, blotting of less whole blood 
volume (e.g. 10 µl) on the smaller pre-cut disk (3 or 6mm)  and analysis of the whole disk is suggested 
(255-258). 3) Similarly, a two-layered polymeric membrane has been utilised to form a separated 
secondary dried plasma spot from the whole blood sample to be analysed following  solid phase 
extraction (259).  Recently, a novel collection card has been developed for DBS sampling, which 
generates a volumetric plasma sample (2.5 or 5.0 µL) from a non-volumetric application of whole blood 
sample. The purported advantages of this collection matrix includes enhanced assay reproducibility and 
selectivity, with a simplified sample extraction procedure and elimination of the haematocrit effect 
(260). 
Elution   
For analysis, the analyte of interest firstly requires elution out of the filter paper along with the whole 
blood matrix by using the appropriate elution and extractor buffers.  The choice of extractor materials 
may vary from one compound to the other.  As an example pure methanol is considered as a generic 
solvent for drugs of abuse extraction of the blood spot sample (261).  Water on the other hand impairs 
the interaction between cellulose and the target analyte’s hydroxyl groups. Hence, the partial addition 
of water prior to the organic extraction advances the efficiency in certain cases (203).  The efficient 
elution of analytes from the DBS sample is challenging and there is always a chance of analyte loss due 
to ineffective extraction; poor sample elution is due to either incomplete extraction or analyte 
degradation.  To achieve effective analyte recovery with maximum extraction efficiency, the extraction 
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parameters, including extractor solution mix, duration, temperature and application of additional 
solvation energy (sonication), need to be optimised for each individual target metabolite (191, 241).   
Sample pre-treatment 
Depending on the molecular characterisation of the target compound, various sample preparation 
approaches have been suggested. These sample pre-treatment methods may be incorporated as a 
combination with each other or may be used in isolation depending on the analytical process developed.  
These techniques include the classic sample preparation process of 1) protein precipitation (PPT); 2) 
liquid-liquid extraction (LLE); 3) solid phase extraction (SPE); 4) supported liquid extraction (SLE); 
and / or 5) derivatisation.   
Extraction and derivatisation procedures applied manually (or offline) are considerably time consuming 
and laborious.  Whilst derivatisation is not required for many plasma-based analytes using LC-MS/MS, 
it is required for many DBS analysis to improve the sensitivity; offsetting the small sample volume.  
However, as the derivatisation process prolongs the overall analysis time, it is considered to be a 
limiting factor. It has been a driver for the development of on-line extraction techniques to facilitate the 
DBS sample pre-analytical treatment.   
Automation of sample preparation directly coupled with the LC-MS/MS system has been introduced to 
improve turn-around time and run cost. PPT is a simple and popular method for automation that has 
been utilised for therapeutic drug monitoring (262).  However, following a single PPT procedure, salts 
and other endogenous analytes are still present which may cause ion alteration in the MS process. SPE-
LC-MS/MS set-up is designed to facilitate online sample desorption. This technique has turned to a 
time and cost effective method for DBS analysis (247, 263-266). Compared to PPT, SPE presents an 
improved sample clean-up (218).  There are specific challenges with on-line extraction approaches, in 
comparison with the off-line extraction methods.  The significant source of assay bias includes; non-
homogenous mixture of internal standard with the analyte in the extract, sample dilution then band 
broadening and in chromatography separation; inadequate focusing of the extract onto the analytical 
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column (128).  Accordingly, as part of the method development process, certain strategies are required 
to eliminate these issues. 
Technology has been developed that allows for the direct sampling of the DBS, without the need for a 
change to liquid or elution. As it is described by the manufacturer, “Liquid Micro-junction Surface 
Sampling Probes (LMJ-SSP) are self-aspirating devices where liquid is pumped to and aspirated away 
from a surface of interest to a mass spectrometer for integrated extraction and ionisation” (267). By 
utilising the LMJ-SSP technology, the analyte of interest could be directly extracted from the different 
surfaces and detected by a mass spectrometer in a short time frame with minimum sample handling 
(268). The  LMJ-SSP device coupled with the MS has been utilised for the determination of proteins in 
the DBS sample (269), direct tandem mass spectrometer for detection of haemoglobin (154), as well as 
therapeutic drugs (270, 271). Likewise, novel “on spot” direct derivatisation approaches provide a time 
and cost effective alternative sample preparation procedure; a technique introduced to determine 
thiorphan drug (196, 272).   
Sample analysis 
The choice of GC or LC instruments depends on the required sensitivity and target analyte 
characteristics.  Despite the fact that the GC-MS provides selectivity, sensitivity and robustness for 
many DBS analytes, the literature demonstrates that, it is not as popular as LC-MS/MS (Table1.1).  This 
is likely to be due to the improved specificity and sensitivity afforded by LC-MS/MS for blood spot 
analysis; associated with a significantly faster and usually more cost effective process compared to GC-
MS (273, 274).   
By introduction of the two-dimensional chromatography (2D-C) tools (applicable on both GC and LC), 
the separation efficiency, analytical sensitivity, quantitation accuracy and precision have been 
improved.  This 2D-C process has reduced the DBS matrix and carry-over effects, with reports 
suggesting improved imprecision and bias (170, 275).  With the further addition of on-line extraction 
joined to the 2D-C system, sensitivity and specificity is maximised when coupled with either a triple-
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quadrupole tandem mass spectrometer or a high-resolution quadrupole time of flight mass spectrometry 
(QTOF-MS) (218, 276). 
The advances in ion source technology have enhanced sensitivity for both polar and non-polar analytes 
from DBS samples (277-279).  Selective / multiple reaction monitoring (SRM / MRM) modes in 
MS/MS detection, focusing on specific transitions, have advanced the assay specificity remarkably 
along with improving linearity and limits of detection (128, 280).  GC-MS analytical techniques often 
offer a higher separating power and efficient reproducibility compared with LC-MS.  Accordingly, GC-
MS is still utilised for the determination of volatile biomarkers with low molecular weight and heat 
resistance fragments. Applications include, steroids, metabolomics and therapeutic drug monitoring 
studies using DBS samples (135, 176, 196, 221, 281) (Table 1.1).   
Negating the pre-analytical clean-up and chromatographic front end separation, direct MS methods and 
surface sampling techniques coupled with MS have been used for DBS samples (282).  Desorption 
electrospray ionisation (DESI), direct analysis in real time (DART) and direct electro spray ionisation 
mass spectrometry (ESI-MS) methods have been utilised in order to generate ions from the surface, 
thus avoiding purification or derivatisation processes (282-289).  However, elimination of this primary 
sample purification and separation may result in loss of sensitivity and precision due to the disintegrated 
metabolite interferences (288).  Thus, the application of non-paper blotting matrices and online SPE in 
conjunction with the direct MS methods is recommended to enhance the sensitivity and measurement 
precision (274, 290).  The gains of time efficiency and throughput need to be balanced with achieving 
the desired method performance. 
Quality considerations 
There are some important considerations in relation to the method validation and acceptance criteria for 
DBS analysis.  Accordingly, the European bio-analysis forum (EBF) has described the details of the 
DBS sample analysis methodology to provide specific recommendations for validation of DBS methods 
(291).  The EBF recommendations document includes specific concepts of; collection card variability, 
sample-to-sample variability, DBS homogeneity, punch point effect, sample stability, blood physical 
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parameters effect, matrix effect, extraction recovery, internal standard (ISTD) application and quality 
control (QC) and calibrator (Cal) preparation.  In addition to the detail provided in this document, 
traceability to the liquid matrix sample, fitness for clinical purpose and reference intervals / decision 
limits for interpretation require consideration.    
Collection cards 
To avoid issues of inter-card variability, calibrator and control material should be prepared using 
identical collection card type/manufacture as the patient samples.  If multiple type/manufacturer of 
cards are used, then a method comparison is required to determine the comparative card stability, 
extraction recovery and matrix effect (292). 
Haematocrit effect  
As mentioned earlier, the physical behaviour of blotted whole blood is influenced by different 
parameters such as; haematocrit level, haemolysis degree and anticoagulant type (if it is applied).  
Currently the haematocrit is recognised as the most significant parameter affecting blood spot 
characteristics (drying time, dimension and homogeneity) and assay reproducibility.  Haematocrit effect 
is more substantial when a sub-sample disk punch is analysed, rather than the whole DBS sample.  
Hence, method validation studies for DBS sample applications also need to include investigations of 
the impact of haematocrit variation on measurement and assay performance (293). 
Application of Internal Standard 
The incorporation of the ISs to the DBS sample processing is an important step and ideally should occur 
early in the process. 1) Collection cards pre-treated with the IS can be prepared prior to the spotting of 
the blood.  This ensures both the ISTD and nominated compounds have undergone the same matrix and 
extraction effect.  However, this approach logistically might not be practicable when dealing with 
multiple studies. 2) Commonly manual extraction methods utilise the approach of integrating the IS 
into the DBS elution reagent / extraction solvent. In this method, the ISTD is co-extracted along with 
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the target analyte.  3) Addition of the IS into the sample along with extraction / preparation process is 
another simple alternative. However, as the ISTD is not fully incorporated with the paper matrix, 
variations in elution recovery are not accounted for. 4) Using on-line DBS sample preparation 
technology, the ISTD is sprayed on the blood spot before the extraction using the Touch-spray technique 
(294-296).  
Carry-over 
Carry-over is a significant issue for DBS-MS analysis.  Carry-over may have different sources 
including: physical card to card contact during storage; spot to spot originated from the puncher head 
and post-preparation initiated from the instrument (e.g. auto-sampler and analytical column) (291). As 
the puncher head is re-used, contamination and sample carry-over are notable concerns.  To overcome 
this issue, either a clean-up step or a blank-card punch in between the samples is recommended (297). 
To investigate the instrumentation carry-over, two injections of sequential blank DBS extracts should 
be performed after an injection of a sample with the upper limit of quantitation concentration.  The 
response for the first and second blank matrix should not exceed 20% and 5% respectively of the mean 
response of the lower limit of detection of the analyte of interest (298). 
Internal Quality control  
Internal quality control (IQC) spiked samples preparation for DBS analysis requires special 
considerations compared to liquid phase biologic samples. The main challenge of IQC is keeping the 
matrix consistent with that of patient’s blood spot sample. Both sample dilution and saturation may 
occur in spiked sample preparations (292).  Ideally fresh non-haemolysed whole blood sample with the 
closely matching haematocrit level of the study group, should be chosen for spiking (298). These IQCs 
should be spotted onto the filter paper and eluted along with the patient samples. 
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External Quality Assurance 
EQA programs are considered essential tools in evaluating the reliability and traceability of the 
analytical assay as well as monitoring the quality of the laboratory performance.  The United Kingdom 
National External Quality Assessment Service (UK-NEQAS), the European Research Network for 
evaluation and improvement of screening, Diagnosis and treatment of Inherited disorders of 
Metabolism (ERNDIM) and the CDC (Newborn Screening Quality Assurance Program (NSQAP)) 
provide a variety of schemes for DBS newborn screening testing.  However, there is no further EQA 
program available to assure the accuracy of DBS analysis outside of NBS.  Hence, for most DBS 
analytes discussed in this review we do not have a peer review process to fully gauge laboratory 
performance. This represents a gap in harmonisation of analytes measured in this matrix. 
Calibration 
Standards preparation for DBS quantitative analysis includes whole blood fortification (replacement of 
certain amounts of plasma with the artificial plasma containing a known concentration of target analyte) 
with a set of commercial or in-house calibrator materials before spotting. The percentage of non-
aqueous components replaced with plasma needs to be minimised to prevent solvent effects creating 
inconsistency between spiked samples (calibrators) and patient samples in terms of spot formation 
(291). Most DBS analytes are small molecular weight well defined compounds. In principle, full 
standardisation with traceability should be achievable. However, in practice the DBS matrix adds an 
extra level of complexity for commutability.   
1.3.5 Post-analytical 
Post-analytical concerns of the testing process phase mainly include; result reporting and interpretation, 
assay total error management and turnaround time (299).  The key for the introduction of DBS analysis 
as a diagnostic tool is the cross validation of the method to a reference plasma/serum base assay.  
However, the fact that the concentration of the biomarkers in whole blood may vary from serum/plasma 
must be taken into account.   
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To turn the numerical result generated from the DBS analysis into clinical meaningful results a reference 
interval (RI) or decision point needs to be established.  DBS specific RI have been developed for many 
analytes (300-304).  For analytes routinely measured in liquid whole blood comparative RI can often 
be transferred to DBS samples.  However, it is often more challenging for DBS analytes that require a 
comparison to serum for their clinical interpretation. 
Some DBS analytes, such as vitamin D, require a conversion to their serum equivalent concentration 
for interpretation.  This requires the development of a robust relationship between the measured analyte 
in the blotted whole blood and the equivalent serum sample.  For this, we need to be able to estimate 
the equivalent blood volume in the blood spot punch.   Two main approaches have been described to 
evaluate the corresponding serum volume; the application of chemical tracers and geometric calculation 
(128). 
Chemical tracers, such as 125I-albumin, 51Cr-haemoglubin and 125I-L-thyroxin, have been used to 
estimate the equivalent serum volume of the blotted whole blood punch.  In this process, the serum 
volume is determined by comparing radiochemical counts of the blood spot punch with the known 
volume of whole blood samples in the liquid phase (239). Geometric calculation has been applied to 
evaluate the ratio of the punched disk to the known volume of the entire spotted whole blood with the 
pre-measured haematocrit (305, 306). However, application of this approach does not fully take into 
account the chromatographic effect of the blood distribution on the filter paper, and still raises issues 
of analytical bias for the final measurement (307).  Which is why it is recommended that the punch is 
taken from the centre of the spot. Considering the fact that these common methods are not applicable 
to archived DBS samples, direct estimation of Hb concentration on the DBS punch is an alternative but 
is currently not described in the literature. 
1.3.6 Conclusions 
The initial widespread application of DBS was utilised for newborn screening.  More recently, it has 
been applied more broadly.  Mass spectrometry-based applications are the dominant techniques for 
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DBS analysis, and liquid chromatography separation is more popular than gas chromatography.  Drug 
monitoring (therapeutic and toxicology) and pharma-toxico-kinetics studies are the major application 
groups outside of newborn screening.  For many analytes, method validation and further bridge 
experiments are required to develop adjustment rules to convert the results obtained from DBS analysis 
to the equivalent serum/plasma values.  Likewise, establishment of robust reference intervals or 
decision limits is essential for DBS analytes.  It is envisaged, with the inherent advantages of the 
alternative DBS sampling technique compared to the classic plasma-based strategies, in future micro-
sampling-based assays will certainly play a substantial role for analysis of biomarkers.” 
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 1.4 Research Project hypotheses, aims and questions 
This research project hypothesises that; vitamin D insufficiency at birth, predicts the higher risk of 
allergic diseases in early childhood.  To address this hypothesis, this project aims to; 1) Develop an 
accurate method for measurement of vitamin D metabolites from archived dried blood spot samples, 2) 
Investigate the association between early life vitamin D insufficiency and paediatric food allergy. 
Research Questions  
1. Can the current dried blood spot sample derivatisation and preparation technique be optimised for LC-
MS/MS measurement method? 
2. What is the sample specific distribution of vitamin D at birth in a population-based cohort of 
metropolitan Melbourne? 
3. Are vitamin D levels at birth associated with subsequent IgE-mediated food allergy at age 12 months? 
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Chapter 2 
 
General materials and methods 
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2  General materials and methods  
This chapter defines the design and requirement of the samples, general equipment / tools, chemicals 
and data analysis procedures utilised in this project. This chapter also includes the details of method 
validation and population study sample resources, collection, storage and preparation processes. An 
additional methodology section is included in each chapter to detail specific material and methods used 
for the study. 
2.1 Sample collection and storage 
Dried blood spot (DBS) samples were retrieved from a biobank of archived Newborn blood spot 
Screening (NBS) Guthrie card samples from the Victorian Clinical Genetics Service (VCGS) biobank.  
These 2700 samples were collected as part of the NBS program and consent for this research was 
obtained from the guardians. These DBS specimens have been collected from two internationally 
unique NHMRC funded population cohorts (HealthNuts ref. 1006215 - RMIT ethics approval number: 
0000019315) from participants at birth (< 3 days old). The NBS sample collection dates varied between 
15/03/2006 and 14/08/2010. The participant population includes 1315 female and 1385 male newborns. 
DBS samples were collected on the Whatman 903 filter paper collection cards (one drop on each 
collection area, air dried) and stored in archive boxes at room temperature. In September 2014 Guthrie 
cards were retrieved from archive boxes, and two 3.2 mm punches were collected in two sets of 96-well 
plates (one with flat the other with conical bottom). Each DBS punch-plate was covered plates with the 
web-sealer and stored in archive boxes at room temperature until examination time.  DBS samples were 
ideally punched from the centre of the blood spot (one spot per each plate-well), and in case of 
unavailability of two intact blood spots, were consistently punched from the edge for both punches. 
Observations and discrepancies related to the blood spot quality and punch point were recorded. The 
blank filter paper punch was collected if there was no suitable blood spot available for collection (Figure 
2.1).  
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Figure 2.1 2700 NBS Guthrie cards sample retrieval and collection and storage process (Appendix 3) 
Whole blood samples (n=80, de-identified human sourced) for method validation studies were collected 
from the Royal Children Hospital (RCH) Laboratory Services archive (patient’s median age = 10 years) 
and Austin Pathology (patient’s median age = 63 years). Fresh EDTA specimens (less than 48 hs old) 
were retrieved from and stored at 4o C before blotting on collection cards (Whatman 903) or separation 
of plasma. One drop (50 µl) of whole blood was spotted on each spotting area (four per card), then air 
dried for 2 hours and stored at room temperature cabinet (in plastic specimen storage zipper-bag) until 
analysis. Plasma samples were prepared by centrifugation of whole blood at 3000 rpm for 5 minutes 
and stored in -20oC until examination time.  
2.2  Equipment and tools 
Three main sets of equipment were utilised for this project: 1) sample collection and preparation 
materials, 2) sample analysis equipment and 3) data processing tools. 
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2.2.1 Sample collection 
Study subject DBS samples, in-house quality control and method development/validation samples were 
collected on FDA proven collection cards; Whatman 903. Semi-automated and manual punchers were 
used to collect the DBS disk of the spotted samples; 3.2 and 6 mm manual punchers and 3.2 mm semi-
automated (Perkin Elmer Precisely 1296-071 Delfia dried blood spot punch, Wallac DBS pincher). 
VCGS-NBS lab standard operation procedure was followed to punch Guthrie cards. DBS punches were 
collected, stored and analysed in 96-well plates; Thermo Scientific flat-bottom clear 96-well plate, Cat 
no. 9502227 for spectrometric scanning and Greiner Bio-one v-bottom 96-well microplates (part no. 
65/201). Plates containing DBS punches were covered by a closing-mat for 96-well plate sourced from 
Agilent Technologies (Santa Clara, California, United States, part no. 5042-1389) for storage and 
analysis. 
Whole blood samples were collected in EDTA contained collection tube: (Becton Dickinson, VIC, 
Australia, part no. 369651 and 367873). Whole blood and plasma samples were transported and stored 
in microcentrifuge propylene tubes (1.5mL, Cat no. 72.690.001) supplied by Sarstedt (Adelaide, 
Australia).  
2.2.2 Sample analysis 
A range of different equipment and tools were utilised for different studies including; sample 
preparation, haemoglobin derivatives estimation and vitamin D measurement tools.  
Sample preparation 
Heraeus centrifuge multifuge 1 S-R and temperature adjustable laboratory oven were sourced from 
Thermo Scientific (VIC, Australia). Dry block heater, 3x4 nozzle gas manifold, roller mixer and vortex 
mixer were obtained from Ratek (VIC, Australia). A set of pipettes including 1-25, 20-200, 200-1000 
and 10-300 µl were obtained from Thermo Scientific Finnpipette (VIC, Australia) and Eppendorf 
(NSW, Australia). A water purification system (Milli-Q Direct 8) was sourced from Merck Millipore 
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(VIC, Australia) and an electronic balance (Mettler AT261 Deltarange®) used for weight measurement 
was sourced from Mettler (VIC, Australia). A UCT 69-well plate positive pressure manifold (UCT inc. 
Bristol, USA, part no. VMFPPMIK) provided by PM Separations (NSW, Australia) was used for the 
sample extraction process and supported liquid extraction (SLE) plates (Biotage, Uppsala, Sweden, Cat 
no. 820-0200-P01) were obtained from Shimadzu Oceania (NSW, Australia) for sample purification. 
Extracted samples were collected, derivatised and loaded into the LC-MS/MS in the Agilent 96-deep 
well plate (1 ml) (part no. 5042-1389). A rotational vacuum concentrator (RVC 2-33 CP Plus, CHRIST, 
Osterode, Germany, part no. 101233) supplied from John Morris Scientific (VIC Australia) was used 
for extracted sample drying. An ultrasonic bath (40kHz, Unisonics, Part No; FXP) obtained from 
Unisonics Australia (NSW Australia) was utilised for blood spot sample elution and extraction. 
General laboratory glassware items were sourced from Schott-Duran (NSW, Australia) and the Pacific 
laboratory products (Melbourne, Australia) supplied the KIMAX glass tubes (13 × 100 mm, Cat no. 
45066A-13100). Glass Pasteur pipettes (Cat no. NAAU92501.01) were acquired from the Merck (VIC, 
Australia). The screw cap Amber vials (Cat no. 5183-2081) and flat bottom glass inserts (400 μl, Cat 
no. 5181-3377), were procured from the Agilent Technologies. 
Haemoglobin derivatives estimation 
A PerkinElmer - EnSpire Multimode Plate Reader (2300) using wavelengths of 520-600 nm with band 
pass width of 8nm was utilised for the spectrophotometric scanning at 540 nm wavelength. 
Vitamin D measurement 
A Liquid chromatography tandem mass spectrometry (LC-MS/MS) system including; Agilent 1290 
infinity LC and Agilent 6490 triple quadrupole mass spectrometer supplied from Agilent Technologies 
(Santa Clara, CA, United States) was used for vitamin D (native and derivatised) metabolites 
quantification. The columns used for liquid chromatography procedures are: Pursuit Pentafluorophenyl 
(PFP) column (100 mm × 2 mm× 3 µm, Cat no. A3051100X020), MetaGuard column 2.0 mm Pursuit 
3 µm PFP (Cat no. A3051MG2) from Agilent Technologies. The core-shell column (2.6µm, 2.1 mm 
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x100mm, Kinetex F5, 100A, Cat no. 00D-4723-AN), Security Guard ULTRA Cartridges (UHPLC F5 
for 2.1 mm ID columns, Cat no. AJ0-9322) were purchase from PHENOMENEX (Torrance, CA, USA).   
Performance specifications of the liquid chromatography and the tandem mass spectrometry systems 
used in this project for measurement of vitamin D are summarised in table 2.1 and 2.2. Please note that 
the general concept and structure of these tables has been adopted from Ali Al-Bahrani’s PhD thesis 
(308). 
Table 2.1. Performance specifications of Agilent LC-1290. 
Specification* Agilent LC-1290 (309-311) 
P
u
m
p
 
Hydraulic system Two dual pistons in series, pumps with proprietary servo-
controlled variable stroke design and smooth motion control 
Settable flow range 0.001 – 5 mL/min, in 0.001 mL/min increments  
Flow precision ≤0.07 % RSD  
Flow accuracy ±1%  
Pressure operating range Binary Pump: up to 120 MPa (1200 bar) up to 2 mL/min,  
80 MPa (800 bar) at 5 mL/min 
Binary Pump VL: up to 105 MPa (1050 bar) up to 2 mL/min 
Pressure pulsation < 1 % amplitude  
Gradient formation High pressure binary mixing 
Delay volume JetWeaver V35: < 45μL, JetWeaver V100: < 75μL 
Composition range Settable range: 0 - 100 % 
Composition precision < 0.15 % RSD or 0.01 min SD 
A
u
to
sa
m
p
le
r Injection range 0.1–20 μL in 0.1 μL increments 
Injection precision  <0.3% from 5–40μL, <0.5% from 2–5μL,<0.7% from 0.5–2μL 
Sample viscosity range 0.2–5 centipoise 
Injection cycle time Typically < 21 s depending on draw speed and injection vol. 
Carryover Typically < 0.004 %  
C
o
lu
m
n
 O
v
en
 
Temperature range 10 °C below ambient to 100°C 
Temperature stability ± 0.05°C 
Temperature accuracy ± 0.8°C 
Column capacity 2 columns of 300 mm with individual solvent heating 
Internal volume 3 μL left heat exchanger, 6 μL right heat exchanger 
* These performance specifications are based on data analysed by Agilent technologies. 
 
Table 2.2. Performance specifications of Agilent MS/MS-6490. 
Specification* Agilent MS/MS-6490 (312) 
Sensitivity: 1pg reserpine# quantifying on m/z 609→195 using ESI positive 
mode 
S/N > 50,000:1 
Sensitivity: 1pg chloramphenicol# quantifying on m/z 321→152 using ESI 
negative mode 
S/N > 50,000:1 
Linear dynamic range  > 6.0 × 106 
Mass range 5–1,400 Da 
Maximum scan rate 12,500 Da/sec 
Minimum MRM dwell time 1 milliseconds 
MRM transitions 
500 per TS, >40,000 ion 
transitions per method 
Polarity switching (from positive to negative) 30 milliseconds 
Collision cell ion clearance < 1 milliseconds 
Agilent Jet stream technology$ Yes 
Agilent iFunnel technology$ Yes 
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# Agilent technologies use reserpine and chloramphenicol compounds to compare their MS/MS systems.  
$“Jet Stream sample introduction, providing high-efficiency ESI ion generation and focusing; a hexabore capillary; and a unique dual-stage 
ion funnel assembly. Together these technologies reduce neutrals and increase ion sampling to dramatically improve overall signal within the 
system, delivering significant increases in sensitivity compared with conventional instruments.” (313).  
2.2.3 Operation of the LC-MS/MS system 
The LC-MS/MS system was operated using Agilent MassHunter data acquisition software (version 
B.4.01) following the standard operation procedure document generated by RMIT MS lab research team 
and general operation manual published by LC-MS/MS research group, for the Agilent LC-MS/MS 
1200/6400 that was available as a hardcopy in the LC-MS/MS laboratory also saved on a shared Google 
drive. 
2.3  Reagents and chemicals  
The reagents and chemicals used in this project were procured from different manufacturers and 
suppliers (Table 2.3). The following were obtained from Merck: ethanol gradient grade for HPLC, 
hexane for liquid chromatography, 2-Propanol for liquid chromatography, methanol for liquid 
chromatography and nitric acid 65% suprapur. Thermo Scientific also provided Optima methanol for 
liquid chromatography. Formic acid (purity ≈98%) was supplied by Sigma-Aldrich. Seracon human 
plasma matrix match diluent (Material no.1800-0027) was purchased from SeraCare. The high purity 
grade/ extra high pressure/ compressed nitrogen (Purity ≥ 99.99%) was supplied by BOC. Derivatising 
reagents including Amplifex™ Diene and 4-Phenyl-1,2,4-triazoline-3,5-dione (PTAD) were purchased 
from Sciex and Sigma-Aldrich respectively.  
Pure compounds and internal standard materials were sourced from different manufacturers. Retinol 
(purity ≥95%) and lyophilised human haemoglobin were obtained from Sigma-Aldrich. 25-
hydroxyvitamin D3 (purity ≥98%), 3-epi-25-hydroxyvitamin D3 (purity ≥98%), 25-hydroxyvitamin 
D3-[2H3] (purity ≥98%), 25-Hydroxyvitamin D3-[13C5], 25-Hydroxyvitamin D3-[2H6]-Monohydrate 
and 3-Epi-25-Hydroxyvitamin D3-[13C5] were purchased from IsoSciences. 
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 Table 2.3. List of reagents and chemical used in the project. 
Chemicals Cat*/order no. Manufacturer 
25-hydroxyvitamin D2/D3 Calibrator set 62039 ChromSystems (Munich, Germany) 
25-hydroxyvitamin D3 (CAS** No 19356-17-3) S4163UNL IsoSciences (Ambler, USA)  
25-Hydroxyvitamin D3-[13C5]  S13125-0.1  IsoSciences (Ambler, USA) 
25-hydroxyvitamin D3-[2H3] (CAS No 140710-
94-7)  
S4163 IsoSciences (Ambler, USA) 
25-Hydroxyvitamin D3-[2H6]-Monohydrate   S13085 IsoSciences (Ambler, USA) 
2-Propanol (CAS No 67-63-0) 1.01040.2500 Merk (Darmstadt, Germany) 
3-epi-25-hydroxyvitamin D2/D3 Calibrator set 62029 ChromSystems (Munich, Germany) 
3-epi-25-hydroxyvitamin D3 (CAS No 73809-
05-9)  
S7004 IsoSciences (Ambler, USA) 
3-Epi-25-Hydroxyvitamin D3-[13C5]   14041 IsoSciences (Ambler, USA) 
4-Phenyl-1,2,4-triazoline-3,5-dione (CAS No 
4233-33-4) 
42579 Sigma-Aldrich (VIC, Australia) 
Amplifex™ Diene   5037804 Sciex (Framingham, USA)  
Compressed nitrogen (N5.0)  Gas Code: 035 BOC (VIC, Australia) 
Ethanol (CAS No 64-17-5) 1.11727.1000 Merk (Darmstadt, Germany) 
Formic acid (CAS No 64-18-6)  94318 Sigma-Aldrich (VIC, Australia) 
Hexane (CAS No 110-54-3)  1.04391.2500 Merk (Darmstadt, Germany) 
Liquid Meter Trax control 970-211870 BioRad Laboratories (California, USA) 
Lyophilised human haemoglobin   H7379 Sigma-Aldrich (VIC, Australia).  
Methanol (CAS No 67-56-1) 1.06018.4000 Merk (Darmstadt, Germany) 
Nitric acid 65% suprapur (CAS No 7697-37-2)  1.00441.1000 Merk (Darmstadt, Germany) 
Optima methanol (CAS No 67-56) A456-4 Thermo Fisher Scientific (Waltham, USA) 
Quality Assurance Program materials  
 
Royal College of Pathologists of 
Australasia (NSW, Australia) 
Retinol (CAS No 68-26-8) R7632 Sigma-Aldrich (VIC, Australia) 
Seracon human plasma matrix match diluent   1800-0027 SeraCare (Milford, USA) 
Serum quality control for vitamin A  10081-10082 UTAK Laboratories Inc. (Valencia, USA) 
Vitamin D quality control 10060-10061-
10062 
UTAK Laboratories Inc. (Valencia, USA) 
Vitamins A and E calibrator set   3.004 ChromSystems (Munich, Germany) 
* Cat no; Catalogue number     ** CAS No; Chemical Abstracts Service number 
 
2.4 Chemical preparation  
2.4.1 Preparation of solutions for liquid chromatography  
Needle wash solution  
To minimise the potential carry-over contamination and clean the auto-sampler needle, needle wash 
solution was used prior to each sample injection into the LC-MS/MS. The needle wash solution 
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contained 50% methanol, 10% 2-propanol and 40% water, which was prepared fortnightly and stored 
at ambient temperature. 
Mobile phases 
Two mobile phases were utilised for the reversed-phase chromatography. The hydrophilic mobile phase 
consisted of 0.1% formic acid and 2% methanol in Milli-Q water. The organic mobile phase consisted 
of 0.1% formic acid in methanol.  
2.4.2 Reagent preparation 
All pure compounds and reagents were prepared in amber or aluminium-foil-wrapped glass vials / 
bottles under the fume hood.  
 25-hydroxyvitamin D3 and 3-epi-25-hydroxyvitamin D3 stock solutions  
Stock 1; 25-hydroxyvitamin D3 (12,480 nmol/L) and 3-epi-25-hydroxyvitamin D3 (253,338 nmol/L) 
were provided in sealed glass ampoules (in 1 mL of ethanol). Stock 2; was prepared by diluting 25-
hydroxyvitamin D3 and 3-Epi-25-hydroxyvitamin D3 stock 1 with HPLC grade methanol (10,000 
nmol/L). Stock 1 ampoule content was transferred and diluted into an Agilent amber glass vial, which 
the cap was tightly wrapped with the parafilm and stored at -20 °C.  
Internal standard (25-Hydroxyvitamin D3-[2H3], [2H6], [13C5] and 3-epi-25-
Hydroxyvitamin D3- [13C5]) stock solutions 
Stock 1; the internal standard solutions were supplied in sealed glass ampoule (1mL) with 1 g/mL in 
ethanol. Stock 2; stock 1 was transferred into an aluminium-foil-wrapped glass bottle containing 49 mL 
of HPLC grade methanol to prepare 50 mL of 1/50 diluted material. Stock 3 (working solutions); was 
prepared by diluting stock 2 with the HPLC grade methanol (1/20 dilution) at concentrations of 247.75, 
246.3 and 246.91 nmol/L of [2H3], [
2H6] and [
13C5] internal standards respectively. 
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Retinol stock solution 
Stock 1; retinol crystal was dissolved into HPLC grade methanol at a 1,000 μmol/L concentration. 
Stocks 2 and 3; were prepared by diluting stock 1 with HPLC grade methanol at 100 μmol/L and 10 
μmol/L concentrations respectively. 
Vitamin D, A and IS mixture in methanol  
Spiked methanol (with vitamin D, A and IS) was used for LC-MS/MS method development and system 
performance check prior to each analytical batch. Spiked methanol was prepared by diluting each stock 
solution with HPLC grade methanol to prepare a mixture with concentrations of; 100 nmol/L, 60 
nmol/L,150 nmol/L, 10 μmol/L of 25-OHD3, epi-25-OHD3, 25-OHD3-d6 and retinol respectively. 
This mixture was stored at -20 C.  
Derivatising reagents 
As part of the method development process for measurement of vitamin metabolites from DBS samples 
we trialled PTAD to derivatise and enhance the assay sensitivity. Its working solution was prepared 
with the concentration of 0.1 g/mL in acetonitrile. The working solution was stored at 4 C with the 
stability time of 8 weeks.   
Amplifex™ Diene working solution reagent was prepared by the addition of 3 ml of diluent 
(acetonitrile) into the reagent bottle (contains 1 gr dry Amplifex™ Diene) and was vortexed for 20 
seconds followed by 20 seconds sonication. Working solution was stored at -20 C while was stable for 
4 weeks.  
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2.4.3 Calibrators 
Commercial calibrator sets for vitamin D metabolites and vitamins A were sourced from 
Chromsystems, while dried calibrator spot standards were prepared in-house using Sigma human 
haemoglobin material. 
 In-house DBS haemoglobin calibrators 
In-house calibrators were prepared from Sigma lyophilised human haemoglobin in milli-Q water.  A 
five-point calibration curve was generated using in-house Hb standard materials (50, 100, 150, 200, 250 
g/L).  50µl of each level of standards were spotted on the collection cards (Whatman 903) and air-dried 
overnight at room temperature (RT). 
Commercial calibrators  
Lyophilised commercial calibrators were used in this project. Lyophilised serum calibrator sets for 25-
hydroxyvitamin D2/D3 (6 Plus1 Multilevel Serum Calibrator set, Masschrom), 3-epi-25-
hydroxyvitamin D2/D3 (3 Plus1 Multilevel Serum Calibrator set, Masschrom) and vitamins A and E 
were purchased from ChromSystems (distributed by PM separations - QLD, Australia). These calibrator 
sets are traceable to the National Institute of Standards and Technology-standard reference material 972 
(NIST972a) (314). Lyophilised calibrators were reconstituted in milli-Q water following the 
manufacturer’s instructions and the labelled aliquots (in polypropylene microcentrifuge tubes) stored at 
-20 °C. 
2.4.4 Controls 
Separate commercial sets of quality control (QC) material for vitamin D metabolites and vitamins A 
were sourced from UTAK, while dried quality control spots were prepared using BioRad human blood 
control materials and in-house DBS controls. 
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In-house DBS quality controls 
In-house QC sets were prepared for DBS vitamin D and haemoglobin. These control materials were 
concurrently prepared with the unknown human blood samples at the beginning of the study. Results 
from the controls were used to monitor the assay performance. The In-house QC was prepared from 50 
µl spotted unknown human whole blood sample on the filter paper and air-dried overnight at RT.  
Commercial quality controls  
Liquid and lyophilised controls were used in this project. Lyophilised serum quality control sets for 
vitamin A (low and high) and for vitamin D (low, medium and high) were procured from UTAK 
Laboratories Inc. Liquid three-level human blood quality control material (Meter Trax control, low, 
mid, high) were purchased from BioRad Laboratories. 
External quality control materials were supplied by the Royal College of Pathologists of Australasia 
(RCPA). RCPA quality assurance program (QAP) for endocrine and vitamins materials were utilised 
for the method general performance testing. RCPAQAP lyophilised materials were reconstituted in 
milli-Q water following the manufacturer’s instructions. Samples were analysed after preparation and 
the excess were stored at 4 °C and -20 °C for retesting (if it was required).   
2.5 Glassware cleaning 
Glassware was well-maintained and cleaned regularly meeting the requirements of the mass 
spectrometry analysis and standard laboratory practice. All cleaned reusable glassware was kept in 
capped containers and allocated cabinets. 
Initially bottles and reusable glassware including KIMAX screw cap culture glass tubes were washed 
with Milli-Q water and rinsed with methanol prior drying in the 50°C oven (to avoid diluting the nitric 
acid in the following step). Nitric acid solution (65%) and Milli-Q water were used to clean and rinse 
the glassware respectively prior to the final step of hot oven drying (Appendix 8.1). 
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2.6 Safety 
The biological samples, medical waste and chemicals were handled and disposed following the 
laboratory safety procedures. The biological samples used included human samples, calibrators, quality 
controls and external quality assurance materials. These biological specimens need to be considered as 
potentially infectious agents and were handled and disposed based on the RMIT University, School of 
Health and Biomedical Sciences (SHBS) laboratory safety procedures (available online and hardcopies 
accessible in the LC-MS/MS laboratory). Safety Data Sheet (SDS) and risk assessments procedures 
(provided by the manufacturers and / or created at the commencement of the project) were followed to 
safely handle the chemicals. A hard copy and electronic copy of safety procedures and documents were 
available in the LC-MS/MS laboratory and a shared Google drive. Biohazardous waste and disposable 
labware were also disposed according to the SHBS laboratory waste disposal management strategy 
procedure (315). 
2.7 Data analysis 
Agilent MassHunter data acquisition, quantitative analysis (version B.05.00/B5.0.291.0) and qualitative 
analysis (version B.04.00) software were used for LC-MS/MS data analysis. Agilent LC-MS/MS 
1200/6400 general operation manual was available in the LC-MS/MS laboratory. Collected data was 
stored and backed-up in the main computer of the LC-MS/MS laboratory and an external memory drive; 
both of which are password protected. 
Microsoft Excel software (scatter chart, trend-line equation) was used for calibration curve generation 
and Hb-drv concentration calculation.  “Method Validator” software (Philippe Marquis 1999, version; 
1.19) was used for accuracy testing and method correlation studies (Linear regression, Passing-Bablok 
and Difference Plot). Assay linearity was assessed with LinChecker software (Philippe Marquis 2001, 
version; 1.1.2.0).  
   
Rosita Zakariaee Abkoo  62 
 
Chapter 3 
 
Determination of Haemoglobin 
Derivatives in Aged Dried Blood Spots to 
Estimate Haematocrit  
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3 Determination of Haemoglobin Derivatives in Aged Dried 
Blood Spot to Estimate Haematocrit  
The levels of the haematocrit and haemoglobin at extreme high or low ends may influence the accuracy 
of the measurements quantification of the DBS sample. To alleviate the potential errors associated with 
the dried matrix of DBS sample which could span the total testing process, we aimed to predict the 
haematocrit of the punched dried blood spot through primary spectrophotometric estimation of its 
haemoglobin content.  This correction could be incorporated into DBS standard operation procedures 
for measurement of different types of biomarkers. 
This chapter has been peer reviewed and published with contribution of other co-authors as an analytical 
full paper (316). My contribution to this study and subsequent publication was included; developing the 
concept for the study in conjunction with my senior supervisor (RG), performing the experiments and 
method development, analysis and interpretation of data, writing the first draft of the publication and 
reviewing and incorporating all suggestions from the co-authors. 
3.1 Introduction 
“The micro-sampling technique associated with dried blood spot (DBS) samples is considered to be 
less invasive, requiring only a small sample volume (usually capillary) applied to filter paper, that is 
easy to transport and store with a lower risk of infection transmission (119, 121, 317).  These advantages 
have prompted the interest in utilising DBS for clinical assessment outside of newborn blood spot 
screening (NBS).  As such, DBS applications now encompass analytes related to clinical diagnosis, 
epidemiological studies, therapeutic drug monitoring, pharmacokinetics and toxicokinetic studies (10). 
However, the accuracy of DBS quantitation requires additional considerations over the conventional 
“liquid” blood sample. This is due to the physical characteristics of the blotted whole blood sample 
affecting the quality of the measurement. In particular, potential irregular errors associated with 
haematocrit (Hct) span the DBS total testing process: 
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Pre-analytically, the levels of a patient’s haemoglobin (Hb), and therefore Hct, at extreme high 
or low ends may influence the viscosity and fluidity of the spreading sample (241).  Hence, 
there would be sample volume dissimilarity for a fixed size punch from the DBS originating 
from whole blood samples with different levels of Hct (Figure 1) (10, 240, 241, 254). 
 
 
 
 
 
Figure 3.1. Calibrators set for estimation of Hb-drv of DBS samples. Haemoglobin concentration effects on the measured vitamin D of DBS 
sample and whole blood samples with different levels of Hb do not diffuse similarly on the Guthrie card. 
Analytically, Hct can influence the extraction of a measurand from the filter paper.  This has 
been demonstrated in the quantitative bio-analysis of drugs where Hct has been identified as a 
causal factor of assay bias due to variations in the efficiency of the extraction process (305).   
Post-analytically, the reference intervals and decision points for biomarkers and clinical 
assessments are predominantly described for samples with a liquid matrix (serum/plasma).  The 
accurate conversion of dry matrix results (i.e. from the DBS) requires a consistent relationship 
with the liquid form (serum/plasma).  Hence it is useful to know the Hct value (306).   
DBS laboratories are often keen to know the Hct in order to account for, and ideally correct for, 
associated sample variation across the total testing procedure.  The additional collection of a liquid 
sample (venous or capillary) for Hct measurement at the time of the DBS collection is recommended 
(318).  However, there are many archived DBS samples that have limited biological information 
(including Hct), where prediction of the spotted blood Hct level is warranted.  As such, the indirect (e.g. 
potassium measurement) or direct determination of Hct from the DBS cards is proposed (319-323). 
To alleviate the DBS-Hct problem, scientists have employed a variety of correction techniques.  The 
strategies used can be broadly divided into the following groups: 1) measuring the Hb and/or Hct 
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independently at the time of collection from a whole blood liquid sample; 2) determining the Hb and/or 
Hct from the DBS sample; or 3) not determining Hb and/or Hct at all.  Where a Hct correction option 
is sought, practical solutions to minimise bias have been devised.  These include: analysis of the entire 
blood spot; determination of the spotted blood volume by weighing the whole spot; using dried plasma 
collection; pre-cutting the filter paper prior to application of the blood; assessment or prediction of Hct 
from the spotted whole blood; and normalising the DBS measurement using the average value of Hct 
for males/females (10, 167, 318, 324).  Whilst each of these correction approaches has merit, none have 
been widely adopted due to inherent limitations within the individual approach. 
Over time, Hb converts to various Hb derivatives (Hb-drv) (Figure 3.2).  Estimation of Hb-drv from the 
actual DBS punch could potentially be used as a surrogate for Hct to account for physiologically low 
or high Hct levels.  We propose this might be possible spectrophotometrically using the eluted 
(solubilised) punched DBS (hence taking into account both diffusion and extraction differences).  In 
this study, we aimed to predict the Hct of the punched archived DBS through primary 
spectrophotometric estimation of its Hb-drv content.  Successful confirmation of this hypothesis would 
enable this technique to be incorporated into DBS standard operation procedures, allowing the 
laboratory to account for Hct in association with their DBS analyte of interest. 
 
Figure 3.2. Haemoglobin is an oxygen transport protein in the form of oxyhaemoglobin (Hb-O2). As soon as fresh whole blood is air exposed 
outside the body, Hb is completely oxygen saturated and converts into Hb-O2. Over time, Hb-O2 is auto-oxidised to met-haemoglobin (met-
Hb). Met-Hb eventually denatures into hemi-chrome (HC) (known as the most stable Hb derivative) . HC is a common name for group of low 
spin forms of the ferri-Hb (met-Hb) constituting ferri-alpha / beta subunits. The distinct feature of the met-Hb is its six liganded state of the 
haem iron that formed through the separate alterations of the globin conformation so that atoms endogenous to protein became bound as a 
sixth ligand of the haem iron. The abundant majority of HC have a proximal (F8) and a distal (E7) His as fifth and sixth ligands respectively 
(325, 326). Following our observations using direct spectrometry method after week 8 HC is measured. 
 
   
Rosita Zakariaee Abkoo  66 
 
3.2  Materials and methods  
3.2.1 Subjects 
Study samples 
One hundred and twenty de-identified venous whole blood ethylenediaminetetraacetic acid (EDTA) 
samples were sourced from two laboratories; Laboratory A - the Royal Children’s Hospital Melbourne 
(RCH) Laboratory Services (Approval no. S73) (n=60, age range: 9 month – 90 years, median age: 10 
years).  Laboratory B - Austin Pathology (Approval no. 16.3162) (n=60, age range: 26-81 years, median 
age: 49 years).  Eight of the 60 samples from Laboratory B were specifically used for the initial proof 
of concept studies and 32 samples from Laboratory B were used to assess punch location; leaving 80 
samples (Lab A: n=60 and Lab B: n=20) used for the remaining method development and evaluation 
studies.  All specimens were previously collected by the two hospitals from the in-patients (signed the 
collection form including informed consent for research purposes) for routine analysis.  Information 
related to age, gender and the laboratories Hb and Hct results were provided. The Hb and Hct levels 
were determined on the laboratories’ (Siemens ADVIA® 2120i -Lab A and Sysmex XE-5000 –Lab B) 
instruments.  Both laboratories routinely participate in the Royal College of Pathologists of Australasia 
Quality Assurance Programs (RCPAQAP) for Haematology and are accredited to ISO15189-2012. The 
whole blood samples, prior to initial retrieval, were stored post analysis by the pathology laboratories 
for up to 48 hours or, 24 hours at 4oC by Lab (A) and (B) respectively.  
The retrieved EDTA sample tubes were mixed on a roller mixer for 30 minutes followed by 20 times 
using “figure 8” hand mixing, prior to blotting on the collection cards.  50 µL of whole blood was 
spotted on the filter paper (Whatman 903) (eight spots for each sample), then air-dried at room 
temperature (RT) overnight. To minimize and prevent pre-analytical errors affecting the quality of DBS 
analysis, we followed (and advise) the recommended standards for blood spot preparation including 
DBS quality, collection card choice, blood collection technique, transport and storage (10). For note, 
whilst capillary blood is the standard approach for DBS collection, studies have demonstrated that 
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variation of measured total Hb from capillary and venous samples is within the acceptable range for 
screening purposes (327-329). We spotted the whole blood samples onto Whatman 903 paper. This 
filter paper follows the CLSI recommendation and is approved by the Food and Drug Administration 
(FDA), Newborn Screening Quality Assurance Program (NSQAP) and also the Centers for Disease 
Control and Prevention (CDC)  (234, 239). 
Calibrators 
Lyophilised human haemoglobin (Sigma-Aldrich, Australia, Cat no. H7379) reconstituted in milli-Q 
water was used as in-house calibrator.  A four-point calibration curve was generated using the in-house 
Hb standard materials (100, 150, 200, 250 g/L).  50 µL of each level of standard was spotted on the 
Whatman 903 collection cards and air-dried overnight at RT (Figure 1). Calibrators were prepared and 
spotted at the same time as the first set of study samples were collected and spotted. In addition, the 
same calibrator batch was used across the entire study. 
Internal quality control (IQC) 
Commercial IQC (BioRad liquid tri-level human blood quality control material - Cat no. 970X) were 
spotted on the collection card and air-dried overnight at RT. The IQC material was prepared, and 50μl 
spotted at the same time and under the same storage conditions as the calibrators and other study 
samples. The In-house DBS control was prepared 12 months prior to the study commencement date. 
3.2.2 Measurement 
Pilot study 
The calibrator set along with the commercial and In-house IQC materials and eight pilot whole blood 
samples were used for the primary method development steps. These were run weekly for 14 
consecutive weeks. The aim was to observe the specimen behaviour over time in order to predict the 
appropriate time of analysis after spotting. Based on our observations and outcomes of this pilot study, 
a long-term stability testing procedure and other method validation studies were developed.  
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Sample preparation 
100µl of extraction solution of deionised water containing 0.1% formic acid (Sigma-Aldrich, Australia, 
Cat no. 5.33002) was added to one 3.2 mm DBS. All DBS samples were punched peripherally except 
for the “effect of punch point on measurement” study. The samples were subjected to 30 minutes 
shaking at ambient temperature followed by 10 minutes sonication.  85 µL of the sample eluate was 
then transferred into the standard flat-bottom clear 96-well plate (Thermo Scientific, Australia, Cat no. 
9502227) for spectrometric scanning.  
Spectral scan and photometric measurement 
A PerkinElmer - EnSpire Multimode Plate Reader (2300) using wavelengths of 520-600 nanometre 
(nm) with band pass width of 8 nm was utilised for the spectrophotometric scanning.  Sixty patient 
samples in conjunction with calibrators and IQC material were prepared as described above and scanned 
between 520 and 600 nm. Optical density values for all subjects were plotted against the wavelength to 
investigate the corresponding optimum absorbance. The wavelength of 540 nm was selected for Hb-
drv quantitation. 
Method evaluation studies 
Method evaluation studies were performed on DBS samples between 8 to 12 weeks post spotting time, 
unless otherwise specified in the relevant section. 
Imprecision 
The Intra-assay imprecision study was performed across three measured Hb-drv concentrations 
(average 123, 191 and 227 g/L).  The Hb-drv concentration of each sample was estimated in twenty 
replicates within the same run and the coefficient of variation (CV) calculated as a percentage (CV%). 
The IQC samples’ results, across the 26 distinct analyses, were used to estimate the inter-assay 
imprecision. 
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Linearity 
One human whole blood sample was used to generate two aliquots of extremely low and high levels of 
Hb (20 and 270 g/L).  Whole blood was spun, and the red cell fraction and separated plasma were mixed 
in different proportions to generate the highest and lowest levels.  Then the two samples were serially 
mixed at different ratios to generate a final nine-level set (20.00, 51.25, 82.50, 113.75, 145.00, 176.25, 
207.50, and 270.00 g/L) to study linearity on human blood matrix-match DBS sample.  DBS samples 
were processed in duplicate as described above.  LinChecker software was used for linearity testing.  
Stability 
A total of 60 samples were measured to determine the Hb-drv concentration.  Analysis occurred in 
weeks 2, 8, 12 and 48 weeks of spotting.  Measures were plotted against time to monitor the change 
over the 48 weeks period. 
Punch location   
To determine the effect of punch location on DBS Hb-drv results; each sample was double punched 
with punch 1) central-punch and 2) peripheral-punch, for the calibrators, controls (n=2) and samples 
(n=32). All were analysed 40 weeks post collection.  The central-punch was used as the “true” value 
and the peripheral-punch results were compared to the central-punch results with both the central-punch 
as the calibrator and also the calibrator set from the peripheral-punch.  Passing-Bablok regression and 
Bland-Altman difference plots were assessed to determine if the 95% confidence intervals (CI) 
demonstrated equivalence based on slope (where the CI should include 1.0) and intercept and mean 
difference (where the CIs should include zero).  A Student Paired T-test was used to determine statistical 
significance where p<0.05 was deemed to be a significant difference. 
Method comparison 
The correlation study was performed on 80 DBS samples 48 weeks post spotting. Hb and Hct levels of 
the human whole blood samples tested by two laboratories were considered as the reference values.  
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Measured Hb-drv values were plotted against the fresh whole blood Hct values measured by the 
reference method to predict the linear equation and the 95% confidence intervals.  DBS Hb-drv 
measures converted to their equivalent Hct using regression equation. 
Recovery study 
To determine the recovery a human whole blood sample collected on EDTA was used to generate a pair 
of diluted and spiked samples. Each sample included 450 µL of whole blood while sample A was spiked 
with 50 µL H2O and sample B was spiked with 50 µL Hb standard material (250 g/L) (i.e. adding 25 
g/L of Hb into the spiked sample). These samples were spotted onto filter paper and analysed 12 weeks 
post spotting. The calculation used to estimate recovery was; 
Recovery % = (Spiked DBS Hb-drv - Diluted DBS Hb-drv) × 100 / 25 
           = (Sample B Hb-drv – Sample A Hb-drv) × 100 / 25 
 
3.2.3 Calculations and statistics 
The Ricos C, et al data-base and rules in desirable analytical quality specifications for imprecision, bias 
and total error for whole blood samples  were utilised to evaluate the within-subject and between-subject 
CV values (330). Microsoft Excel software (scatter chart, trend-line equation) was used to generate the 
calibration curve and Hb-drv concentration calculation.  The “Imathas Boxplot Grapher” software was 
used to create Whisker and box plot was utilised for the stability study.  “Method Validator” software 
(Philippe Marquis 1999, version; 1.19) was used for accuracy testing and method evaluation studies 
(linear regression, Passing-Bablok and Bland-Altman difference plots). Assay linearity was assessed 
with LinChecker software (Philippe Marquis 2001, version; 1.1.2.0). The two-tailed t-test (Microsoft 
Excel software) was utilised to study the significance of the punch point of DBS samples. 
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3.3  Results 
3.3.1 Spectral scan and measurement method 
Our initial method development studies involved performing a spectral scan of all study samples over 
time.  The spectral scan of the 60 study samples (collected from Lab A) on the second week of spotting 
showed the two maximum absorption peaks at 540 and 576 nm, corresponding to oxy-haemoglobin 
(Hb-O2) as the major type of Hb present in fresh DBS samples (Figure 3.3.a).  However, following the 
transition of Hb-O2 into met-haemoglobin (met-Hb) and then hemi-chrome (HC) and other haemoglobin 
derivatives, the optimum optical absorption observed was at 540 nm for the aged DBS samples, IQCs 
and standard materials (Figure 3.3.b).  
a) 
 
b)  
 
Figure 3.3. Spectral scan of study samples (n=60; from Laboratory A) between 520 and 600 nm at: 
a) week 2 of spotting – Corresponding to the absorption spectra of Hb-O2, b) week 8 of spotting – Hb is denatured and its absorption spectra 
follows HC pattern 
3.3.2 Method evaluation studies 
The calibration curves were plotted using In-house calibrators with the concentrations ranging from 100 
to 250 g/L of haemoglobin (coefficient of determination (r2) = 0.99) (Figure 3.4.a). The linearity 
experiment determined the reportable range for the Hb-drv assay.  The assay was linear for whole blood 
samples from 82.5 to 207.5 g/L of haemoglobin (Figure 3.4.b). Biological range for Hb concentration 
for healthy individuals across the different ages and genders is between 90 – 175 g/L (331). Considering 
the range of calibration points and assay linearity testing data, the concentration within the linear range 
were deemed fit for purpose using the current method.  The calculated intra-run coefficient of variation 
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(CV %) for different levels was; 3.6, 2.4 and 4.3 %.  While the inter-run imprecision was calculated as 
a CV % of 7.9 and 7.5 for mean concentrations of 117 and 197 g/L respectively.  The recovery was 
84%. 
a) 
 
 b) 
 
Figure 3.4. a) Calibration curve; calibrators were prepared and spotted at the same time as other study samples were collected and spotted. 
The calibrator batch was consistent across the entire study. b) Linearity experiment using human whole blood demonstrating the method is 
linear between 82.5 and 207.5 g/L Hb-drv. 
 
 
 
 Figure 3.5. Stability testing results of the 60 DBS samples from Laboratory A analysed over 48 weeks of spotting. Analysis occurred in 
weeks 2, 8, 12 and 48. This report demonstrates that the samples are stable after week 8. a) Visual plot (vertical dash-lines represent the 
measurement time points). b) Whisker and Box plot with the box showing the 25th to 75th percentile and whiskers demonstration the lowest 
and highest results obtained at the time points. 
The measured Hb-drv from DBS samples over the 48 weeks, demonstrated that the samples are stable 
after week 8 (Figure 3.5). Using the Passing-Bablok regression procedure, correlation coefficient (r) 
value was 0.88 for week 48 of post spotting (slope: 4.3, intercept: 26.6) (Figure 3.6). The second set of 
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samples were analysed at week 40 of the study using the central and peripheral punches of DBS 
samples.  Comparison of the central and periphal-punch location demonstrated agreement based on the 
slope 0.93, intercept 6.1 and difference -6.4 using the central-punch calibrator for both (and difference 
2.6 using the central-punch calibrator for both).  Using the calibrator punched from the respective 
samples’ punch locations, the agreement was slightly improved with the slope 1.046, intercept -1.2.  
The t-Test was also not significant with p>0.05. 
a) 
 
b) 
 
Figure 3.6. Comparison of estimated Hb-drv (g/L) and equivalent Hct (calculated based on whole blood Hct and DBS Hb-drv relationship 
equation) (%) of the 48 weeks old DBS samples (n=80; from both Laboratories A and B). a) Passing-Bablok regression plot for comparison 
of measured Hb-drv from DBS versus whole blood Hct measure by the reference method (        indicating regression line).  The equation 
demonstrating the relationship is y = 4.3x + 26.6; r = 0.88. b) Bland-Altman plot demonstrating a mean difference of 2.4 % (95% CI: 1.8-3.0 
%) between calculated DBS Hct (from the Passing-Bablok relationship equation) and measured Hct of original whole blood samples, 
demonstrated by the black solid line (       ), compared to the expected difference of zero demonstrated by the red solid line (        ) and 95% 
range of difference as demonstrated by the two red dotted lines (- - - ). 
3.4  Discussion 
We have successfully developed and validated a simple assay to estimate the Hct in aged DBS samples, 
such as those available from newborn screening programs.  This assay can be used for bio-bank DBS 
samples that are at least two months of age.  Prior to 8 weeks, the samples are still undergoing change 
so the level of hemi-chrome (HC) is unstable.  The current DBS Hb-drv method can be directly 
incorporated into the measurement method, or alternatively the analysis can be done on a reserved DBS 
punch.  This will depend on the extraction procedure of the analyte to be measured. We therefore 
suggest this approach for screening of low and high Hct and subsequent adjustment of the analyte results 
to improve their quantitation accuracy. 
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Previously other groups have attempted to correct for Hct effect on DBS analysis (10, 167, 318-324).  
The obvious approach is to measure Hct on the fresh whole blood at the time of collection.  Recently, 
three studies have looked at Hb fractions, the first two used a spectrophotometric method for the 
determination of Hb in fresh DBS samples (one to 10 days post collection) from human and lamb blood 
however,  as the Hb molecule on the DBS changes over time (due to instability of Hb), the Hb analysis 
of “fresh” DBS samples would be different to “archived”  DBS samples (332, 333). A third study used 
non-contact diffuse reflectance spectroscopy technology with a quasi-isosbestic point of 589 nm for 
samples from 2 days to 5 months post spotting (323). Our method extends further providing a simple 
and robust assay for archived DBS analysis of Hb-drv that takes into account extraction efficiency and 
uses a spectrophotometer plate reader; an instrument readily available in most laboratories. In addition, 
this method is validated for analysis of DBS samples that extends to 48 weeks post spotting. 
The starting rationale for our method development was based on the measurement of Hb in the plasma 
of haemolysed blood samples, as part of the serum/plasma indices measurement on a general 
biochemical analyser. DBS size for sample analysis varies from as small as one 3.2 mm punch 
(containing approximately 3 µL of blood) to the analysis of the whole blood spot (containing 
approximately 50 µL of blood).  In either extreme, the DBS sample is highly diluted in the extraction 
solution as part of the sample preparation process (which includes matrix conversion from solid into 
the liquid) and the overall concentration of Hb in the extract is low.  Likewise, the concentration of Hb 
in plasma (due to red blood cells haemolysis) is also low (compared to whole blood Hb); which is 
measured routinely using a direct spectrometric principle (334, 335). 
The basic “Beer-Lambert” equation (A=ɛbc) principal has been previously employed for assessment of 
Hb concentration in tissue diagnosis (336). We therefore investigated the use of the Hb molar extinction 
coefficient and a direct spectrometric technique with calibrators for Hb-drv estimation.  However, as 
the extinction coefficient is defined for fresh and intact whole blood samples, and our samples are air 
exposed (causing the conversion of Hb into its variants; Hb-O2, met-Hb and HC), this approach was not 
possible; to achieve this we would need to know the ratio of the various derivatives and apply their 
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specific extinction ɛ coefficients.  Hence, we chose to develop aged DBS calibrators for incorporation 
into our method to generate a standard curve. 
We have confirmed that the total Hb-drv concentration is directly measurable by using visible 
absorption spectroscopy.  As the Hb-O2 spectrophotometric band is known to be proportional to the 
concentration of Hb (337), we scanned for the expected absorption peaks in the visible region between 
520-580 nm (338). Both foetal and adult haemoglobin variants (HbF and HbA) are known to follow 
similar optical absorption spectra patterns with the maximum absorbance at around 540 and 575 nm 
(339). Over time, Hb-O2 under the influence of oxidants converts to met-Hb, and then transforms to HC 
resulting in a change in the spectral scan. 
The transition time for Hb conversion to Hb-drv is unpredictable. The transition of Hb-O2 into met-Hb 
and HC is rapid over the first 10 hours, after that the transition rate slows down over the period of 7-10 
days (34). Also, the rate of Hb degradation (Hb-O2 into met-Hb then HC) in dried samples become 
stable after 8 weeks (1500 hrs) of drying or spotting on the filter paper become stable and the change is 
then close to zero (35). Our stability data supports and extends these studies as we also demonstrate the 
stability of Hb-drv from 8 weeks and the validation of the Hb-drv for at least 48 weeks (323, 338-340).  
 Our observations from processing 60 human DBS samples shows the optimum optical density (quasi-
isosbestic) to be at 540 nm, which represents a high positive correlation for measured Hb-drv versus 
the reference Hct.  For comparison, in parallel over the three-month period we used two wavelengths 
for the direct spectrometric method calculation to estimate the total Hb fraction content of the DBS and 
convert it to its corresponding Hct level. Comparing the correlation coefficient of the measured Hb-drv 
using both wavelengths against the reference Hct, reading at 576 nm demonstrated inferior correlation 
at 576 nm compare to 540 nm. Therefore, the wavelength of 540 nm was chosen for Hb-drv estimation 
of the archived DBS samples.  In addition, this Hb-drv spectra pattern is not significantly affected by 
pH variations (340) and we observed enhanced extraction efficiency with slight acidification of the 
extraction solution.  
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Our method validation included assessment of imprecision and bias compared to biological variation 
(330, 341). The correlation between the measured Hb-drv and the reference Hct were consistently good 
over the study time (week 1 to 48) (342). However, as it was expected from the Hb degradation process, 
the slope and intercept continued to change for the first 8 weeks but then remained consistent for the 
remainder of the study period (48 weeks).  The total error was also assessed by comparison to biological 
variation and Clinical Laboratory Improvement Amendments guidelines for Total Allowable Error 
(CLIA 88 TEa) (343). We found that our imprecision compared to the biological variation criteria was 
less than the minimum criteria.  Bias, and therefore, TEa was assessed based on the recovery data and 
also did not meet these specifications.  Hence this assay is not fit for the retrospective diagnosis and 
monitoring of blood pathologies such as anaemia and polycythaemia.  However, as biological variation 
data is generated for Hb in whole blood and our assay is not intended for this purpose we deemed the 
other method validation components to be acceptable, we propose this method is fit for purpose. 
3.5 Conclusions 
We have successfully developed a simple Hb-drv method to estimate Hct in aged DBS samples. This 
method can be incorporated into DBS analytical work-flow for the in-situ estimation of Hct and 
subsequent correction of the analyte of interest.”  
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Chapter 4 
 
Determination of Vitamin D from Dried 
Blood Spot Samples  
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4 Determination of Vitamin D from Dried Blood Spot Samples  
Vitamin D conventionally is measured as 25-hydroxy vitamin D3 in serum / plasma and the 
interpretation cut-offs are well-defined. However, for large-scale population studies sample handling 
procedures including; collection, transport and storage are cumbersome for serum/plasma specimens.  
Accordingly, the interest in the use of dried blood spots (DBS) as an alternative matrix for vitamin D 
assessment has increased.  Following the project aim of investigation of the association between early 
life vitamin D insufficiency and paediatric food allergy, we developed an accurate method for 
measurement of 25-hyroxy vitamin D3 (25-OHD3) from archived DBS samples.  
This chapter with contribution of other co-authors has been submitted to the (The Journal of Steroid 
Biochemistry and Molecular Biology) for peer revision and to be published as an analytical full paper. 
4.1 Introduction 
A century has now passed since the flurry of research leading to the discovery of vitamin D and its role 
in bone health (344). More recently it is the activities of the current millennium that have expanded our 
understanding of the vitamin D pathway and the potential implications of vitamin D deficiency on a 
range of pathologies.  As the increasing involvement of vitamin D in physiological functions has been 
elucidated, requests for evaluation of patient vitamin D status have increased exponentially.  The 
overarching aim of these requests is to clinically stratify patients as replete or deficient in vitamin D 
(9). 
Despite awareness of the importance of vitamin D, deficiency is still considered a global health 
challenge (345), and the application of vitamin D testing is extended further from monitoring into 
broader areas such as epidemiological and population studies.  The use of the traditional measurement 
of vitamin D (i.e. serum/plasma 25-OHD3) by automated immunoassay (referenced to LC-MS/MS 
methods) has limitations when applied to population studies, especially those involving children.  These 
limitations range from the volume of blood required to be collected, how it is transported and associated 
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cost, through to the amount of storage space required (either refrigerated or frozen).  It is these 
cumbersome steps that have resulted in the push for alternative micro-sampling techniques (i.e. 
collection and analysis of ≤ 50 µL of biological samples) utilising a dried blood matrix for the 
assessment of vitamin D.  
DBS matrices have been applied to many applications both within and outside of newborn blood spot 
screening (NBS) (10).  The various hydroxylated forms of vitamin D are all small well defined 
hydrophobic seco-steroids, with 25-OHD3 the most commonly measured.  The long-term stability of 
25-OHD3 on DBS is detailed in the literature (118, 167, 346, 347) and its analysis by LC-MS/MS has 
also been previously demonstrated (118, 167, 169-171, 347, 348).  Hence this micro-sampling 
application can be readily applied for the measurement of 25-OHD3.  This also means that archived 
DBS samples e.g. those collected from NBS programmes can be retrospectively analysed for vitamin 
D population studies. 
Whilst, the pre-analytic components are simplified through application of the DBS matrix, there are 
new analytical and post analytical challenges to consider using this approach.  These considerations 
include: 
1) How to ensure traceability is maintained - Serum/plasma vitamin D is standardised and 
traceable to Certified Reference Materials (CRM), Reference Measurement Procedures (RMP) 
and for Reference DBS Measurement Laboratories (RML).   
2) The lack of peer review programs to support ongoing standardisation and there are no evidence-
based agreed decision limits that are broadly applied (349).  
3) How best to achieve the required sensitivity? 
4) Interpretation of data by comparison to serum / plasma equivalent and the cut-offs for 
interpretation are clearly defined (350-352).  
To advance the literature regarding measurement of vitamin D the following study aimed to develop a 
sensitive and robust local DBS vitamin D method, that is traceable to serum for use in population-based 
studies.  
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4.2  Materials and Methods 
4.2.1 Chemicals, calibrators and quality control materials 
Collection card; To prepare DBS samples whole blood specimens were blotted on Whatman 903 filter 
paper, following the Clinical and Laboratory Standards Institute (CLSI) guidelines (234, 239).  This 
filter paper is approved by the Food and Drug Administration (FDA), Newborn Screening Quality 
Assurance Program (NSQAP) and also the Centers for Disease Control and Prevention (CDC) (239). 
Chemicals; Hexane for liquid chromatography was purchased from Merck (VIC, Australia): hexane 
(CAS No. 110-54-3, Cat no. 1.04391.2500), also Thermo Scientific (VIC, Australia) provided Optima 
methanol for liquid chromatography (CAS No. 67-56-1, Cat no. A456-4). Amplifex™ Diene Reagent 
was purchased from Sciex (MA, USA) (product no. 5037804) and was prepared following the 
manufacturer’s instructions and diluted (1:1) with acetonitrile prior to use. Formic acid (purity ≈98%, 
CAS No. 64-18-6, Cat no. 94318) was obtained from Sigma-Aldrich (VIC, Australia). 25-
hydroxyvitamin D3 (purity ≥98%, CAS No. 19356-17-3, Cat no. S4163UNL), 3-epi-25-
hydroxyvitamin D3, (purity ≥98%, CAS No. 73809-05-9, Cat no. S7004), 25-hydroxyvitamin D3-[2H6], 
(purity ≥98%, CAS No. 140710-94-7, Cat no. S4163 were purchased from IsoSciences (PA, USA) via 
their Australian distributer (PM Separations, QLD, Australia). The nitrogen gas cylinder (N5.0 [Purity 
≥ 99.999%], CAS No. 7727-37-9) was supplied by Coregas (VIC, Australia). Seracon human plasma 
matrix matched diluent (Material Number1800-0027) was purchase from SeraCare (Milford, MA, 
USA). 
Calibrators; The multi-level NIST-972a traceable ChromSystems calibrator set (seven levels, Cat no. 
62039) was used for 25-OHD3 quantitation. It was prepared according to the manufacturer’s 
instructions and stored at -20°C. The calibration curve covered blank to 376 nmol/L 25-OHD3 
concentrations. Based on our theoretical calculation and other practical studies, an average 3.2 mm DBS 
punch contains approximately 3.1 µL of whole blood (353, 354), which is 1/16 of the 50 µL of the 
liquid sample. Different amounts of internal standard (ISTD) material (proportional with the ratio of 
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liquid samples volume to DBS punch) was added into calibrators, quality control (QC) materials and 
DBS samples to correlate the 3.2 mm DBS punch results to equivalent liquid matrix concentration. 
Internal quality controls (IQC) and External quality assurance (EQA) materials; Commercial 
UTAK lyophilised IQC set (tri-levels: low, mid, high – Cat no: 1060-2) was used for vitamin D. An In-
house DBS IQC was prepared using 50 µL of a human whole blood sample, spotted on the filter paper 
(Whatman 903) and air-dried overnight in ambient condition. The Royal College of Pathologists of 
Australasia Quality Assurance Programs (RCPAQAP) samples were used in conjunction with IQC 
materials to certify the traceability of the measurement, which has target values for vitamin D assigned 
by National Measurement Institute Australian Government (NMIA). Our laboratory routinely 
participates in the RCPAQAP for Endocrines (including vitamin D). 
4.2.2 Subjects 
De-identified venous whole blood samples (n=80, collected in ethylenediaminetetraacetic acid 
(EDTA)) were sourced from the Royal Childrens Hospital Melbourne Laboratory Services (Approval 
no. S73) (Lab A) and Austin Pathology (Approval no. 16.3162) (Lab B) and used for the method 
development and evaluation.  Information related to age and gender were provided. The plasma 25-
OHD3 level for these samples was determined in our laboratory using an adaptation of our previously 
validated LC-MS/MS method (355).  Prior to initial retrieval, the whole blood samples were stored post 
analysis by the pathology laboratories for up to 48 hours at 4 °C (Lab A) or, 24 hours at 4 °C (Lab B). 
Samples sourced from Lab A generally included paediatric patients (median age:10 years, gender 
ratio:1) while whole blood specimens obtained from Lab B compromised the adult population (median 
age:63 years, gender ratio:1).  
A whole blood aliquot (1 mL) of each sample was spun at 2000 revolution per minute for 5 minutes 
and separated plasma was stored in -20 °C. The EDTA sample tubes were mixed on a roller mixer for 
30 minutes followed by 20 times using “figure 8” hand mixing, prior to blotting on to the collection 
cards.  50 µL of whole blood was spotted on the filter paper (Whatman 903) (eight spots for each 
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sample), then air-dried in ambient condition overnight. Prepared DBS cards were stored at room 
temperature in a biohazard specimen zipper plastic bag and light protected. 
4.2.3 Measurement 
Sample Preparation 
Liquid calibrators, IQC materials and any other liquid matrix samples were prepared in conjunction 
with the DBS samples (solid matrix); 
DBS, calibrators and control sample preparation, involved a 3.2 mm DBS disk punched from 
the whole blood sample spotted on the filter paper and placed into a 96-well micro plate. 125 µl of de-
ionised water was added to the DBS disk. Concurrently, 50 µL de-ionised water was added to 50 µL of 
calibrators and liquid QC materials, followed by 60 minutes shake; the first 30 minutes at room 
temperature and the second 30 minutes at 60 °C. 75 µl water-methanol mixture containing 10 nmol/L 
and 100 µL of water-methanol mixture containing 123 nmol/L deuterated ISTD (25-hydroxy vitamin 
D3-d6) were added into DBS and calibrators/IQCs samples respectively. Samples were subjected to 
further 10 mins sonication (40kHz, Unisonics, Part No; FXP, Unisonics Australia Pty Limited, 
Australia). 
Supported liquid extraction (SLE) procedure, was adapted from the manufacturer’s published 
application note (356). DBS eluate and pre-treated calibrators and IQCs, were purified by using Biotage 
SLE cartridges (Cat no. 820-0200-P01) and application of 350 µL hexane elution (twice). The sample 
eluates were collected and dried using a rotational vacuum concentrator (Martin Christ, Part No: RVC2-
33PACK, John Morris Scientific Pty Ltd, Australia) at 40oC temperature and 500 rounds-per-minutes 
speed. 
Derivatisation, 50 µL ½ diluted (in acetonitrile) Amplifex diene reagent solution added to the dried 
sample, then vortexed for 20 seconds, followed by 30 mins incubation at 4 °C. The derivatisation 
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reaction was neutralised by the addition of 75 µL methanol/de-ionised water mixture (1:1). Figure 4.1 
demonstrates the derivatisation reaction of 25OH-D3 with Amplifex diene. 
    
Figure 4.1. Derivatisation reaction of 25OH-D3 using Amplifex Diene label (adapted from Müller et.al (357)). In MS method result of 
derivatisation, the molecular weight of the derivatised product would be greater than the initial precursor, where mass to back ground noise 
ratio is relatively decreased. 
 
Liquid Chromatography – Tandem Mass Spectrometry detection 
The water-methanolic extract was injected onto a core-shell column (2.6 µm, 100 mm, Kinetex F5, 
Phenomenex Inc., Australia). An Agilent HPLC Model 1260 infinity coupled with the Agilent Model 
6490 triple-quadrupole mass spectrometer was used for the sample analysis. Derivatised 25-OHD3 was 
eluted using a solvent program. The initial solvent was 60% methanol in water (containing 0.1% formic 
acid) with a flow rate of 0.25 ml/min. The maximum organic solvent gradient was 100% methanol. 
Multiple reaction monitoring (MRM) and electrospray ionisation (ESI) positive mode was applied for 
mass spectrometry measurement with the following mass to charge ratio (m/z) for precursor and product 
ions; 25-OHD3 quantitation using: 732.5673.4 (Collision energy: 30 eV), and qualifier 732217 
(Collision energy: 50 eV), with the ISTD 738.4  679.4 (Collision energy: 30 eV). Ion source 
specifications were as follows; gas temperature: 290 °C, gas flow: 11 L/min, nebulizer pressure: 40 psi, 
sheath gas temperature: 275 °C, sheath gas flow: 7 L/min with the nozzle voltage of 2000 V. 
Assay performance studies  
The method was validated following the Clinical Laboratory Improvement Amendments (CLIA) final 
rules and recommendations (358). The intra-run imprecision study was performed across three 
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measured vitamin D concentrations from DBS samples (low: 7, medium: 22 and high: 50 nmol/L). 
Derivatised 25-OHD3 concentration of each sample was estimated in twenty replicates within the same 
run and the coefficient of variation calculated. The IQC samples were used to estimate the inter-run 
imprecision. The lower limit of quantitation was determined for the lowest concentration with 
coefficient of variation (CV) of <20% for twenty replicates with signal to noise ratio (S/N) >10. In 
addition to track the assay accuracy and traceability, a pair of RCPAQAP samples were analysed and 
reported monthly. Furthermore, assay linearity was checked for DBS by testing a set of spotted whole 
blood samples serially mixed in five different concentrations from low and high levels of 5 and 40 
nmol/L.  
De-identified whole blood samples (n=80) collected from Lab A and Lab B were used for the method 
comparison study and to determine the relationship to the serum calibrator. The matching plasma 25-
OHD3 level was determined in our laboratory using our previously validated LC-MS/MS method (355). 
Measured derivatised 25-OHD3 levels from spotted samples were plotted against the plasma 25-OHD3 
to predict the linear equation and confidence intervals of 95%. To assess the effect of punch location a 
set of DBS samples (n=11) with different levels vitamin D (low, medium and high) were tested in 
duplicate (punched from the centre and edge of the blood spot).    
The recovery study was performed by using a human whole blood sample collected in EDTA to 
generate a set of diluted and spiked samples at low and high concentrations. Each sample included 450 
µL of whole blood, where 50 µL H2O was added to the whole blood to generate diluted sample and the 
other aliquots were spiked with 50 µL 25-OHD3 standard materials (84, 376, 538 nmol/L). DBS 
samples were analysed after 3 months of spotting. Blank samples including 3.2 mm filter paper punches 
and 50 µL deionised water were analysed for the carry-over study in triplicate following the highest 
level of IQC samples for both dried and liquid matrices. 
To investigate the matrix effect and ion suppression, a blank sample including washed red blood cells 
diluted in Seracon (matrix matched vitamin D free serum) (45:55) was spiked with pure 25-OHD3 (25 
µg) and spotted on the filter paper. Vitamin D was measured from the dried spiked sample in 
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conjunction with matrix-free matching derivatised 25-OHD3 (359, 360). Additionally, phospholipids 
(which could induce ion suppression) were consistently monitored using their common ion transitions; 
(104→104 and 184→184). 
Quantitation and statistics 
Stöckl D, et al and Fraser C.G recommendations for the desirable analytical quality specifications for 
imprecision, bias and total error for measurement of vitamin D were utilised to evaluate the within-
subject, between-subject CV values and assay fitness for purpose (330, 361, 362). Agilent MassHunter 
Workstation Data Analysis software (version: B.4.04/B.4.0/B.5.0) was used for qualitative and 
quantitative analysis. LinChecker software was used for linearity testing (Philippe Marquis 2001, 
version; 1.1.2.0). “Method Validator” software (Philippe Marquis 1999, version; 1.19) was used for 
accuracy testing and method evaluation studies (Linear regression, Passing-Bablok and Bland-Altman 
difference Plot). 
4.3  Results 
25-OHD3 was eluted and extracted from a 3.2 mm DBS disk in conjunction with the liquid matrix 
calibrators and quality controls using SLE. Derivatised 25-OHD3 and its relative ISTD were separated 
and detected at 7 minutes retention time on 100% methanol gradient of LC-MS/MS analysis (Figure 
4.2). The 7-point calibration constantly demonstrated a coefficient of determination of, at least 0.99 
(Figure 4.3). The assay has the lower limit of quantitation of 0.5 nmol/L (S/N = 10) and the upper limit 
of linearity of 376 nmol/L. Besides the linear range of the calibration curve, the linearity experiment 
confirmed the linear norm between 5 to 40 nmol/L 25-OHD3 of the raw results for DBS samples (Figure 
4.4). 
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a)  b) 
 
 
Figure 4.2. Example 25-OHD3 chromatography-mass spectrometric peaks. (A) Chromatogram of 25-OHD3 and 3-epi-25-OHD3 from a 50 
μL spiked plasma sample: MRM 401.0 > 383.0 m/z and retention time of approximately 18.4 to 19.2 min [23]. (B) Chromatogram of 
derivatised 25-OHD3 and 3-epi-25-OHD3 from a 3.2 mm spiked DBS sample: MRM 732.5 > 217.0 m/z and retention time of approximately 
7 to 7.5 min.  
 
Figure 4.3. A typical calibration curve generated by MassHunter Quantitative Analysis software; blank to 376 nmol/L 25-OHD3 
concentrations using liquid matrix calibrators. 
 
Figure 4.4. Linearity experiment using spotted human whole blood demonstrating the method is linear between 5 to 40 nmol/L 25-OHD3 
directly measured of DBS samples. 
25-OHD3 
3-epi-25-OHD35 
25-OHD3 
3-epi-25-OHD3 
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Calculated within-run CV for low (15 nmol/L), medium (22 nmol/L) and high (42 nmol/L) level of 25-
OHD3 was; 10.5, 8.1 and 9.3 % respectively. Therefore, calculated uncertainty of measurement is equal 
to +/- 21.0 %. This is in addition of bias of calibrator which is unknown. While between-run imprecision 
was calculated as a CV of 12.9 % for mean concentrations of 7.8 nmol/L for DBS and 8.9, 6.7 and 5.6 
% for respectively for low, medium and high level UTAK liquid quality controls.  
The comparative accuracy of 25-OHD3 measures of DBS samples compared to their matching plasma 
samples demonstrated the coefficient of correlation of R = 0.94 for internal quality controls (n = 7), R 
= 0.91 for Lab A samples (n = 40) and R = 0.96 for Lab B samples (n=40) and R = 0.86 (n=80) for the 
combined analysis (mixed results of lab A and B) (Figure 4.5). 
a) b) 
  
Figure 4.5. Comparison of 25-OHD3 (nmol/L) measures of DBS samples and their matching plasma samples (n=80, combined data analysis 
from both laboratories A and B). a) Passing-Bablok regression plot for comparison of 25-OHD3 (nmol/L) measures of DBS samples and their 
matching plasma samples (- - -  indicating regression line). The equation demonstrating the relationship is; R=0.86, y = 0.41x -0.2. B) Bland-
Altman difference plot demonstrating a mean difference of -2.14% (95% limits of agreement: -5.69 to 1.41 %) between plasma-equivalent 
DBS vitamin D (from Passing-Bablok relationship equation) and plasma measures (black solid line        ). 
Comparison of the central and peripheral punch location demonstrated agreement based on the slope 
1.01 (0.95 confidence interval 0.82 to 1.24), intercept 0.78 (0.95 confidence interval -2.58 to 3.02), 
difference 0.79 (0.95 confidence interval -0.30 to 1.88) and the paired t-test (two-tailed) P value equals 
0.13 (Figure 4.6). The recovery rates were calculated as 94, 84 and 89% respectively for 8.4, 37.6 and 
53.8 nmol/L concentrations of 25-OHD3 from DBS samples. Carry-over was determined as <0.1 and 
<0.5 % respectively for liquid and DBS matrixes. The total ion relative response diffrence between 
spiked DBS sample and pure matrix material, was calculated as 11.5% and phospholipid peak retention 
time was on average 3 minutes distinct from the derivatised vitamin D (Figure 4.7). 
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a) 
 
 
 
 
b) 
 
  
Figure 4.6. Comparison of 25-OHD3 (nmol/L) measures of central DBS punch and their matching peripheral DBS punched disk (n=11); a) 
Passing-Bablok regression plot for comparison of 25-OHD3 (nmol/L) measures of central DBS punch and their matching peripheral punched 
disk (- - -  indicating regression line). The equation demonstrating the relationship is; R=0.98, y = 1.01x =0.8. B) Bland-Altman difference 
plot demonstrating a mean difference of 0.79% (0.95 CI: -0.30 to 1.88 %) between central punched DBS and peripheral punched DBS 25-
OHD3 (nmol/L) measures (black solid line       ). 
 
Figure 4.7. Monitored phospholipids along with MRM detection of derivatised 25-OHD3. Phospholipids are known as the major source of 
interference and potential cause of ion suppression for blood analysis using mass spectrometry. Progressive monitoring of phospholipids 
demonstrated that there was no significant chromatographic effect on derivatised 25-OHD3 peaks (phospholipids’ structure adapted from 
Little et.al (363)).  
4.4 Discussion 
We have successfully developed and validated a LC-MS/MS assay to estimate 25-OHD3 from DBS 
samples, using one 3.2 mm punch. This assay has improved correlation with liquid matrix, sensitivity, 
imprecision and/or robustness over other previously published procedures described for vitamin D 
analysis of DBS sample. In addition, our method extends further to assess vitamin D status using 
archived DBS samples, which is relevant for epidemiological studied by application of semi-automated 
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sample preparation and analysis process (increased throughput). Furthermore, measured 25-OHD3 by 
the current method is traceable to NIST SRM972 standard reference material as the DBS samples were 
linked to the 7-point commercial serum calibrators which is reported by the manufacturer to be traceable 
to NIST, in addition certified external quality control materials (Figure 4.8). 
 
Figure 4.8. The RCPAQAP Endocrine program vitamin D end of cycle report. This report demonstrating the method accuracy and 
performance. To track the assay accuracy and traceability, a pair of RCPAQAP samples were analysed and reported monthly to control LC-
MS/MS method calibration and accuracy to detect 25-OHD3 in liquid samples including the DBS-extracts. All the values of RCPAQAP 
analyses, at different concentrations of 25-OHD3, are within the acceptable range and close to the target values (compared to the different 
method users including other MS method users. The advantages of our DBS-vitamin D method are; high accuracy, precision and the tractability 
of the DBS measures to the liquid sample. 
Previously other groups have attempted to measure vitamin D metabolites from DBS samples, however, 
inadequate assay sensitivity, analytical robustness and / or low throughput has limited their application 
to large population base studies (118, 169-171, 347, 348, 364, 365). Furthermore, a traceability chain 
that links the measured vitamin D from the archived DBS sample to the liquid matrix previously has 
not been clearly defined. 
Pre-analytical variables including storage, punch location and haematocrit effect on DBS analysis are 
considered as a source of bias and inaccuracy of measurement. Additionally, the stability for different 
biomarkers in dried matrix is quite variable. Thus as part of the method evaluation process, analyte 
specific stability study from collection to storage and analysis of the DBS sample is highly 
recommended (10). However, multiple studies have demonstrated that vitamin D metabolites are stable 
on dried matrix for 8-20 years (118, 167, 346, 347). Furthermore, to improve the accuracy, it has been 
recommended to consistently punch the blood spot either from the centre or close to the outer edge 
(254, 366). Nevertheless, more recent reports, similar to our observation from haemoglobin-derivative 
assay method development/evaluation process, and this current study dispute the punch location and 
haematocrit effect as the source of bias for DBS analysis (316, 353, 365). 
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The incorporation of SLE and Amplifex derivation reagent for sample preparation have improved 
sample quality and ionisation efficiency, in conjunction with decreased ion suppression and reduced 
phospholipid interference. Together these have a significant impact on assay sensitivity and lower limit 
of quantitation (0.5 nmol/L) compare to the previously developed methods. Vitamin D metabolites are 
non-polar molecules. Due to lack of naturally charged group, vitamin D metabolites have low ionisation 
efficiency under ESI or atmospheric pressure chemical ionisation (APCI) conditions. This has resulted 
in tagging substances being utilised to increase their ionisation capacity. It is reported that, the 
derivatisation process may improve the sensitivity of MS methods for vitamin D detection by 100-1000 
fold (367), which potentially influences the required sample volume for analysis. In MS based methods, 
as a result of derivatisation process, the molecular weight of the derivatised product is greater than the 
precursor, thus mass to back ground noise ratio is relatively decreased.  
Several highly reactive triazolinedione compounds (TADs) have been described for vitamin D mass 
spectrometer detection methods. These compounds generally are group members of nitro-aromatic 
complexes such as phenyl-triazoline-dione analogues and Cookson-type substances (21-24). TADs in 
general increase the vitamin D metabolites ionisation aptitude with the most stable positive charge. In 
addition, the rapid derivatising reaction of vitamin D analogues with TADs is stable and rationally 
irreversible under LC-MS/MS condition (25). 4-phenyl-1,2,4-triazoline-3,5-dione (PTAD) has been 
previously used, and is commercially available, to enhance the sensitivity of LC-MS/MS methods 
developed for determination of either low concentration metabolites (e.g. 1,25(OH)-D3) or small 
sample volume analysis (e.g. DBS) (170, 348, 364, 368). Lately Amplifex diene derivatising reagent 
became available, which has been specifically designed for LC-MS/MS measurements due to an 
activated dienophile moiety in its molecular structure as well as the positively charged terminal group 
(Figure 4.1). Our observation and other studies have demonstrated the advanced assay selectivity and 
sensitivity using Amplifex over PTAD (369). The advantage of Amplifex over other Cookson-type 
derivatising reagent for vitamin D metabolites analysis is separation of 3-epimer (357, 369) (Figure 2). 
Our method validation included assessment of imprecision and bias compared to biological variation 
(330, 361). Following CLSI guidelines, accuracy studies included the comparison of the experimental 
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method with the reference method (including regression and Bland-Altman difference plots), and 
estimation of the recovery rate of target analyte from its matrix as well as interference detection and ion 
suppression (370). The correlations between the measured vitamin D (25hydroxy-vitamin D3 plus epi 
-25-OHD3; no 25-OHD2 was identified) and the reference plasma 25-OHD3 were consistently high 
positive across the mixture of adults and paediatric samples (371). DBS vitamin D measurements are 
comparable to equivalent plasma values by application of a correction factor derived from the regression 
slope of and intercept (Figure 4.5).  
Assay imprecision experiments, including inter/intra-run reproducibility testing, demonstrated a 
desirable rate of precision for all studied levels (in agreement with FDA guideline; < 15% coefficient 
of variation (372)). Accuracy or systematic error, as well as sensitivity of an analytic method is directly 
influenced by recovery rate and matrix effect (driven by ion suppression and presence of interfering 
substances) (359, 360). Considering recommendations and available data presenting recovery rate for 
different MS methods for measurement of 25-OHD3 (rate range of 86-110 %) (361), our assay 
represents similar acceptable levels of recovery across the pathological range. The Ion suppression 
study demonstrated an insignificant difference (<12%) between the total ion relative response of spiked 
DBS sample and pure matrix material. In addition, progressive monitoring of phospholipids in 
conjunction with total ion respond comparison between spiked DBS and matrix free sample, 
demonstrated that there was no significant chromatographic effect on derivatised 25-OHD3 peaks. 
It is important to note the potential limitations from the DBS sample itself. Apart from the commonly 
raised issues such as Hct effect etc. the age of the DBS may be a significant variable.  Whilst others 
have found vitamin D to be stable long term, during the last 4 years of our studies we have potentially 
observed a visual colour change in extracts as the control samples grow older. A confounder to this 
observation is that we were developing and changing the analytic process over this period to generate 
our final method. It is unclear if this visual change has also an influence in vitamin D extraction 
efficiency or not. As the answer is not clear, we strongly recommend DBS vitamin D methods to be 
used for population studies only and not individual patient measurement. Furthermore, for these 
population studies usually samples should all be of a similar age to negate any potential difference. 
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Finally, we note that this is an observation and this speculation is not substantiated, therefore does not 
necessarily counteract the reported long term stability of vitamin D (5, 6).  
Conventionally vitamin D is measured from the liquid matrix (serum/plasma) and the cut-off for 
interpretation and measures of traceability chain is clear. Certainly, traceability along with cross 
validation of the method to a reference plasma/serum-based method is a vital requirement for offering 
an analytical method as a diagnostic tool (10, 373). The theoretical ratio between the average amount 
of blood sample on a DBS punch and the volume of liquid sample that was applied defines the relative 
quantity of internal standard for both DBS and liquid samples (including commercial standard and 
control materials) within the same analytical method to maintain the traceability chain link between the 
dry and liquid matrices. However, to turn the numerical result from DBS analysis into a clinically 
meaningful result, a reference interval (RI) or decision point needs to be established by further large 
population studies. In addition, this assay potentially can be a candidate reference measurement 
procedure for the determination of 25-OHD3 in DBS sample, since our method validation technique 
meets the ISO 15193:2009 licence criteria including; application of traceable standard material to 
generate the calibration curve, measurement uncertainty assessment (imprecision and accuracy testing) 
and systematic assessment of factors influencing results (point of punch and matrix effect studies) (374). 
4.5  Conclusions 
We have successfully developed an analytical method for quantitation of vitamin D from DBS samples. 
The traceability of the DBS measures is improved by this approach and potentially current method can 
be used broadly for other dried matrix measurands which comparison to serum/plasma is required for 
their interpretation. However, to standardise DBS analysis dedicated EQA programs are crucial. Despite 
the evidence of vitamin D long-time stability in dried matrices, further prospective longitudinal studies 
are required to investigate the influence of aging on DBS vitamin D measures. Also, to turn the 
numerical result from DBS analysis into a clinical meaningful result, age and sample specific RI or 
decision points need to be established.  
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Chapter 5 
 
Is vitamin D level at birth associated with 
paediatric food allergy development in 
early childhood?  
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5 Is vitamin D level at birth associated with paediatric food 
allergy development in early childhood?   
 
Throughout the past decade, there has been a serious concern about the link between Vitamin D status 
and allergic diseases. Earlier studies have provided some direct and indirect evidence suggesting the 
inverse correlation between vitamin D levels and prevalence of food allergy (3, 375). In Victoria, the 
prevalence of both vitamin D insufficiency and challenge-proven food allergy in infants is high and the 
two have been linked (376). However, it remains unclear whether low vitamin D levels play a causal 
role in the development of food allergy, and if so, whether there is a “window of opportunity” during 
which adequate vitamin D levels are most important for immune development and immune responses 
to food.  Potentially, vitamin D status at birth has implications on the prevalence of food allergy and 
other pathologies.  We have therefore aimed to determine the frequency of vitamin D inadequacy in 
newborns from Melbourne, Victoria and investigate the relationship between vitamin D level at birth 
and food allergy in infants.   
5.1 Introduction 
There is evidence that vitamin D supplementation reduces the risk of asthma exacerbations, but no 
strong evidence for a role of vitamin D in other allergic disorders (9). Vitamin D plays a part in immune 
system development and function which may be important in evolution and maintenance of food 
tolerance (60, 75, 377).  This includes its involvement in maintaining intestinal mucosal barrier integrity 
and promoting the expression of IL-10-secreting T-regulatory cells, which is involved in regulation of 
food antigen intake and maintenance of immune tolerance, as well as prevention of sensitization (77, 
378).  Hence, it is biologically plausible for a true link to exist between vitamin D insufficiency (VDI) 
and food allergy (9, 49). 
The prevalence of food allergy has a tentative inverse relationship with ambient ultraviolet radiation 
(UVR) exposure and thus potentially with vitamin D levels (which are known to vary based on variables 
of ethnicity and latitude) (6). Although few studies internationally have measured food allergy 
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prevalence in population-based samples using the gold standard of oral food challenges, several have 
assessed the correlation between proxy markers of food allergy status and latitude (49, 51, 53, 379).  
According to these studies, the areas further from the equator with lower ambient UVR levels have 
higher incidence of food allergy. In Australia, parent-reported egg and peanut allergy and prescriptions 
of hypoallergenic formulas which are used for the treatment of food allergy are more common in 
southern states with less year-round sunlight, as are prescriptions for epinephrine auto-injectors for the 
treatment of anaphylaxis (379). Similar trends in prescription of auto-injectors have been described in 
the United States (US), with these being more common in areas further from the equator (9, 55). 
Only a few studies to date have examined the relationship between measured serum vitamin D levels 
and either food sensitisation or allergy.  In the US-based National Health and Nutrition Examination 
Survey (NHANES 2003-2006), children with 25-hydroxy vitamin D (25-OHD) less than 37.5 nmol/L 
of blood were more likely (odds ratio 2.39; 95% CI, 1.29–4.45) to have allergic sensitisation to peanut 
than children with 25-OHD levels greater than 75 nmol/L.  A separate study found that in children with 
specific genotypes, low vitamin D at birth (cord blood 25-OHD Level < 25 nm/L) was associated with 
food sensitisation, while this association was not present in children with other genotypes (380).  In 
earlier Australian studies of infants of six months and one year old, those with VDI were more likely to 
develop food or other allergic diseases, and suggests that improving vitamin D status in pregnancy and 
early infancy may decrease the risk (376, 380).   
Some studies have also suggested that high vitamin D levels or oral supplementation with vitamin D 
may be associated with an increased risk of allergic disease in general, although these have not 
examined food allergy specifically (50, 72, 381). Conversely, the outcome of another small study on 
two-year-old children, suggests that higher maternal and cord blood vitamin D levels associates with a 
higher risk for food sensitisation and allergy (63). These apparently conflicting findings might be 
explained by a differential immune effect of oral vitamin D supplementation compared with vitamin D 
derived from UVR exposure.  Alternatively, there is some evidence to support a ‘u-shaped association’ 
whereby both high and low serum vitamin D levels may increase the risk of allergic disease (9). 
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Dried blood spot (DBS) cards collected for newborn blood spot screening (NBS) for genetic disorders 
at two to three days of age could be utilised to assess vitamin D levels at birth.  Whilst the analysis of 
vitamin D is usually performed on serum or plasma samples, successful measurement using blood spots 
has been demonstrated (118, 167, 169-171, 347, 348).  There is published data available from relatively 
small study-group studies (using serum sample) reporting mean maternal vitamin D in neonates (380, 
382, 383).  More recently Australian (n=259) and European (n=1451) studies attempted to evaluate the 
neonatal vitamin D status using NBS samples (383, 384). However, to date there is limited information 
available to define adequate infant levels of vitamin D, which might be different from established 
thresholds described for the adults. Therefore, larger population studies are required to establish the 
mean concentration of vitamin D in DBS samples in local cohort. Accordingly, we aimed to utilise our 
in-house DBS vitamin D method (chapter 4) to, a) provide a description of vitamin D levels in the 
Melbournian infant population and b) investigate the association between vitamin D status at birth and 
prevalence of food challenge proven- IgE mediated clinical food allergy and eczema at 12 months of 
age.    
5.2  Subjects and Methods 
5.2.1 Study subjects 
The current study was conducted as part of the HealthNuts study; a large-scale population-based cohort 
study (n=5,300).  Briefly, the HealthNuts study has aimed to assess the risk-factors and prevalence of 
the paediatric food allergy (385).  For this study, infants were recruited between September 2007 and 
August 2011, with the age range of 11- 15 months. Informed consent was obtained from the parents 
who then completed a questionnaire containing information on parents’ ethnicity, children’s skin type, 
season of birth, environmental exposure, supplementation and infant feeding practices in the first year 
of life. Infants were skin prick tested to sesame, peanut and hen’s egg. All participants were examined 
for the presence of eczema. Infants with a detectable reaction on skin prick test to any foods were 
followed up with diagnostic oral food challenges at the Royal Childrens Hospital Melbourne. Those 
infants with both a positive food challenge and a positive skin prick test or elevated specific IgE level 
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(> 0.35 kUA/L) were considered food allergic. We chose not to look at different food-specific IgE cut-
offs as the clinical relevance of food-specific IgE in the absence of a history of reaction to foods or a 
positive oral food challenge is unclear.  2700 participants of the original 5300 provided consent for us 
to access their NBS samples and are therefore involved in the current analysis including 341 with food 
allergy and 2148 controls (Table 5.1).  Ethical approval was obtained from the Office for Children 
Human Research Ethics Committee (HREC) (ref. CDF/07/492), Department of Human Services HREC 
(ref. 10/07), and the Royal Childrens Hospital HREC (ref. 27047). 
Table 5.1. HealthNuts participants characteristics (number and percentage) by gender, parents’ country of birth, gestational age at birth, 
multivitamin / vitamin D supplementation in pregnancy, season of birth, challenge-proven food allergy and eczema. 
Variable 
Guthrie Card Available (%) 
N=2700 
Total (%) Total participant (n) 
Gender   5244 
Male 51.06 50.82  
Female 48.94 49.18  
Parents' country of birth   5098 
Both Australian 65.07 59.30  
One east Asia 4.11 4.30  
Both east Asia 3.56 6.20  
Other 27.26 30.20  
Gestational age at birth (weeks)   5,006 
>36 93.92 93.91  
<=36 6.08 6.09  
Multivitamin in pregnancy   4,808 
Not ingested 19.70 22.34  
Ingested 80.30 77.66  
Vitamin D supplement in pregnancy   4,644 
Not ingested 94.50 94.36  
Ingested 5.50 5.64  
Season of birth   5,272 
Summer 23.43 23.56  
Autumn 23.70 23.96  
Spring 27.26 26.65  
Winter 25.61 25.83  
Challenge-confirmed food allergy   4,907 
No 86.30 89.12  
Yes 13.70 10.88  
Parent reported eczema   4,982 
No 71.84 73.40  
Yes 28.16 26.60  
A total of 2700 DBS samples (archived NBS Guthrie cards) from the recruited infants, were retrieved 
from the Victorian Clinical Genetics Services (VCGS) at the Murdoch Children's Research Institute 
(MCRI) (BIS ref. 607370 and HealthNuts ethics ref. 1006215) (Appendix 8.3). DBS disks (3.2 mm) 
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were punched from NBS cards (in duplicate or triplicate, depending on the viability of the blood spots) 
into 96-well plates and stored at ambient condition prior to analysis.   
5.2.2 Vitamin D measurement method 
We used our previously developed DBS vitamin D method (chapter 4) for analysis of NBS Guthrie 
cards. Water-methanol mixture including deuterated internal standard (25-Dihydroxyvitamin D3-[d6]) 
was used to elute vitamin D content of 3.2 mm spotted blood. The eluate was subjected to a supported 
liquid extraction (Biotage - ISOLUTE® SLE plate) and derivatisation (Amplifex Diene Reagent) 
process prior to liquid chromatography-tandem mass spectrometry (LC-MS/MS) (Agilent 1260 HPLC, 
6490 MS/MS) analysis. Derivatised 25-OHD3 was detected using; core-shell Kinetex F5 column, 
methanol/water gradient, positive ESI mass spectrometry with ion transitions of 732.5 > 673.4 and 
738.4 > 679.4 m/z. NIST972a traceable commercial material from Chromsystems was used to calibrate 
vitamin D. The assay has the lower limit of quantitation of 0.5 nmol/L and the upper linearity limit of 
376 nmol/L, with the average coefficient of variation of 12.9% (inter-assay) and 9.3% (intra-assay).  
5.2.3 Statistical analysis 
Statistical analyses were performed using Stata software (version 14.1, College Station, TX, USA). De-
identified data was analysed to generate histogram graphs and whisker box plots and demonstrate the 
distribution of vitamin D levels within the study group. As the data was not normally distributed, we 
generated the quintiles of vitamin D measures, and Chi-square test was used to compare the quintiles 
versus different variables. 
5.3 Results 
Of the total 2700 collected archived NBS Guthrie cards (aged 8-12 years), 25-OHD3 was measured for 
2615 participants (Figure 5.1). From this study group (49.18% female), 93.9% were born at term (> 36 
weeks) with 59.0% from Australian born parents, and 13.7 % having challenge-proven food allergy in 
early childhood (12 months age) (Table 5.2). Compared to the entire HealthNuts study cohort, those 
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who provided consent for NBS Guthrie card access were more likely to have both parents born in 
Australia and to have a child with food allergy or eczema. Other characteristics were similar between 
the two groups (Table 5.2). 
 
Figure 5.1. Flow diagram of inclusion criteria in NBS sample analysis. 13.7% (n=341 of total n=2489) of HealthNuts participants with 
available blood spot vitamin D data have challenge-proven food allergy. 
The NBS 25-OHD3 measurements were converted to equivalent plasma using the regression equation 
obtained from correlation study in chapter 4.  Predicted 25-OHD3 levels from DBS samples were ≤ 25 
nmol/L in 51%, 25-50 nmol/L in 33.7% and >50 nmol/L in 15.3% of the samples (Figure 5.2). For 
population comparison studies quintiles (<16.15, 16.15-21, 21.3-28.4, 28.4-42.9 and >42.9 nmol/L of 
25-OHD3) were generated for NBS vitamin D measures.  
a) 
 
b) 
 
Figure 5.2. a) Whisker-Box plot and b) Histogram graph demonstrating the distribution of vitamin D levels in NBS study samples.  
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Comparison of estimated NBS vitamin D quintiles versus different variables is demonstrated in table 
5.2. Season of birth and maternal history of vitamin D supplementation were both associated with 
vitamin D levels at birth, with higher levels among those born in autumn season and among those with 
maternal vitamin D supplementation during pregnancy (Pearson chi2(12) = 76.8880, Pr < 0.001 and 
Pearson chi2(4) = 20.4353, Pr< 0.001 respectively). However, there was no association between vitamin 
D levels at birth and challenge-proven food allergy or parent-reported eczema. (Figure 5.2). Similarly, 
the levels of vitamin D were not affected by parents’ country of birth, gestational age or gender of infant 
(Table 5.3).  
 
a) 
 
 
b) 
 
c) 
 
d)
 
Figure 5.3. Whisker-Box plots demonstrating the comparison between distribution of vitamin D quintiles in infants; a) with/without proven 
food allergy, b) with/without parents’ reported eczema, c) born in different seasons and d) with/without maternal supplementation history. 
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Table 5.2. The relationship between infant-related variables (parents' birth country, birth gestational age, pregnancy vitamin D supplement, 
season of birth, challenge-proven food allergy and parent reported eczema) and vitamin D levels (nmol/L) predicted from NBS samples. 
Variables         NBS estimated vitamin D Quintiles (nmol/L) 
Gender <16.15 16.15-21 21.3-28.4 28.4-42.9 >42.9 
Male (n=1316) % 20.14 20.29 18.92 19 21.66 
Female (n=1259) % 19.78 19.78 21.05 20.97 18.43 
      
Total (n=2575) % 19.96 20.04 19.96 19.96 20.08 
      
Pearson chi2(4) = 6.1799, Pr = 0.186 
 
Parents' country of birth 
Australia (n=1634) % 21.36 20.69 19.65 19.77 18.54 
One east Asia (n=100) % 25.00 15.00 17.00 19.00 24.00 
Both east Asia (n=89) % 15.73 17.98 17.98 19.10 29.21 
Other (n=685) % 18.54 19.56 18.25 20.58 23.07 
      
Total (n=2508) % 20.53 20.06 19.10 19.94 20.37 
      
Pearson chi2(12) = 15.9393, Pr = 0.194 
 
Gestational age at birth (weeks) 
>36 (n=2329) % 19.92 19.92 20.22 19.67 20.27 
<=36 (n=151) % 21.85 17.22 15.23 27.81 17.88 
      
Total (n=2480) % 20.04 19.76 19.92 20.16 20.12 
      
Pearson chi2(4) = 7.6348, Pr = 0.106 
 
 
Vitamin D supplement in pregnancy 
Not ingested (n=2158) % 21.08 20.44 19.05 19.46 19.97 
Ingested (n=127) % 15.75 15.75 18.90 13.39 36.22 
      
Total (2285) % 20.79 20.18 19.04 19.12 20.88 
      
Pearson chi2(4) = 20.4353, Pr < 0.001 
 
Season of birth  
Summer (n=609) % 20.03 18.88 20.69 18.56 21.84 
Autumn (n=596) % 20.97 16.11 15.94 21.64 25.34 
Winter (n=668) % 18.86 20.36 22.75 26.05 11.98 
Spring (n=711) % 20.39 23.91 19.97 14.06 21.66 
      
Total (n=2584) % 20.05 20.01 19.93 19.97 20.05 
      
Pearson chi2(12) = 76.8880, Pr < 0.001 
 
NBS estimated 
vitamin D Quintiles 
          Variables 
 Challenge-confirmed food allergy Parent reported eczema 
nmol/L  No % Yes %  No % Yes % 
<16.15 (n=496) 85.28 14.72 (n=494) 74.29 25.71 
16.15-21 (n=491) 87.37 12.63 (n=492) 72.97 27.03 
21.3-28.4 (n=494) 86.64 13.36 (n=490) 71.02 28.98 
28.4-42.9 (n=492) 86.18 13.82 (n=483) 68.74 31.26 
>42.9 (n=494) 86.03 13.97 (n=494) 72.27 27.73 
       
Total (n=2467) 86.30 13.70 (n=2453) 71.87 28.13 
       
 Pearson chi
2(4) = 0.9966, Pr = 0.910 
 
Pearson chi2(4) = 4.2844, Pr = 0.369 
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5.4 Discussion 
This is the largest longitudinal population study determining the distribution of vitamin D at birth in 
Melbournian infants, and it has examined whether vitamin D status at birth predicts the risk of food 
allergy and eczema in early childhood. We found that the prevalence of vitamin D inadequacy is very 
high among the studied cohort (born between September 2007 and August 2011), comparing the DBS 
measures with the Institute of Medicine adult values and our defined quintiles for 25-OHD3 measures. 
However, there was no evidence of an association between the NBS vitamin D levels and challenge 
proven food allergy (to sesame, peanuts and egg) or eczema in this large cohort of 2615 participants. 
As would be predicted, season of birth and maternal vitamin D supplementation were associated with 
DBS vitamin D levels. While no other significant predictor (such as; gender, parents’ region of birth 
and gestational age) of vitamin D level in DBS samples was observed. 
The large size of study cohort, including a large number of individuals with challenge-proven food 
allergy and eczema, in a multi-ethnic population with available information of both environmental and 
individual variables of infants, added to the strength of the study. To estimate vitamin D levels in 
archived NBS samples we utilised our novel validated analytic method, with enhanced sensitivity and 
accuracy compare to the previously introduced procedures, as is described in chapter 4. However, 
absence of availability of maternal vitamin D status or alternatively mothers’ serum / cord blood sample, 
was a limiting factor for this study, since we were unable to examine the correlation between the 
predicted vitamin D concentration from DBS with cord-blood and/or maternal levels. Thus, we are not 
able to compare our results with other studies which have measured cord blood or maternal levels. Some 
studies have found that the average ratio of birth vitamin D (cord-blood 25-OHD3) to maternal vitamin 
D is less than 0.50-0.6 (386, 387). Whereas, other study has argued that, within their fifty study subjects, 
all cord blood vitamin D measures were higher (approximately 40%) than their corresponding maternal 
levels (388). Hence, the relationship between maternal, cord blood and archived NBS samples remains 
unclear.    
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Our study confirmed that, the levels of 25-OHD3 in Victorian infants’ dried capillary blood were very 
low. Comparing DBS vitamin D measures with defined thresholds for adults, 51% of study population 
were vitamin D deficient and 85% were insufficient. This high prevalence of infants’ vitamin D 
inadequacy is in keeping with other Australian and international studies. Recently other two studies 
also have reported the high prevalence of VDI (45% and 48% ) among healthy Victorian neonates 
looking at 25-OHD3 measures from NBS samples (n=259, DBS age < 4 years old) and cord bloods 
(n=233) with the median of 29.2 nmol/L (383, 386). Similarly, a high rate of newborns’ VDI (57%) is 
reported in New Zealand (n=929) by measuring cord blood 25-OHD3 (382). Consistently, international 
studies have indicated the low mean values of vitamin D at birth such as; 34 nmol/L in European (> 5 
years old) NBS (n=1451), 27.2 nmol/L in an American cord blood cohort (n=241), 28.5 nmol/L (with 
56% 25-OHD < 25 nmol/L) in Turkish newborns’ serum (n=750), as well as 80% rate of 25-OHD < 25 
nmol/l in Tanzanian neonates (n=170 serum) (supplementation history was not available) (384, 387, 
389, 390). Considering the plausible disparity between measures of serum and archived dried blood 
samples, due to 25-OHD3 degradation or impaired extraction efficiency influenced by aging of the 
DBS, and lack of age-adjusted 25-OHD3 recommended ranges, we have generated quintiles for NBS 
25-OHD3 measures when examining associations with clinical outcomes.  
Consistent with the Barwon Infant Study (BIS) findings (n=233) (386), the data from this current study 
also indicates no association between low levels of vitamin D at birth and the development of paediatric 
food allergy (at 12 months of age). Furthermore, other studies in US, Germany and Poland have 
demonstrated that infants’ cord blood vitamin D concentrations were not associated with risk of asthma, 
wheeze, food allergy or atopic outcomes in children whom were followed up by the age of 5 to 6 years 
or during the first 2 years of life (63, 391, 392). By contrast, in our cohort (the HealthNuts cohort), low 
vitamin D levels at 12 months of age were associated with an increased risk of food allergy (393), 
suggesting that if vitamin D does play a role in the development of food allergy, vitamin D levels in the 
first year of life might be more important than vitamin D levels at birth. Randomised controlled trials 
of vitamin D supplementation in the first year of life are required to determine whether vitamin D levels 
in infancy do in fact play a causal role in the development of food allergy (5). It has been hypothesized 
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that vitamin D status during the solid food introduction period could be a more powerful predictor for 
infants’ food allergy (394) but the outcome of BIS did not support the relationship between 25-OHD3 
levels at six months and the prevalence of paediatric food allergy (386).   
Findings from our study are in keeping with earlier data associating the levels of infants’ vitamin D 
with the season of birth. It is well known that solar radiation is the trigger for natural endogenous 
vitamin D synthesis. The higher UVR during the summer season (compared to the other seasons) and 
the increased chance of skin exposure lead to the higher levels of maternal vitamin D synthesis as 
predicted, which may reflect the 25-OHD3 concentrations in autumn born infants (388, 395). For note, 
the association between season of birth and allergy has been examined previously in this cohort. There 
was no convincing evidence of an association between season of birth and allergy (37). 
Within our study samples, the median of NBS vitamin D was higher in autumn born neonates. 
Considering the half-life of circulatory 25-OHD3, shifted seasons in Melbourne (climate summer 
season is delayed compared to the calendar summer) and cultural behaviour, vitamin D levels projects 
the higher endogenous vitamin D production over late summer and early autumn. In contrast the lowest 
vitamin D median was observed in infants born in winter and spring time, where the concentrations of 
25-OHD3 represent the low rate of vitamin D synthesis during winter with low UVR and the least 
chance of skin exposure.  However, it has been shown that the ambient UVR effects on immune system 
modulation, are independent from vitamin D pathways, and may protect against allergic disorders 
development (396, 397). 
Vitamin D supplementation in pregnancy was also linked with increased levels of 25-OHD3 at birth. 
By contrast, in the same cohort, infants whose mothers used vitamin D supplements during pregnancy 
had lower levels of 25-OHD3 at one year of age (398).  This might be due to the fact that, mothers with 
a history of low vitamin D levels (whose babies are therefore also at risk of low vitamin D) are more 
likely to be supplemented, and the beneficial effect of maternal supplementation, although present at 
birth, does not persist to one year of age. Our current study also found low levels of vitamin D in NBS 
samples even in the presence of maternal vitamin D supplementation, indicating the inefficiency of 
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supplementation dosage to maintain infants’ adequate vitamin D levels at birth and throughout the first 
year of life. 
5.5 Conclusion  
Adding to previous studies which have examined smaller cohorts, our large population study confirmed 
that the prevalence of vitamin D inadequacy among the infants born in Victoria is high. Nonetheless, 
further studies are required to develop a robust adjustment factor corresponding to the age of specimens 
to standardise the measurements of archived dried samples. Further studies are also needed to define 
age-adjusted reference intervals and recommended ranges in infants. Our study did not provide any 
evidence of association between challenge proven food allergy and eczema at 12 months of age, 
suggesting that if vitamin D does play a role in the development of food allergy, maintaining sufficient 
levels in infancy might be more important than vitamin D levels at birth. Current evidence supports the 
feasibility of widespread education of safe sun exposure and perhaps season-focused supplementation 
during pregnancy and early infancy. Also, further studies are required to define recommendations for 
optimal dosage and timing of supplementation.  
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Chapter 6 
 
General Discussions and Conclusions 
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6 General discussion and conclusions 
6.1 Discussion 
Epidemiological evidence has shown a concordant increase in the prevalence of allergic diseases 
including food allergy and eczema, and decreased vitamin D levels in both developed and developing 
countries. Also, it has been revealed that the incidence of allergic reactions is more significant in regions 
further from the equator with lower ultra violet radiation (UVR). This suggests that vitamin D 
inadequacy may play a role in allergic disorder development. The current literature describes the 
biological mechanism by which vitamin D affects the incidence of allergic diseases through its influence 
on intestinal epithelial barrier integrity and the immune system. In addition, earlier research has shown 
evidence of a relationship between vitamin D inadequacy and the increased risk of food allergy in early 
childhood in Victorian population (376).  
Validation of this putative association between early life vitamin D insufficiency (VDI) and food allergy 
has clear public health implications. However, further studies were required to investigate whether 
levels of vitamin D at birth predict the risk of paediatric food allergy. In addition, we noted that there 
was no population data available regarding vitamin D levels in Australian infants and children. 
Accordingly, we aimed to demonstrate the relationship between vitamin D levels at birth and the 
development of food allergy in early childhood, as well as predicting the sample specific distribution 
of vitamin D in the Victorian infant population. 
In our review of the literature we also proposed a link between vitamin A and the process of immune 
system development. Increased levels of vitamin A may be associated with an increased risk of 
development of early childhood food allergies. As vitamin A can potentially be measured in the same 
mass spectrometry analysis as vitamin D, it was proposed to also investigate the level of vitamin A 
metabolites in relation to the development of food intolerance / allergy concurrently with vitamin D. 
DBS samples would contain protein bound retinol, which if the DBS is stored in the dark and moisture 
protected, would be stable. However, our observational study demonstrated that whereas retinol was 
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detectable in fresh dried blood spot (DBS) samples, it was undetectable from the older (>4 weeks) DBS 
samples. Hence, it was not possible to determine the relationship between vitamin A levels and 
childhood food allergies with the samples available. 
Our project used newborn blood spot screening (NBS) Guthrie cards, which were collected from two 
to three-day old infants and stored in Victorian Clinical Genetics Services (VCGS) bio-bank, to assess 
vitamin D levels at birth. Whilst the analysis of vitamin D is usually performed on serum or plasma 
samples, successful measurement in dried matrices has been demonstrated. However, the measurement 
of vitamin D in children was known to be complicated by the presence of the inactive epi-vitamin D3. 
As such, mass spectrometry analysis coupled with chromatographic separation was the only accepted 
method for the quantitation of this isomer from the predominant form of active vitamin D3. A method 
for the separation of these forms of vitamin D simultaneously with other fat-soluble vitamins including 
vitamin A had been developed at RMIT University (355). This was used as the foundation for the DBS 
vitamin D method which constitutes the first part of this thesis. 
In preparation for analysis of vitamin D we punched 2700 DBS disks from NBS Guthrie cards from the 
VCGS bio-bank with the very limited available sample resource (maximum 3 punches per sample), to 
investigate the association between the rate of VDI at birth and challenge proven IgE mediated food 
allergy (FA) at 12 months of age. Blood spot samples belonged to the infants recruited for a National 
Health and Medical Research Council (NHMRC) granted study; HealthNuts. The HealthNuts study is 
the world's first longitudinal (birth to 10 years age) population (5,300 children) study with unbiassed 
measurement of challenge-proven paediatric food allergy (PFA) in a Melbourne cohort. This study aims 
for a better understanding of the natural history of allergic diseases including FA and eczema, and the 
risk factors for developing these conditions in children. Individual information and allergic disorders 
related data was already collected (or under collection) from the HealthNuts cohort. 
To predict the vitamin D metabolites (including its epimer) levels in the DBS punches, we aimed to 
optimize and improve sensitivity and specificity of the available in-house liquid chromatography 
tandem mass spectrometry (LC-MS/MS) method (355). The method was adapted for DBS sample 
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preparation including extraction and derivatisation, with specific challenges including the limited 
sample volume and extraction from the solid matrix. Moreover, interpretation is challenging as the 
recommended ranges for vitamin D is predominantly described for the samples with a liquid matrix 
(serum/plasma). Hence, for the effective interpretation of the DBS measurements, accurate conversion 
of dry matrix results to the equivalent liquid form was required. To determine this relationship, we 
analysed 80 paired serum/plasma and DBS samples. 
Accuracy of DBS quantitation has been reported to be Haematocrit (Hct) dependent and requires 
additional considerations over the conventional “liquid” blood sample. This is due to the physical 
characteristics of blotted whole blood affecting the quality of the measurement. We discussed these 
aspects in detailed as part of our review and DBS Hct estimation paper. Potential errors associated with 
Hct variation span the DBS total testing process. Where a Hct correction option is sought, practical 
solutions to minimise bias have been devised including assessment or prediction of Hct from the spotted 
whole blood. Hence, we aimed to develop a method for prediction of Hct of the DBS punch (described 
in chapter 3). 
We successfully developed a simple method to estimate Hct in archived DBS samples. In this method 
the haemoglobin (Hb) derivative (drv) content of spotted blood sample was eluted from the dried matrix, 
using a formic acid solution. Then, we utilised a direct spectrometry method to scan the extracts for 
measurement of Hb-drv. We then applied the linear relationship between an individuals’ Hct percentage 
and measured Hb-drv to estimate the dried sample’s Hct. Potentially our method can be incorporated 
into various DBS analytical sample preparation process for correction of measured analytes of interest. 
However, following our observations throughout method development for measurement of 25-OHD3 
concentrations in DBS samples, due to the relative diffusion rate of whole blood samples on the 
collection card, as well as different degrees of extraction efficiency of samples with different levels of 
Hb/Hct, the Hct effect might not be as significant in practise for samples with a Hb/Hct level within the 
normal range. Hence, we consider that the levels of a patient’s Hb (and therefore Hct) may influence 
the measurement from the DBS sample only at extreme high or low ends of the pathological spectrum. 
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Therefore, we see our DBS Hb-drv best utilised as a screening tool to predict Hct levels at extremes 
which may then affect the DBS distribution of an analyte. 
For DBS analysis, the change of dry matrix into the liquid and elution of the analyte of interest from 
the filter paper is the first step. Depending on the chemical characteristics of the target analyte, the 
choice of an appropriate elution and extractor buffer is critical. Considering the hydrophobic molecular 
structure of 25-OHD we initially tried a water-methanol mixture (3:5) for elution of vitamin D contents 
from DBS, in conjunction with 30 minutes shaking at ambient temperatures followed by a brief 
sonication process. This approach was satisfactory for the trial DBS samples with <3 years spotting 
age, whereas it was not efficient enough for our archived NBS study samples (older than 8 years). The 
efficiency of elution could be challenging, as there is always a chance of analyte loss, incomplete 
extraction or analyte degradation during the extraction process. Hence, to achieve effective analyte 
recovery, we applied a high-temperature, high-speed shaking procedure with the additional solvation 
energy (sonication). 
A significant improvement on our original vitamin D method was the change from liquid-liquid 
extraction (LLE) to supported liquid extraction (SLE). This offset the small sample volume and 
laborious manual procedure, by the process with a 96-well plate. This adapted extraction process was 
still consistent with the original in-house method by using a water-methanol mixture for protein 
precipitation followed by hexane for extraction, when method comparison was performed by analysis 
of multi levels of QAP samples.  This extraction technique improved not only the turn-around time, but 
also the extraction efficiency, sensitivity and overall imprecision of our analytical method. 
The limited sample volume of dried blood samples is not compatible with most measurement methods 
and a distinctive analytical technique is required to support the desirable sensitivity. Whereas, currently, 
derivatisation is not utilised for most LC-MS/MS analyses for measurement of serum/plasma 25-OHD3, 
it has been used for many DBS testing studies to maintain the required assay sensitivity.  However, the 
derivatisation process prolongs the overall turnaround time. Moreover, a review of the literature has 
indicated that the common derivatising reagent used for mass spectrometric measurement of vitamin D 
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metabolites, 4-Phenyl-1,2,4-triazoline-3,5-dione (PTAD), does not allow discrimination of 3-epi-25-
OHD3. This inactive epimer is seen at high levels in paediatric samples and it is important to be able to 
discriminate this from the active 25OHD. Several other research groups had unsuccessfully attempted 
to separate PTAD-derivatised 3-epi-25OHD3 (365, 368, 399) and Higashi et al. demonstrated 
structurally that this was not possible to separate the epimer from the isomeric forms during the 
derivatisation process (348). We felt these outcomes were limiting factors for our large sample 
population study which needed to be overcome.  
As enhanced sensitivity and separation of 3-epi-25OHD3 were the required and primary considerations 
of our study, we had two options; 1) return to the non-derivatised method, or 2) find an alternative 
derivatising agent. We first explored option (1) by attempting to develop a 2-dimentional 
chromatography holding set-up, where we would effectively load the first column (multiple injections) 
with high volume of the extracted sample. Then, adjusting the gradient by increasing the methanol 
percentage and directing the sample to the second column for the chromatography separation. This 
approach worked to a limited degree but was cumbersome for our proposed automation and lacked the 
required assay robustness. We continued to pursue this approach whilst continuing to review the 
literature. 
A new derivatising agent (Amplifex, Sciex) was commercially released in 2013. We therefore adapted 
our methodology to utilise this reagent in our vitamin D assay. This derivatising reagent proved 
successful in separating 3-epi-25OHD3 and demonstrated enhanced signal compared to the PTAD. This 
was in-part because it separated vitamin D chromatographically from phospholipids (ion transitions; 
104 > 104 and 184 > 184 m/z). The package inserts for this reagent stated 2-hours stability. However, 
we found it to be stable for 4 weeks if stored at -20oC and furthermore it could be effectively used at 
much lower concentrations than the manufacturer’s recommendation, which were important 
considerations as the cost of Amplifex is substantially more than PTAD. Ultimately, we succeeded to 
incorporate DBS vitamin D analysis into the serum/plasma vitamin D assay. To achieve this outcome, 
we needed to adopt our validated in-house method to derivatise vitamin D, to attain the traceability link. 
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Chromatographic and mass spectrometric conditions of the in-house serum/plasma vitamin D assay 
were optimized for the derivatised 25-OHD3. The assay’s overall performance was enhanced through 
further studies and improvements applied to the previously referenced LC-MS/MS method. The 
adjustment included; an altered extraction method for sample preparation (LLE changed to SLE), 
internal standards and utilisation of a different isotope (25-OHD3-[2H3] replaced with 25-OHD3-[2H6] 
for the derivatised compound and a Carbon-labelled internal standard (13C and epi-13C) were utilised 
for measurement of native 25OHD3 and its epimer). Variations were qualified through assay evaluation 
analysis and reporting The Royal College of Pathologists of Australasia Quality Assurance Programs 
(RCPAQAP) samples continuously (Figure 6.1). However, quantitation of epimer was eventually 
disregarded in the DBS method due to insufficient sensitivity required for measurement of epimer from 
DBS samples. 
Traceability of the DBS measures to the standardized reference plasma/serum base assay, is a crucial 
requirement for offering a DBS analytical method as a reliable tool. To maintain the traceability link, 
we used National Institute of Standards and Technology (NIST) traceable commercial materials to 
calibrate our vitamin D assay. Furthermore, to certify the accuracy of the measurement, external quality 
control materials were analysed as part of our analytical process, in conjunction with routine analysis 
of commercial quality control material (Figure 6.1). We applied the theoretical ratio between the 
average amount of blood sample on a DBS punch and the volume of liquid samples to define the relative 
quantity of internal standard for both dry and liquid matrices within the same analytical method. Hence, 
different amounts of internal standard material, which were proportional to the ratio of liquid sample 
volume to DBS punch, was added into calibrators, quality control materials and dried blood samples to 
correlate the dried-matrix measures to equivalent liquid sample concentration. The serum / plasma 
vitamin D  decision points could then be applied to the DBS samples.   
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Figure 6.1. The RCPAQAP report demonstrating the method accuracy and performance. All the values of RCPAQAP analyses, at different 
concentrations of 25-OHD3, are within the acceptable range and close to the target values (compared to the different method users including 
other MS method users. One of the uniqueness of our DBS-vitamin D method is; the traceability of the DBS measures to the liquid sample. 
The developed method was then utilised to analyse NBS samples to investigate the prevalence of 
vitamin D adequacy in a Melbourne paediatric population. The information was used to examine the 
association between vitamin D levels in early life and the prevalence of paediatric food allergy. This 
was the first, large population-based study of vitamin D status in new-born infants in Victoria. Our data 
demonstrated the seasonal pattern of vitamin D levels in archived dried bloods and identified that the 
prevalence of vitamin D inadequacy is considerably higher among the nominated cohort cut-offs. 
The current multi-ethnic study is the broadest investigation of vitamin D measures at birth in relation 
to Ig-E mediated challenge-proven food allergy at 12 months of age.  Among the study cohort there 
was no evidence of a relationship between vitamin D levels and food allergy or eczema. As expected, 
the prevalence of lower vitamin D levels was decreased in the population with a history of maternal 
vitamin D supplementation. However, the high prevalence of vitamin D insufficiency suggests that 
further pharmacokinetic investigations are required to optimize the dosage regime for effective 
supplementation. 
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6.2  Need of a dedicated isotopic internal standard for accurate 3-epi-25-
OHD3 quantification by LC-MS/MS. 
A requirement for a dedicated isotopic internal standard for accurate measurement of 3-epi-25-OHD3 
was examined, and the outcome of the study has been communicated as a letter to the editor in Clinical 
Chemistry and Laboratory Medicine journal.  This study was a sub-study of the HealthNuts project and 
my contribution to this study and subsequent publication was included; developing the concept for the 
study in conjunction with my senior supervisor (RG), analysis and interpretation of data, writing the 
first draft of the publication and reviewing and incorporating all suggestions from the co-authors. This 
section has been peer reviewed and published with the contributions of other co-authors (400).  
“We have read with interest a report by Flynn and colleagues which demonstrates significant 
enhancement of the 3-epi-25-hydroxy vitamin D3 (3-epi-25-OHD3) signal when co-eluted with 25-
hydroxy vitamin D3 (25-OHD3) and also when fully resolved (401).  Co-elution of 3-epi-25-OHD3 
with 25-OHD3 results in a 60% increase in signal enhancement from the epimer and hence the vitamin 
D result cannot be considered the sum of the two.  With resolution and the use of a specific in-house 
epi calibrator Flynn demonstrated a reduction in bias to +20%.  Hence, Flynn’s group has recommended 
the chromatographic resolution of 3-epi-25-OHD3 from 25-OHD3 and use of a dedicated 3-epi-25-
OHD3 calibrator (401).  These recommendations are potentially important for clinical stratification as 
the epimer is added to the vitamin D3 to quantitate the total vitamin D against the clinical decision 
points, and these positive biases may change the interpretation of a patient’s vitamin D status. 
The +20% bias remains a concern and we believe the choice of isotopic internal standard is also 
important for the accurate quantitation of 3-epi-25-OHD3.  Traditionally, deuterated internal standards 
directly related to the compound of interest have been applied and ideally, these internal standards 
should co-elute so that they enter the MS at the same time and conditions.  However, for vitamin D 
analysis the same isotopic internal standard is often used for quantitation of both 25-OHD3 and its 
epimer (401, 402).  We hypothesise that this may be the cause of the overestimation of the resolved 3-
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epi-25-OHD3 from Flynn's study.  Our aim was therefore to determine the need for the inclusion of a 
dedicated internal standard in our method for the quantitation of 3-epi-25-OHD3. 
Some experts have questioned the stability, and therefore accuracy, of using deuterated internal 
standards (403-405). This has led to increased advocacy for internal standards with closer physio-
chemical properties, such as the use of carbon 13 (13C) labelled internal standards for LC-MS/MS 
methods when available (406).  As there are now dedicated 13C labelled internal standards commercially 
available for both 25-hydroxy vitamins D3 and also its epimer, we purchased 25-Hydroxy vitamin-D3-
[23,24,25,26,27-13C5] (abbreviated to 13C) and 3-Epi-25-Hydroxyvitamin D3-[13C5] (abbreviated to 
epi-13C) from Isosciences, via PM Separations, Qld, Australia), to analyse 425 paediatric samples for 
vitamin D using an adaptation of our published method (308).  The blood samples were part of the 
Vitality trial (407); Royal Children’s Hospital Human Research Ethics Committee approval number 
34168H. 
Briefly, calibrators, controls and patient samples were initially prepared by supported liquid-liquid 
extraction employing hexane.  For the liquid chromatography separation, a core-shell Kinetex F5 
column (Phenomenex Inc., Australia) was used as the stationary phase and a gradient of water and 
methanol with 0.1% formic acid for the mobile phase was applied.  The mass selective detection was 
performed utilising an Agilent 6490 system in positive ESI mode with multiple reaction monitoring 
(MRM) applied for quantitation of 25-OHD3 and its epimer (m/z 401>383) and the 13C-labelled 
isotopes (m/z 406.3>107).  The performance of the adopted method is: imprecision of <5.0%; average 
bias of 0.04 μmol/L; and lower limit of quantitation (LLOQ) of 1.0 nmol/L.  The method is standardised 
using the Chromsystems 25-OHD3 and 3-epi Calibrators (Astral Scientific, NSW, Australia).  The 3-
epi-25-OHD3 was quantitated against both internal standards and compared. 
The results from our study demonstrate that 65 of the 425 paediatric patients had detectable 
concentrations of 3-epi-25-OHD3 above the LLOQ when quantitated against the 13C-epi internal 
standard (Figure 6.2).  These 65 participants represent 15% of the study cohort and had a median age 
of 7 months (minimum of 2 months and maximum of 25 months).  Comparison of the 13C versus the 
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epi-13C internals standards for quantitation of the epimer demonstrated a significant positive bias of 
+30% when the non-retention time matched internal standard was applied (Figure 6.3).  The data also 
demonstrates the variation of 3-epi-25-OHD3 in the samples, with 85% having no detectable 3-epi-25-
OHD3 to a significant proportion having concentrations up to 30 nmol/L.  This in itself confounds the 
interpretation of results, but the use of a non-epi internal standard would artificially inflate these results 
and potentially change the clinical interpretation. 
 
Figure 6.2. Chromatogram of 25-OHD3 and 3-epi-25-OHD3 from a paediatric patient plasma sample. 
 
 
Figure 6.3. Comparison of 3-epi-25OHD3 concentration (nmol/L) (n=65); a) Bland Altman plot demonstrating a mean difference: of 6.2 
nmol/L (0.95 CI: 5.1-7.2nmol/L) demonstrated by the black solid line (    ), compared to the expected difference of zero demonstrated by the 
red solid line (    ) and 95% range of difference as demonstrated by the two red dotted lines (- - - ). b) Passing Bablok regression plots for 
comparison of measured 3-epi-25OHD3 using the 3-epi-25OHD3-[13C] versus the 3-epi-25OHD3-[epi-13C] internals standards (-- - - : line 
of equivalence, and ------ indicating regression line).  The equation demonstrating the relationship is y=1.3x + 1.0; r = 0.89.  This indicates a 
positive bias for quantification against [13C] internal standard. 
The study participants’ 25-OHD3 concentrations ranged from 4 to 150 nmol/L with a median of 58 
nmol/L.  159 of these participants had vitamin D deficiency, when epi-25-OHD3 was separated 
(deficiency defined as less than 50 nmol/L (350-352)).  A change in the clinical interpretation occurred 
 
3-epi-25-OHD3 
25-OHD3 
 
3-epi-25-OHD3 
25-OHD3 
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in ten of the 65 patients when the dedicated epi-13C internal standard was applied (in preference to the 
C13-25-OHD3 internal standard): one patient was reclassified from adequate to insufficient based on 
the 50 nmol/L decision point; nine patients were reclassified from optimal to adequate based on the 75 
nmol/L decision point; and no patients were reclassified based on the 25 nmol/L decision point.  These 
irregular errors potentially confound the clinical interpretation of the vitamin D results in cohorts where 
epi-25-OHD3 is reported to be present in significant amounts (93, 308, 408). 
Still to date, the physiological action of 3-epi-1,25-OHD3 is not known.  The 3-epimerisation may be 
an inactivation mechanism, as the epimer has reduced binding affinity to the vitamin D receptor (409).  
Yet, it does inhibit parathyroid hormone production as much as calcitriol (409).  Regardless of its 
biological activity, it is worthwhile to measure the epimer accurately and precisely, as its presence can 
significantly affect the total 25-OHD3 test results of those individuals with detectable concentrations of 
epi-25-OHD3.  This is relevant as the current international guidelines for the interpretation of vitamin 
D add the forms of 25-OHD together for interpretation against the clinical decision points (350-352).   
Accurate assessment of vitamin D status requires both the separation and quantification of epi-25-
OHD3.  Even with the separation and accurate quantitation of 3-epi-25-OHD3, the summation with 25-
OHD3 leads to a change in the clinical interpretation for 18 of our 65 patients with detectable 
concentrations of epi-25-OHD3.  This raises the question of whether future clinical guidelines for 
vitamin D status should be redefined to be specific for 25OHD3 only (i.e. excluding 3-epi-25-OHD3) 
to ensure consistent interpretation. 
In conclusion, in our study we have demonstrated that the use of a dedicated epimer internal standard 
corrects the positive bias as hypothesised.  We support the prior recommendations of chromatographic 
resolution and use of a dedicated calibrator for the quantitation of 3-epi-25-OHD3.  Based on our 
findings, we strongly recommend where practical, that serum vitamin D measurement by LC-MS/MS 
includes the chromatographic resolution of the epimer, a specific calibrator and an epimer matched 
internal standard, preferably 13C is applied when quantitation of the epimer is required.  LC-MS/MS 
methods that do not fulfil these requirements risk overestimating an individual’s vitamin D status.  
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Quantification of epi-25-OHD3 is also recommended for future discoveries regarding the biological 
function of epi-25-OHD3 which may require all accurate vitamin D assessments to include epimer 
quantification.  This will allow for clear and accurate data analysis of clinical studies.” 
6.3  Conclusions 
In this project we have successfully developed a robust vitamin D DBS method that has significant 
advantages including its ability to separate 25-hydoxy vitamin D epimer if required, with its application 
extend into liquid sample analysis. Furthermore, we developed a method to predict Hct level in archived 
blood spot samples, which can be incorporated into DBS analytical work-flow to alleviate the Hct effect 
at extreme levels. Ultimately the value of a method is in its clinical application. The DBS vitamin D 
method has been successfully used to address the question of whether there is an association between 
vitamin D levels at birth and paediatric food allergy. The findings from our large data set of 2489 
participants’ samples indicate that the vitamin D levels at birth do not predict / influence the onset of 
challenge proven food allergy in infants (11-12 months) as no association was found. As newborn 
vitamin D levels were variable in those with maternal vitamin D supplement, further studies are 
warranted to determine the appropriate regime to ensure vitamin D sufficiency.  
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Appendices 
App.1 LC-MS lab glass-ware washing standard procedure  
☺ Cleaning Tips 
✓ Wash lab glass wares as quickly as possible after use. If a thorough cleaning is not 
possible immediately, put glass wares to soak in distilled water! 
✓ Most new glassware is slightly alkaline in reaction. For precision chemical tests, new 
glassware should be soaked several hours in acid water (1% solution of hydrochloric 
or nitric acid) before washing. 
 
1. Wash the tubes with distilled water until all specimen residues are well rinsed. Use 
the glassware brush if required.  
2. Oven-dry tubes at 50°C.  
3. Fill the tubes with 65% nitric acid under the chemical fume hood, stand for 10mins.  
4. Pour back nitric acid into the nitric acid bottle for further use. (Nitric Acid recycling 
frequency; to be determined)  
5. Rinse tubes with distilled water five times and stand overnight distilled water- filled 
tubes. 
6.  Rinse tubes with Milli-Q water two times.  
7. Oven-dry tubes at 50°C.  
References:   
● Suggestions for Cleaning Glassware, AL-228 Technical Bulletin, Aldrich, Sigma-Aldrich family, http://www.sigma-aldrich.com 
●Ali Al-Bahrani, PhD thesis 
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App.2 Development of a DBS vitamin D quantitation method, incorporated 
into the serum/plasma vitamin D assay 
Introduction 
Vitamin D is chemically a group of seco-steroids, which possesses an open cyclo-pentano-
perhydrophenanthrene ring (ring B on carbon 9, 10). These seco-steroids are structurally comparable to 
the steroid hormone group. The biologically active vitamin D metabolite (1α-25(OH)2-D), exhibits 
hormone like behaviour. However, 25(OH)-D (Calcifediol) is the analogue of vitamin D with the higher 
circulatory concentration and longer half-life in adults, while its epimer (epi-25(OH)-D) is significantly 
expressed in paediatric group. Apart from its seco-steroid form, the presence of a side chain provides a 
more flexible molecular structure compare to classic steroids (Figure 3.1). 
 
Figure 8.1: Chemical structure of Calcifediol 
 
Cholesterol, then 7-Dihydroxycholestrol is the launch point of vitamin D3 (cholecalciferol) formation 
in the human skin due to sunlight exposure. Ultra-violet light initiates a series of photochemical 
reactions to convert this seco-steroid to pre-vitamin D3 in malpighi-layer of skin. Pre-vitamin D3 can 
isomerase to vitamin D3 within 2 or 3 days. Vitamin D metabolites mostly expose a high affinity to the 
plasma vitamin D binding protein (DBP). However, DBP circulatory concentration is in a great molar 
excess compare to vitamin D metabolites, only very limited portion of metabolites circulate freely.  This 
vitamin D-binding protein (DBP) carries cholecalciferol to the liver; where the 25-hydroxylase enzyme 
effects the formation of 25(OH)-D3.The complex of DBP-25(OH)-D3 then takes the journey to  the 
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kidney for a further hydroxylation step, mediated by 1α-hydroxylase to produce the active hormone-
like 1α,25(OH)2-D3 (Calcitriol) and 24,25(OH)2-D3 metabolites. 
Regulation of 1α,25(OH)2-D is under the control of a complex positive and negative feedback system 
which effects the expression of the hydroxylase enzymes. Decreased dietary calcium and phosphate 
intake and elevated PTH, due to low circulatory calcium concentration, induce the activation and gene 
transcription of 1-α-hydroxylase. In turn, elevated PTH supresses the gene transcription. However, the 
regulation of 24-hydroxylase is under control of 1α,25(OH)2D status, plasma calcium concentration 
and PTH level. Along with the regulatory role on mineral homeostasis, a wide range of various 
physiological functions are assigned to hormonal action of vitamin D. These include; effect on cancer 
cells growth rate, immune system development and protection against certain immune disorders. 
Traditionally vitamin D is measured as serum/plasma 25-hydroxy cholecalciferol and the cut-off for 
interpretation is clearly defined.  However, the collection, transport and storage requirements for 
serum/plasma are cumbersome for large scale population-based studies.  As a result, there has been 
increased interest in the use of dried blood spots (DBS) as a matrix for the assessment of vitamin D.  
Following the project aim of investigation of the association between early life vitamin D insufficiency 
and paediatric food allergy, we developed the accurate method for measurement of vitamin D 
metabolites from archived DBS samples.  
Current SOP explains the procedure of the measurement of 25-hydroxy-vitamin D3 measurement from 
the serum/plasma and the DBS sample, utilizing liquid chromatography coupled with tandem mass 
spectrometry technique.   
 Principle of the method 
Serum/DBS proteins are precipitated using Water/Methanol mixture. Deuterated 25-hydroxyvitamin 
D3 (d6) added as internal standards. The analytes are extracted into hexane through solid phase 
extraction (SLE) procedure. The hexane is recovered and evaporated to dryness under a speed-vacuum 
condition at 40oC temperature and 500 rpm speed. After evaporation of the hexane eluate residue is 
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dissolved in methanol-water mixture. Amplifex Diene reagent is used to derivatise vitamin D of the 
DBS samples.  
The methanolic extract is injected onto a core-shell Kinetex F5 column (Phenomenex Inc., Australia). 
The vitamins are eluted using a solvent program. The initial solvent is 35% methanol in water. The 
maximum organic solvent gradient is 100% methanol. Vitamin D (non-derivatised) is detected by m/z 
ratio transitions of 401383 and 401365. Vitamin D (derivatised) is detected by m/z ratio transitions 
of 732.4673.4 and 732217.  
The calibration curve (7 points) is linear (1/X) and the origin is ignored in the regression analysis. 
DBS Hct is estimated to correct variations and convert the measures into the equivalent serum 
Formic acid solution (0.1%) is used to elute haemoglobin content of DBS. 
Specimen and sample storage 
Specimen type 
Serum or EDTA/ heparinised plasma and, also air dried whole blood spot are suitable for vitamin D 
assay.  A minimum volume of 150 µL of light protected serum/plasma and one drop (~ 50 µL) whole 
blood spotted on the filter paper (Whatman 903) is required. 
Effect of diet / sun exposure 
Non-fasting samples are routinely analysed at RMIT LC-MS/MS lab.  Perhaps the seasonal effect may 
need to be considered for vitamin D results interpretation. 
Specimen storage 
Blood should be centrifuged, and the serum/plasma separated within 30 minutes of venesection. The 
separated serum or plasma is transferred to a storage tube and stored at -20oC until analysis. Spotted 
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blood should air dry for minimum 2 hours. Dried blood samples store in darken container, kept in 
biohazard specimen zipper bag at room temperature.  
Reagents 
Safety warnings 
Inflammable solvents (hexane and methanol) had to be kept away from sources of ignition including 
electrical switches that may cause sparking. And, also must be used in a fume hood. Storage bottle were 
tightly capped when were not in use. The chemical spill kit (located in room under the washing basin) 
and the safety shower/eye wash stations were located in the room. Skin contact and inhalation of solvent 
vapour were avoided to prevent solvent toxicity. 
Nitrogen gas cylinders were stored in cylinders under high pressure. Ensured the cylinders were secured 
so that they could not topple and fracture the high-pressure fittings. Standard safe operation procedure 
of the high pressure shut-off valve was followed before changing the regulator to a fresh cylinder. 
Chemicals 
Milli-Q water 
Supplies by Millipore water filter-Element A10, located in Biochemistry Laboratory-Module H 
(223.01.07) 
Nitrogen, high purity 
Nitrogen, high purity, Coregas Cat. No. 221150 or equivalent 
Methanol 
Methanol, gradient grade for liquid chromatography-mass spectrometry, cat no. 1.06018.4000 (Merck).  
Do not substitute with any other grade of methanol. 
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N-Hexane 
N-Hexane, for liquid chromatography-mass spectrometry, cat no. 1.04391.2500 (Merck). 
Formic acid 
LC-MS Ultra, eluent additive for UHPLC-MS, cat no. 94318 (Sigma-Aldrich) 
Derivatising agent 
Amplifex™ Diene reagent, product no. 5037804 (Sciex)-the material prepared following manufacturer 
instruction as the stock solution. Stock solution was diluted with the diluent (acetonitrile) 1:1 (50%) to 
prepare the working-solution (prepared fresh per batch). 
Stock internal standard solution 
 Deuterated 25-hydroxyvitamin D3-[2H6], in ethanol, 100 µg/mL, cat no. S4163 (Iso-Science) 
Stock internal standard solution preparation (4926 nmol/L) 
Deuterated 25-hydroxyvitamin D3 ampule has been removed from storage (-20oC) and allowed it to 
warm to room temperature. The entire ampule contain was added into the HPLC grade methanol to 
make up the final volume of 50 mL (including methanol wash step of the ampule to ensure whole 
content has transferred into the glass Schott storage bottle) and was stored at -20oC (stable for at least 
one year). 
Working internal standard solution; deuterated 25-hydroxyvitamin D3 (d6) in methanol 
246 nmol/L 
Deuterated 25-hydroxyvitamin D3 stock solution bottle was removed from the storage (-20oC) and 
allowed the standard material to warm to room temperature. 5 ml of stock internal standard solution 
was diluted in the HPLC grade methanol to make up the final volume of 100 mL (including methanol 
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wash step of the ampule to ensure whole content has transferred into the glass Schott storage bottle). 
Working IS solution was stored -20oC (stable for at least six months). 
Diluted internal standard solution; deuterated 25-hydroxyvitamin D3 (d6) in methanol 
for liquid matrix and DBS samples (123 and 10 nmol/L) – to be prepared fresh for each 
batch of analysis 
Working internal standard (IS) solution; deuterated 25-hydroxyvitamin D3 (d6) in methanol (246 
nmol/L) was removed from the storage (-20oC) and allowed the standard material to warm to room 
temperature. Estimate the required volume of internal standard for the batch (100 µL per each liquid 
sample) and dilute working internal standard solution in milli-Q water-methanol mixture (2:1:1) to 
make up the total required volume. (e.g. for one 96-well plate batch including 7+3 calibrators and 86 
DBS samples mix 1500 µL working IS with 750 µL milli-Q water and 750 µL methanol for the total 
volume of 3 mL). 
Use diluted-IS (123 nmol/L) as the stock material for preparation of DBS-match IS solution; mix 1 part 
of diluted IS with 11 parts of milli-Q and methanol mixture to obtain the required volume with the 
concentration of 10 nmo/L. (e.g. for one 96-well plate batch including 7+3 calibrators and 86 DBS 
samples; mix 675 µL diluted-IS with 1240 µL milli-Q water and 6185 µL methanol).  
Mobile phase A 
10 mL methanol and 500 µl of LC-MS ultra-grade formic acid were added into a LC-MS/MS lab 
standard washed 1L measuring cylinder to make up to the 500 mL mark by adding milli-Q water. It was 
refreshed weekly to minimize the possible bug growth incidence. 
Mobile phase B 
500 µl of LC-MS ultra-grade formic acid was added into a LC-MS/MS lab standard washed 500mL 
measuring cylinder and then HPLC grade methanol was added to make up 500 mL total volume. It was 
refreshed per run batch to maintain the chromatogram integrity. 
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Calibrator material 
Vitamin D calibrator set 
Chromsystems 6PLUS1® Multilevel Serum Calibrator Set, 25-OH-Vitamin D3/D2, cat no. 62039 was 
used as calibrator for quantification. Stock materials received as 7x1 mL lyophilised materials. Working 
solutions were prepared according the manufacturer instruction by adding 1mL milli-Q water into each 
bottle. The bottles were left on the working bench for 10mins, following 5mins on the low speed rolling 
mixer. Aliquots of 130 µl into 2 mL – properly labelled (ID, lot no, expiry date, reconstitution date, 
initial) plastic Eppendorf tube were stored at -20oC. 
External / internal quality control material 
Vitamin D control set 
UTAK Vitamin D Plus; 3 levels control, cat no.10060/10061/10062 were used to control the assay 
performance. Stock materials received as 5 mL lyophilized bottles. Working solution were prepared 
following the manufacturer instruction by adding 5mL milli-Q water using 5mL glass volumetric 
pipette into each bottle. The bottles were left on the working bench for 10mins, following 5mins on the 
low speed rolling mixer. Aliquots of 130 µl into 2 mL – properly labelled (ID, lot no, expiry date, 
reconstitution date, initial) plastic Eppendorf tube were stored at -20oC. 
External quality control 
RMIT LC-MS/MS laboratory participates in Vitamins and Endocrine RCPA-QAP program for vitamin 
D. Materials are received annually to be prepared (following the package insert instruction), analysed 
and reported bases on the report schedule calendar.  
Analytical procedure 
Work-list generation 
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The excel work-list template is generated and used to prepare the work-list, incorporating calibrators, 
controls and unknown samples (DBS and serum). The patient name and ID were recorded in columns 
B and C. The sample type was recorded in column D – either serum. For DBS samples, the disc size 
was entered in column E. Samples were initially prepared in 96 well micro plates. 
• Record the patient name and ID in column A. 
• Record the sample type in column B – Liquid / DBS 
• Print the worksheet and use for the sample preparation 
• Let frozen and refrigerated material defrost and reach the room temperature  
• Label a 96 micro-well plate matching the work-list numbers 
*Note; maximum batch size is 96 for plate format set up. 
 
Sample Preparation 
Liquid calibrators, QC materials and any other liquid matrix samples were prepared in conjunction with 
DBS samples (solid matrix); 
DBS, calibrators and controls sample preparation, 125µl of 0.1% formic acid solution is added on 3.2 
mm punch DBS and 50µL de-ionised water is added to 50µL of calibrators and QC materials samples, 
followed by 60mins shake; the first 30mins at RT and the second 30mins at 60oD. 75 µl water-methanol 
mixture containing 10 nmol/L and 100 µL of water-methanol mixture containing 123 nmol/L deuterated 
internal standard (ISTD) (25-hydroxy vitamin D3-d6) were added into DBS and calibrators/QCs 
samples respectively. Samples subjected to further 10mins sonication. 
DBS eluate and pre-treated calibrators and QCs, purified by using Biotage SLE cartridges (Cat no820-
0200-P01) and application of 350 µL hexane elution (twice). Sample eluate is collected and dried using 
rotational vacuum concentrator (Martin Christ, Part No: RVC2-33PACK, John Morris Scientific Pty 
Ltd, Australia) at 45oC.    
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Derivatisation, 50 µL Amplifex diene reagent solution was added to the dried sample, then was vortexed 
for 20sec, followed by 30mins incubation at 4OC. The derivatisation reaction was neutralised by 
addition of 75 µL methanol/de-ionised water mixture (1:1). 
• If not already punched, punch out one 3mm disk from the DBS directly into the matching 
well of the plate. 
• Note any spot that is not as expected. 
• Pipette 50µL of the serum calibrators, control and unknown liquid samples in their assigned 
micro-plate well numbers matching the work-list order. 
• Add 125µl of 0.01% formic acid solution to the DBS punches  
• Add 50µl 0.01% formic acid solution to liquid samples  
• Cover the plate with the sealing mat 
• Shake the plate for 30mins at 700 rpm / RT 
• Prepare diluted IS solutions (whilst plate shaking) 
a) Make 1/2 dilution from the 246 nmol/L stock IS (50:25:25 – IS:H2O:MeOH) 
b) Make 1/12 dilution from liquid matrix match IS working solution (1:11(1:6) -  
ISLa:H2O/MeOH(1:6) to be added to 3mm DBS 
• Take the plate off the shaker and remove the sealing mat  
• Add  
a) 100µL of 1/2 diluted IS (123 nmol/L) to the liquid matrix samples 
b) 75µL of 1/12 IS (10 nmol/L) to DBS samples 
• Cover the plate with the sealing mat (ensuring same orientation) and shake for 30secs 
• Sonicate the plate for 10mins 
• Remove the Biotage SLE plate (Part no. 820-0200-P01) from the box and locate it on the 
collection plate 
• Transfer the spiked samples from the extraction plate using multichannel pipette into the 
matching well of SLE plate 
• Let samples absorb for 1 minute 
• Apply positive pressure using ‘UCT positive pressure manifold’ briefly onto the SLE plate; 
10 bar, for < 1sec 
• Wait for 5mins  
• Add 350 µl Hexane to SLE wells in two episodes and collect all total app. 700 µl hexane-
eluate into the Collection plate (250, 250, 200µl if using 300µl multichannel pipette) 
• Leave to elute with gravidity for 5mins 
• Apply positive pressure for 1-2sec 
• Use the SpeedVac (RCV 2-33 CD Plus) to dry the hexane-eluate (evaporation program no. 
22-Rosy) 
• Take collection plate out of speed-vac and add 50 µL ½ diluted Amplifex solution (50:50 – 
Amplifex:AcN) to the dried samples 
• Re-seal the collection plate and shack the plate for 30secs 
• Incubate plate at 4oC for 30mins 
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• Prepare Stop-solution (50:50 – H2O: MeOH)  
• At the end of 30mins incubation, take the plate out of the fridge, then take the sealing mat off 
and add 75 µL Methanol-water mix (50:50) stop-solution, to stop the derivatisation reaction 
• Re-seal the plate properly and shake it for 30secs  
• Place the plate on the LC auto-sampler and set up LC-MS/MS to run   
Chromatographic-Tandem mass spectrometric analysis 
Chromatographer and Mass spectrometer 
The routine HPLC was an Agilent Model 1260 infinity, it consists of the following modules: Degasser; 
Quaternary Solvent pump; Columns Oven which is coupled with the Agilent Model 6490 triple-
quadrupole mass spectrometer. LC-MS/MS module control, data acquisition and data processing were 
provided by MassHunter software (Version B.4.04/B.4.0/B.5.0) (Referred to “General Operation for 
the Agilent 1290/6490” manual for full general operational details). 
Data acquisition work-list example 
Referred to “General Operation for the Agilent 1290/6490” manual for full general operational details. 
LC-MS/MS analytic method 
Referred to “General Operation for the Agilent 1290/6490” manual for full general operational details. 
“20180124-29-F5100-binpump” analytical method was used. 
Chromatographic column 
Analytic column is core-shell column (2.6µm, 100mm, Kinetex F5, Phenomenex Inc., Australia) 
Guard column is Pursuit 3 PFP-10x2mm (Agilent Technologies cat no. A3051MG2). 
Quantitative data processing 
“Agilent MassHunter Workstation Software Quantitative AnalysisQuant method” was used for LC-
MS/MS results quantification (Refer to “General Operation for the Agilent 1290/6490” manual for full 
general operational details). 
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Quality control reports 
Internal QC reports were archived on “MedLab QC” software for each analysis batch, and external 
QA results were reported to RCPA-QAP website monthly.  
Reporting of patients results and reference intervals 
Results for Vitamin D are reported in nmol/L. The values >75 nmol/L for 25OH-D3 indicate the 
vitamin D sufficiency, while vitamin D deficiency is defined as different levels of; Mild (serum 
25OHD3: 25-50 nmol/L), Moderate (serum 25OH-D3: 12.5-25 nmol/L), Severe (serum 25OH-D3 < 
12.5 nmol/L) 
 
Figure 8.2. Vitamin D external quality control (RCPAQAP) end of cycle report 
 
Figure 8.3. 7 point-calibration curve for derivatised 25-OHvitamin D3 
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Figure 8.4. Chromatogram of detection of 25OH-vitamin D3 and 3epi-25OH-vitamin D3 from DBS sample. 
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App.3 3000 NBS Guthrie cards sample retrieval and collection and storage process 
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